CHEMISTRY A EUROPEAN JOURNAL

BURGESS-TYPE REAGENTS © SULFAMIDATES GLYCOSYLAMINES SULFAMIDES OH HO CO₂Y 0 R HO OMe Et₃ RO OH RO 10 O2Me NHCO₂Y RO 10 RO :0 NHCO₂ RO USEFUL CHEMICAL BUILDING BLOCKS

For more details see the following pages.

DOI: 10.1002/chem.200400503 Chem. Eur. J. 2004, 10, 5581-5606

© 2004 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim

5581

New Uses for the Burgess Reagent in Chemical Synthesis: Methods for the Facile and Stereoselective Formation of Sulfamidates, Glycosylamines, and Sulfamides

K. C. Nicolaou,^{*[a, b]} Scott A. Snyder,^[a] Deborah A. Longbottom,^[a] Annie Z. Nalbandian,^[a] and Xianhai Huang^[a]

Abstract: Although the Burgess reagent (methoxycarbonylsulfamoyltriethylammonium hydroxide, inner salt) has found significant use in chemical synthesis as a dehydrating agent, almost no work has been directed towards its potential in other synthetic applications. As this article will detail, we have found that the Burgess reagent is remarkably effective at accomplishing a number of non-dehydrative synthetic tasks when applied to appropriate substrates, such as the formation of sulfamidates from 1,2-diols or epoxyalcohols, α - and β -glycosylamines

Keywords: amines • Burgess reagent • diazo compounds • sulfamides • sulfur from carbohydrates, and cyclic sulfamides from 1,2-aminoalcohols. Beyond delineating the power of these new reaction manifolds, we also describe the construction of a group of alternative Burgess-type reagents that extends the scope of these new reactions even further.

Introduction

Ever since its introduction over three decades ago, the Burgess reagent (**1**, Scheme 1)^[1] has proven to be a powerful tool in chemical synthesis as an agent for effecting a diverse set of dehydration reactions.^[2] For example, it has been employed on numerous occasions to smoothly convert secondary and tertiary alcohols into their corresponding alkenes by means of *cis*-elimination pathways^[3] as well as to dehydrate amides to their nitrile counterparts (Scheme 1a,b).^[4] The Burgess reagent is also an excellent initiator of cyclodehydrations leading to heterocycles, such as the transformation of hydroxyamides into oxazolines^[5] and the Robinson– Gabriel reaction converting ketoamides into oxazoles.^[6] It

[a] Prof. K. C. Nicolaou, S. A. Snyder, Dr. D. A. Longbottom, A. Z. Nalbandian, Dr. X. Huang Department of Chemistry and The Skaggs Institute for Chemical Biology The Scripps Research Institute 10550 North Torrey Pines Road, La Jolla California 92037 (USA) Fax: (+1)858-784-2469 E-mail: kcn@scripps.edu
[b] Prof. K. C. Nicolaou Department of Chemistry and Biochemistry University of California, San Diego 9500 Gilman Drive, La Jolla, California 92093 (USA) was the latter of these processes that originally brought the Burgess reagent to our attention as we sought methods to complete the heteroaromatic core of the originally proposed structure of diazonamide A (2) by transforming advanced intermediate 3 into $4^{[7]}$ While the Burgess reagent would ultimately fail to accomplish that rather difficult dehydration, our efforts in that context inspired us to ponder the following, more general, question: are there powers for this reagent beyond its capacity to remove water?

As a subsequent search of the literature revealed, there were only a few such reports in existence, all dedicated to the same process shown in Scheme 1c: the conversion of primary alcohols into their corresponding methyl urethane derivatives.^[8] This finding, in turn, led us to wonder if related processes leading to the incorporation of nitrogen could be accomplished on other substrate types, such as 1,2-diols (a compound type that had seemingly never been subjected to its powers). Our subsequent efforts to answer that question began a line of investigation that ultimately revealed a wealth of newfound potential for the Burgess reagent, not as a dehydrative agent, but rather as a convenient source of multiple heteroatoms (S, O, and N). This article recounts those studies, work which has led to new methods for the stereoselective formation of diverse sulfamidates, α - and β glycosylamines, and sulfamides.^[9]

5582



Scheme 1. Selected uses of the Burgess reagent (1) in chemical synthesis.

Results and Discussion

Sulfamidate synthesis from 1,2-diols using the Burgess reagent: Our expectation for what could happen to a 1,2-diolcontaining substrate (I) following exposure to an excess amount of the Burgess reagent (at least two equivalents) is drawn in Scheme 2. Namely, if that starting material could be coaxed to form an intermediate of type II prior to either alcohol participating in a typical dehydrative pathway, then perhaps a sulfamidate (III) product could arise through the indicated S_N2 reaction. Assuming that this transformation would proceed through displacement of the more activated of the two potential leaving groups, then variation of the R¹ and R² substituents on enantiopure I could enable the stereo- and regioselective synthesis of sulfamidates (III) on a potentially large number of diverse structural types.

Abstract in Greek:

Παρόλο αντιδραστήριο π_{00} το Burgess (εσωτερικό άλας του μεθοξυκαρβονυλσυλφαμούλο-τριαιθυλαμμώνιου υδροξειδίου) έχει βρει σημαντική εφαρμογή στην οργανική σύνθεση ως αφυδατικό μέσο, η έρευνα δεν έχει στραφεί σχεδόν καθόλου προς δυνητικά διαφορετικές συνθετικές εφαρμογές. Όπως αυτό το άρθρο αναλύει, βρήκαμε ότι το αντιδραστήριο Burgess είναι αξιοσημείωτα αποτελεσματικό κατά την πραγματοποίηση ενός αριθμού μη αφυδατικών συνθετικών αντιδράσεων, όταν εφαρμόζεται στα κατάλληλα υποστρώματα, όπως ο σχηματισμός σουλφαμιδικών εστέρων από 1,2-διόλες ή εποξυαλκοόλες, α- και β-γλυκοζυλαμινών από υδατάνθρακες, και κυκλικών σουλφαμιδίων από 1.2-αμινοαλκοόλες. Πέρα από την παρουσίαση της δύναμης αυτών των νέων πολλαπλών αντιδράσεων, περιγράφουμε επίσης την δημιουργία μιας ομάδας εναλλακτικών αντιδραστηρίων τύπου Burgess που επεκτείνει το πεδίο αυτών των νέων αντιδράσεων ακόμα περεταίρω.



Scheme 2. Proposed conversion of 1,2-diols (I) to cyclic sulfamidates (IV) using Burgess reagent (1) and proof of principle $(5 \rightarrow 6)$.

The proposed chemistry appealed to us not only because it would highlight a new use for the Burgess reagent if it worked, but also because its success would deliver an impor-

Chem. Eur. J. 2004, 10, 5581–5606 www.chemeurj.org © 2004 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim

- 5583

Table 1. Regioselective synthesis of sulfamidates from precursor 1,2-diols using Burgess reagent (1).



[a] As determined by ¹H NMR analysis of the crude reaction products.

tant pharmacophore in far fewer steps than other methods could achieve.^[10] Equally attractive, since sulfamidates are well precedented to undergo highly selective reactions with O-, S-, N-, and F-based nucleophiles to afford compounds of general structure **IV**,^[11] we could subsequently use our synthesized materials to access a diverse array of products, including such valuable synthons as β -aminoalcohols.^[12] To test the key element of this hypothesis, we heated a solution of diol **5** (synthesized from the precursor olefin by dihydroxylation under standard conditions) in THF at reflux for one hour in the presence of 2.5 equivalents of the Burgess reagent (**1**).^[13] In line with our expectations, at the end of this time we obtained the desired sulfamidate product (**6**) in 84% yield as a single regioisomer based on NMR spectroscopic analysis. With this important proof of principle achieved, we next sought to test the generality of this reaction process on a selection of styrene-derived diols possessing a broad range of aromatic substitution patterns to explore whether inductive effects would have any impact on the regioselectivity of the S_N 2-based cyclization. Although we could have chosen any number of diols to probe the process further, we selected this particular class of compounds for two key reasons: 1) styrenes are the best substrates for Sharpless asymmetric dihydroxylation (AD)^[14] in terms of both catalytic activity and enantioselectivity, and 2) styrene-type olefins display good, but highly variable, yields and regioselection in carbamate-based asymmetric aminohydroxylation (AA).^[15]

As indicated by the results in Table 1, our Burgess-mediated sulfamidate synthesis proved quite effective with this group of substrates as long as the aromatic ring was electron-rich (entries 1-4) or electron-neutral (entry 5). However, when substituents with increasing electronegativity were appended onto the styrene core (entries 6 and 7), a second reactive pathway leading to substantial amounts of a sevenmembered side-product was opened up. Scheme 3 provides two mechanisms that could account for the formation of these types of products (i.e., 23), using styrene for the sake of their illustration. The first of these scenarios invokes the resonance form of 21 (i.e., 22) as the source of an oxygen nucleophile that could displace the activated benzylic leaving group and lead to 23 directly. The second assumes only partial reaction of the Burgess reagent with substrate 24 to initiate entry into a different intramolecular displacement reaction leading to epoxide 26, a compound already demonstrated to provide heterocycle 23 in its reaction with the Burgess reagent.^[16] Although the results described thus far did not allow us to discern which, if either, of these two possible pathways was active, one experiment described below



Scheme 3. Degenerate mechanistic proposals to account for the formation of the minor seven-membered ring product **23** in the reaction of 1,2diols with excess Burgess reagent.

would provide such an insight. For now, however, we think it important to note that the desired sulfamidate products listed in Table 1 could be readily separated from their seven-membered ring counterparts by standard chromatography. In addition, the especially poor selectivity observed in the conversion of **19** to **20** (entry 7) could be improved to 75:25 by performing the reaction at 25°C, albeit at the expense of yield (35%).

Having explored electronic effects, we then sought to examine the role of steric encumbrance on the reaction process as well as its applicability to non-styrene derived diols by testing the substrates listed in Table 2. As one might

Table 2. Further examples of the regioselective synthesis of sulfamidates from precursor 1,2-diols using Burgess reagent (1).



[a] Determined by ¹H NMR analysis of the crude reaction products.

expect, increasing steric bulk at the terminal position of the styrene core, simply through the addition of a single methyl group (entry 1), increased the selectivity of cyclic sulfamidate formation compared to that observed for the corresponding example in Table 1. This outcome suggests that the epoxide pathway mentioned above is the source of any seven-membered products, as the other mechanistic picture would not predict a different ratio based on this one simple change. Importantly, no decrease in yield or selectivity for the desired five-membered sulfamidate was observed when steric bulk was added onto the aromatic ring (entries 2 and 3). Equally significant, esters were well tolerated in the reaction. In entry 5, the near exclusive formation of sulfamidate 36 was achieved from 35 due to the reinforcing effects of α position deactivation by the ester moiety and steric bulk imposed at that site by a methyl group, while competitive steric and electronic effects in entry 6 led to retarded $S_N 2$ displacement at the preferred terminal site, leading to increased formation of the seven-membered side product and decreased reaction yield. Simple aliphatic examples (entries 7 and 8) proceeded with extremely high regioselectivity, presumably due to the well-established preference for nucleophilic displacement of primary or activated leaving groups over their secondary counterparts. Finally, to verify the potential of this reaction manifold for asymmetric synthesis, as all of the examples listed in Tables 1 and 2 were performed on racemic diol substrates, an X-ray crystal structure was obtained for sulfamidate 36; this confirmed that inversion of stereochemistry had occurred at the benzylic position relative to the racemic *cis*-diol starting material (see Figure 1).



Figure 1. X-ray crystallographic structures for sulfamidates 36 and 42.

Additionally, both racemic and enantiopure **33** were synthesized,^[17] and comparison of the chiral HPLC traces of the resultant products (**34**) indicated that preexisting stereochemical information was communicated in the reaction with complete fidelity.^[18]

With a much clearer sense of the scope possessed by our Burgess-mediated sulfamidate synthesis, we now desired to extend its overall utility one step further by constructing compounds bearing N-protection other than a methyl carbamate, a task which could be achieved simply by modification of **1**. To our surprise, however, such reagents represented novel chemical entities, as an extensive search of the literature indicated that no efforts had been expended to prepare any Burgess-type salts other than those originally described almost thirty years ago.^[19] This result was unexpected, as **1** is known to be both thermal and moisture sensitive,^[2a] features which might be modulated by differentiation of the carbamate portion. In any case, as shown in Scheme 4, we found



Scheme 4. Synthesis of the novel variants (**48–51**) of the original Burgess reagent: a) chlorosulfonyl isocyanate (1.0 equiv), ROH (1.05 equiv), CH₂Cl₂, 0 °C, 30 min, 89–95 %; b) Et₃N (2.5 equiv), C₆H₆, 25 °C, 1 h, 81–87 %.

it quite easy to prepare four different Burgess-type reagents (**48–51**), representing an orthogonal set of amine-protecting groups (based on deprotection by hydrogenation, photolysis, exposure to palladium-based catalysts, or treatment with Zn, respectively) by treating chlorosulfonylisocyanate (**43**) with the alcohol of interest and then exposing the resultant product to $\text{Et}_3\text{N}^{[20]}$ Now the question was whether these reagents would perform with equal facility as **1** in sulfamidate synthesis. Pleasingly, the answer was yes as their exposure to several diol substrates resulted in the formation of the desired sulfamidate products (**52–60**, Table 3) in comparable efficiency and selectivity as observed previously with **1**.

Having synthesized such a diverse group of sulfamidates, we were now in a position to attempt their conversion into β -aminoalcohols. Accordingly, using a literature procedure^[11k] that had been examined on only one sulfamidate substrate, we exposed a variety of these products (see Table 4) to a 1:1 mixture of aqueous HCl and 1,4-dioxane at 25°C. In every case, a high yield of β -aminoalcohol product was observed irrespective of carbamate protecting group used. As such, the applicability of this method to a diverse set of 1,2-diol classes, combined with its facile use in a subsequent step to deliver β -aminoalcohol products, renders it an attractive alternative to protocols such as Sharpless AA should they fail to deliver a given product with acceptable levels of regio- and/or stereocontrol.

Glycosylamine synthesis using the Burgess reagent: In assessing additional directions in which we could take the Burgess reagent, new inspiration came when we thought more carefully about the conversion reported in entry 8 of Table 2 leading to the synthesis of **42** (whose *cis*-fused sulfamidate ring was verified by the X-ray crystal structure shown in Figure 1). Specifically, we wondered what would happen if this reaction were applied to a sugar template (**V**, see Scheme 5). Our experience suggested that the same type of sulfamidate product (**VII**) should arise through the departure of the most activated hydroxyl, either by the indicated S_N2 mechanism or by an oxonium alternative (not shown), with the C-2 group orchestrating the stereoselective delivery

Table 3. Use of the new Burgess-type reagents **48–51** to prepare orthogonally protected sulfamidates (**52–60**).



[a] As determined by ¹H NMR analysis of the crude reaction products. $Cbz = CO_2CH_2Ph$, o-NO_2Cbz = CO_2CH_2 -o-NO_2Ph, Alloc = $CO_2CH_2CH = CH_2$, Troc = $CO_2CH_2CCl_3$.

of nitrogen. In this case, however, subsequent opening of this ring with a heteroatomic nucleophile would afford a 1,2-*trans*-difunctionalized glycosylamine product.^[11] Thus, based on this model, a starting material derived from D-glucose would provide an α -glycosylamine product (**VIII**). Al-

Table 4. Deprotection of cyclic sulfamidates using aqueous HCl in 1,4-dioxane at ambient temperature to yield β -aminoalcohols (**61–68**).



ternatively, if lactols bearing C-2 protection (**IX**) were exposed to the same general reaction conditions, it would be reasonable to expect that these materials would afford *N*,*O*-acetal products instead of sulfamidates, through the indicated mechanism, with stereocontrol in this "self-displacement" reaction arising from the established preference for anomeric triflates to exist as α -anomers (**XI**) over their β -disposed counterparts (**X**).^[21] As such, D-glucose-based materials would afford only β -glycosylamine products (**XII**) in this reaction paradigm.^[22]

While relatively simple ideas based on our previous success in reacting 1,2-diol substrates, their success would be of considerable value, since glycosylamines have proven to be exceedingly difficult to synthesize. Indeed, available methods based on the use of glycosyl azides, glycals,^[23] Kochet-



Scheme 5. Proposed synthesis of both α - and β -glycosylamines using Burgess-type reagents.

kov aminations,^[24] and α -hydroxy nitriles,^[25] among others, typically lack substrate generality and often result in variable stereoselectivity, especially in complex contexts. In addition, none of these methods singularly provides a means to obtain both α - and β -anomers at will and in a controlled manner. As such, we immediately set out to test whether the Burgess reagent could rise to this task.

Gratifyingly, the Burgess reagent (1) and its relatives (50 and 51) did just that. As shown in Table 5, a variety of diols on diverse carbohydrate templates (D-glucose, D-galactose, L-rhamnose) were smoothly converted into their α -disposed sulfamidate counterparts (cis-fused rings) upon the action of 2.5 equivalents of 1, 50, or 51 in refluxing THF/CH₂Cl₂ (4:1) over the course of 6 h.^[26] In every case, yields and α : β selectivity (determined by ¹H NMR spectroscopy; the minor isomer presumed to be the *trans*-fused β -anomer was not isolated but observed by NMR spectroscopy) were exceptionally high irrespective of which Burgess-type reagent was employed. As such, these findings can be taken as a sign that any carbamate-protecting group can be appended onto the sulfamidate products in Table 5, though we have only demonstrated that principle directly for D-glucose. Such flexibility is important, since we were able to subsequently open these products with nucleophiles to afford a-disposed glycosylamines such as 83, or alternatively, convert them into functionalized sulfamidates like 84 simply by removing the carbamate protecting group and alkylating as shown in Scheme 6. Both of these manipulations should prove important in future applications relevant to the study of chemical biology, though compounds of type 84 offer several unique advantages as their sulfamidate ring provides untapped



[a] The minor isomer (β -anomer, *trans*-fused ring) was not isolated, but presumed to be that on the basis of ¹H NMR data (of the α/β mixture).



Scheme 6. Synthesis of functionalized α -glycosylamines from precursor sulfamidates: a) NaN₃ (5.0 equiv), DMF, 60 °C, 5 h, 83 %; b) Pd(OAc)₂ (0.1 equiv), TPPTS (0.2 equiv), Et₂NH (40 equiv), MeCN/H₂O (1:1), 25 °C, 30 min; c) NaH (5.0 equiv), DMF, 25 °C, 5 min, then allyl bromide (4.0 equiv), 25 °C, 15 min, 73 % over two steps. TPPTS = 3,3',3''-phosphidinynetris(benzenesulfonic acid) trisodium salt.

structural novelty and ensures that the disposition of the nitrogen atom cannot anomerize (as often occurs with unprotected α -glycosylamines simply upon standing in solution).

As indicated in Table 6, C-2 protected lactols reacted with Burgess-type reagents in a level of smoothness that matched their diol counterparts, affording a β -disposed, protected glycosylamine on every six-membered carbohydrate probed (entries 1–5), as verified by both X-ray crystallographic (see Figure 2)^[27] and ¹H NMR analyses. Five-membered furanose



Figure 2. X-ray crystallographic structure of compound 86.

substrates performed equally well (entries 6–8), with anomeric stereochemistry in these products presumably controlled by the orientation of the C-2 substituent in a level commensurate to its bulk.^[28] As discussed earlier, the reactions performed equally well irrespective of which Burgess-type reagent was employed in this manifold, though Alloc protection did provide one important benefit over the other carbamate alternatives: facile removal in near quantitative yield under conditions^[29] that did not initiate any anomerization (see, for example, **89** \rightarrow **102**) to afford free glycosylamines.

In closing this section, it is clear that the Burgess reagent (1) and its analogues (50 and 51) afford powerful and highly selective tools for the synthesis of both α - and β -glycosylamines on a wide variety of carbohydrate scaffolds. This new approach is not only exceedingly mild, operationally simple, and tolerant of numerous functional and protecting groups, but also appears to be applicable for large-scale syntheses (reactions up to 5 mmol have been performed with no drop in efficiency) and late-stage operations relevant to the synthesis of complex aminoglycosides and/or N-linked glycopeptides.^[30]

Hydroxysulfamidate synthesis using epoxyalcohols and the Burgess reagent: Having proven that 1,2-diol substrates could lead to sulfamidate products, we then wondered whether or not additional classes of molecules could be converted into similar materials. For example, would a hydroxylepoxide (XIII) derived from an allylic alcohol prove to be a willing participant in the pathway delineated in Scheme 7 leading to a hydroxysulfamidate product (XV)? As matters would transpire, the answer to that question was yes, though a great deal of reaction scouting was required before we identified conditions capable of reliably effecting that conversion.

Table 7 shows the final solution leading to five hydroxysulfamidate products: heating a hydroxyepoxide substrate with 1.3 equivalents of the Burgess reagent for 3 h in a 4:1 solvent mixture of THF/CH₂Cl₂, followed by column purification using the slightly basic material Florisil[®] instead of Table 6. Direct conversion of anomeric alcohols to β -glycosylamines.





Scheme 7. Proposed conversion of epoxyalcohols into sulfamidates through the action of the Burgess reagent (1).

Chem. Eur. J. 2004, 10, 5581-5606 www

www.chemeurj.org

© 2004 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim

5581-5606

standard, acidic silica gel. Any deviation from this procedure led to a multiplicity of products.^[31] We think it important to emphasize that, although we could reliably obtain the sulfamidate adducts shown in the yields indicated with this protocol, this particular reaction with the Burgess reagent is by far the most capricious of those that have been described to this point, and certainly the most experimentally challenging.^[32]

Sulfamide synthesis using the Burgess reagent and 1,2-aminoalcohols: Within the realm of proven pharmacophores, the sulfamide functional group (thiadiazine-1,1-dioxide) stands out as one of the most important structural motifs found in high-affinity protein ligands and pharmaceutically useful agents. Indeed, a survey of the recent patent literature reveals several hundred proprietary documents illustrating that the incorporation of a sulfamide group within a suitable scaffold, often cyclic, leads to compounds with an impressive and diverse array of biological activities.[33] For instance, these agents have proven to be particularly effective as inhibitors of key enzymes, including HIV protease^[34] and serine protease,^[35] and have demonstrated utility as both agonists and antagonists of critical molecular receptors such as those used to regulate endogenous levels of seratonin^[36] and histamine.^[37] Beyond their evident significance in the treatment of disease, cyclic sulfamides have also been employed with considerable success as chiral ligands and auxil-

iaries,^[38] and constitute an increasingly popular set of building blocks within the field of supramolecular chemistry.^[39]

Despite the indisputable utility of these compounds, existing routes for their construction, particularly in a cyclic setting, are far from ideal. For example, typical procedures to fashion cyclosulfamides rely upon the reaction of a diamine with either SO_2Cl_2 or $H_2NSO_2NH_2$ at elevated temperatures,^[40] conditions which often lead to a low yield of product due to the concomitant formation of polycondensation

Table 7. Synthesis of sulfamidates from epoxyalcohols.



[a] All reactions were performed in THF/CH₂Cl₂ (4:1) at reflux with 1.3 equiv of **1**, followed by column chromatography using Florisil[®].

side-products. Equally problematic is the scarcity of these starting materials in the repertoire of commercially available chemicals,^[41] thereby resulting in only a limited collection of sulfamides. While these issues have led to the development of several alternative protocols for sulfamide synthesis,^[42] these additional technologies have proven amenable only to specific substrate classes and have not yet alleviated the need for multistep protocols. Most significantly, none of these methods has enabled the efficient and selective synthesis of nonsymmetrical N,N'-disubstituted cyclosulfamides (see **XIX**, Scheme 8), perhaps the most versatile class of



Scheme 8. Proposed conversion of amino alcohols (**XVI**) to cyclic sulfamides (**XVIII**) using Burgess (1) and related reagents (48 and 50) and further elaboration leading to nonsymmetrically substituted, structurally diverse products (**XIX**).

these compounds for generating pharmaceutically relevant molecular diversity.

Once again, we felt that the power of the Burgess reagent could be employed to solve these problems and smoothly deliver sulfamide products. As shown in Scheme 8, our expectation was that treatment of an aminoalcohol starting material (**XVI**, R^1 =H or alkyl) with at least two equivalents of the Burgess reagent would lead to a monoprotected, nonsymmetrical, cyclic sulfamide (**XVIII**) in a single, stereocontrolled operation. Assuming that this reaction course could be successfully realized in preference to the typical rearrangement/dehydration pathways promoted by these reagents, subsequent deprotection of the carbamate in **XVIII**, followed by substitution with an appropriate electrophile, would then provide access to an assorted collection of sulfamides (**XIX**) with the potential to incorporate diversity at all possible sites.

To test this attractive hypothesis, we began our investigations of this new Burgess-mediated reaction by exploring a representative set of commercially available and easily synthesized secondary β-aminoalcohols. Most gratifyingly, exposure of all substrates listed in Table 8 to excess Burgess reagent (1) or its relatives (48 and 50) in refluxing THF for 8 h led to the formation of the desired cyclic sulfamide product in high yield, regardless of the nature of the group attached onto the amine. Of particular note, neither placing the amine in a hindered cyclic setting (entries 8 and 9) nor adding a bulky tert-butyl substituent (entries 6 and 7) retarded product formation. The latter of these substrates (122) is a particularly effective test for the power of this synthetic technology, as starting materials bearing this functionality have, in general, proven recalcitrant to sulfamide formation with other available methods.^[36] Of equal importance, all aniline-derived systems (entries 12-14) proved readily amenable to the cyclization process regardless of the electronwithdrawing (entries 12 and 13) or donating (entry 14) properties of the appended aromatic ring, results indicative of the versatility of this intramolecular Burgess-mediated cyclization.[43]

While certainly satisfied by these initial successes in which the two nitrogen atoms of the sulfamide product had been effectively differentiated, we next sought to more fully probe the limits of the Burgess-mediated sulfamide synthesis by exploring more challenging substrates. As shown in Table 9, employing a secondary alcohol (entry 1), even in a relatively hindered context, failed to engender any particular difficulties, although extension of the reaction time beyond the standard 8 h of heating was required to optimize yields. A double cyclization seeking to generate a bis-sulfamide (140, entry 2) was also smoothly effected, with reduced yield in this case solely due to difficulties encountered during isolation, because of this product's polar nature. Finally, following optimization of the reaction conditions, extension of the sulfamide cyclization to ring sizes beyond the five-membered ring products formed in the previous examples also proved attainable. Initial efforts focused on 141 (entry 3), wherein commencing the reaction at 0°C and allowing it to warm to 25 °C overnight led to the desired product (142) in 45% yield. All other conditions probed led to

Table 8. Synthesis of nonsymmetrical cyclic sulfamides from precursor aminoalcohols using Burgess-type reagents: initial explorations.



[a] All reactions were performed in refluxing THF for 2 h.

significant amounts of a major rearrangement side-product in which the alcohol had been converted to a urea derivative^[8] (see Scheme 1c) instead of serving as a leaving group for the desired cyclization. Fortunately, when non-benzylic (i.e., less activated) alcohols were employed instead (entries 4–9), the propensity for this side-reaction was completely suppressed, leading to a series of six- and sevenmembered ring analogues in excellent yield under standard reaction conditions (THF, reflux, 2 h). The smooth generation of compound **154** among these is of particular significance, because this bicyclic product is analogous to the benTable 9. Synthesis of nonsymmetrical cyclic sulfamides from secondary ami-

5581 - 5606



[a] THF, Δ , 21 h; [b] THF, Δ , 8 h; [c] 0 °C, 1 h, then 25 °C, 5 h; [d] THF, Δ , 2 h.

zodiazepine nucleus, a molecular scaffold that has been the subject of intensive biological investigations and the source of several clinically employed agents.^[44]

Based on the successful formation of the latter sulfamide substrate in Table 9, we were hopeful that other primary aliphatic aminoalcohol substrates would perform in this Burgess-based protocol with equal proficiency as both sides of the resultant sulfamide product could then be substituted in turn, leading to greater structural diversity. Unfortunately, all three substrates examined within this class (entries 1–3, Table 10) gave rather disappointing yields of sulfamide products, leading in each case to the formation of side-products resulting from undesired rearrangements. In retrospect, the poor performance of these substrates in an intramolecular cyclization relative to their secondary amine counterparts is not so surprising, as in the absence of an additional alkyl or aryl substituent the nitrogen atom is far less nucleophilic, thereby leading to prolonged reaction times and greater op-

- 5591

Table 10. Synthesis of nonsymmetrical cyclic sulfamides from primary aminoalcohols.



[a] THF, Δ, 8 h; [b] THF, 0 °C, 1 h, then 25 °C, 5 h.

portunities for material to travel down alternative pathways. The modest yields observed in these examples, however, do not really reflect a limitation in strategy, as the successful debenzylation of 117 (entry 3, Table 8) through hydrogenation in the presence of Pearlman's catalyst [Pd(OH)₂/C] provided a route to the same product (159, entry 1, Table 10) in quantitative yield, thus alleviating the need to start with ethanolamine (155). As such, this approach provides a tactic to sequentially substitute both sides of any cyclic sulfamide product, if so desired. Finally, in contrast to the results in the rest of Table 10, when primary aliphatic amines were utilized in conjunction with a secondary benzylic alcohol (entries 4 and 5), product yields were excellent when the reaction was performed at low temperature. While these results were unanticipated based on the preceding discussion, they suggest that the activated nature of the leaving group (i.e., benzylic) is responsible for this altered, but useful, reactivity. The smooth formation of the last of these products (164) is especially interesting, for it is a desymmetrized, meso-sulfamide that could, in principle, be employed as a chiral ligand for applications in asymmetric synthesis.

With this collection of cyclic sulfamides in hand, we then verified that the subsequent removal of the carbamate group can be easily achieved (see Table 11) with conventional procedures and can be readily followed by substitution of appropriate electrophiles (see, for example, the conversion of **166** into **171**).^[45] As such, the general and efficient synthesis of compounds represented by structure **XIX** (Scheme 8) has been realized.

Finally, beyond the synthesis of cyclic sulfamides, we have also verified that the Burgess reagent (1) can smoothly effect the generation of nonsymmetrical, linear sulfamides from all classes of amines in excellent yield (Table 12).

Table 11. Deprotection of carbamate protecting groups from selected sulfamides.



While this same conversion is more typically achieved by adding the amine to an appropriate chlorosulfonylisocyanate,^[37,46] the present conditions provide a mild alternative, avoiding the direct use of these rather toxic and corrosive agents which often contain traces of HCl, making them incompatible with acid-sensitive functionality (such as that carried by amine **186**, entry 8).^[47]

Conclusion

As these investigations have revealed, the Burgess reagent (1) and its relatives (48–51) are notably effective at accomplishing a number of non-dehydrative synthetic tasks when applied to appropriate substrates, such as the formation of sulfamidates from 1,2-diols or epoxyalcohols, α - and β -glycosylamines from carbohydrates, and cyclic sulfamides from 1,2-aminoalcohols. In each case, the synthetic approach is a marked improvement over those currently in the literature and should extend the potential of these synthesis as tools

Table 12. Synthesis of linear sulfamides from primary and secondary amines.



[a] THF, −10→25 °C, 24 h.

for chemical biology, ligands for asymmetric synthesis, or starting materials for a variety of other applications. On a more global level, these discoveries validate the power of natural product total synthesis in leading to new chemistry, as we would not have been inspired to pursue these reactions in the absence of our attempts to use the Burgess reagent as part of our campaign to synthesize diazonamide A.^[7]

Experimental Section

General procedures: All reactions were carried out under an argon atmosphere with dry solvents under anhydrous conditions, unless otherwise noted. Dry tetrahydrofuran (THF), toluene, diethyl ether (Et₂O), and methylene chloride (CH₂Cl₂) were obtained by passing commercially available pre-dried, oxygen-free formulations through activated alumina columns. Yields refer to chromatographically and spectroscopically (¹H NMR) homogeneous materials, unless otherwise stated. Reagents were purchased at the highest commercial quality and used without further purification, unless otherwise stated. Reactions were monitored by thin-layer chromatography (TLC) carried out on 0.25 mm E. Merck silica gel plates (60F-254) using UV light as visualizing agent and an ethanolic solution of phosphomolybdic acid and cerium sulfate, and heat as developing agents. E. Merck silica gel (60, particle size 0.040-0.063 mm) was used for flash column chromatography. Preparative thin-layer chromatography (PTLC) separations were carried out on 0.25 or 0.50 mm E. Merck silica gel plates (60F-254). NMR spectra were recorded on Bruker DRX-600, DRX-500, AMX-500 or AMX-400 instruments and calibrated using residual undeuterated solvent as an internal reference. The following abbreviations were used to explain the multiplicities: s=singlet, d=doublet, t=triplet, q=quartet, m=multiplet, quin=quintuplet, sext=sextet, sep=septet, br=broad, app=apparent, AB=AB quartet. IR spectra were recorded on a Perkin-Elmer 1600 series FT-IR spectrometer. Electrospray ionization (ESI) mass spectrometry (MS) experiments were performed on an API 100 Perkin-Elmer SCIEX single quadrupole mass spectrometer at 4000 V emitter voltage. High-resolution mass spectra (HRMS) were recorded on a VG ZAB-ZSE mass spectrometer using MALDI (matrix-assisted laser-desorption ionization).

General procedure for diol synthesis: The appropriate styrene (2.0 mmol, 1.0 equiv) was dissolved in acetone/H₂O (19:1, 20 mL) and OsO₄ (0.641 mL, 2.5 wt % in *t*BuOH, 0.05 mmol, 0.025 equiv) and quinuclidine (0.010 g, catalytic) were added sequentially at 25 °C. The resultant mixture was then stirred for 12 h at 25 °C. Upon completion, the reaction contents were quenched by the addition of saturated aqueous Na₂SO₃ (5 mL). After the resultant slurry had been stirred for an additional 30 minutes at 25 °C, the reaction mixture was poured into water (25 mL) and extracted with CH₂Cl₂ (3×25 mL). The combined organic layers were then washed with water (50 mL), dried (MgSO₄), and concentrated. The resultant yellow-brown residue was purified by flash column chromatography (silica gel) in an appropriate solvent system to give the desired product in high purity.

Data for 7: $R_{\rm f}$ =0.29 (silica gel, EtOAc/hexanes, 2:1); IR (film): $\nu_{\rm max}$ = 3359, 1616, 1515, 1459, 1247, 1182, 1081, 1026, 893, 818, 548 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ =7.35 (d, *J*=8.8 Hz, 2H), 6.96 (d, *J*= 8.5 Hz, 2H), 4.83 (dd, *J*=8.1, 3.3 Hz, 1H), 3.88 (s, 3H), 3.78 (dd, *J*=11.4, 3.3 Hz, 1H), 3.71 (dd, *J*=11.0, 8.1 Hz, 1H), 2.61 (brs, 2H); ¹³C NMR (125 MHz, CDCl₃): δ =159.3, 132.6, 127.3, 113.9, 74.3, 68.0, 55.3; MS (ESI) calcd for C₉H₁₂O₃Cl⁻ [*M*+Cl⁻] 203; found: 203.

Data for 9: $R_{\rm f}$ =0.11 (silica gel, EtOAc/hexanes, 2:1); IR (film): $\nu_{\rm max}$ = 3447, 1739, 1636, 1508, 1373, 1236, 1202, 1081, 1019, 670 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ =7.33 (d, *J*=8.2 Hz, 2H), 7.04 (d, *J*=8.2 Hz, 2H), 4.71 (dd, *J*=7.6, 2.6 Hz, 1H), 3.66 (d, *J*=11.2 Hz, 1H), 3.56 (dd, *J*=10.8, 8.2 Hz, 1H), 3.37 (s, 2H), 2.29 ppm (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ =169.8, 150.0, 138.2, 127.2, 121.5, 74.0, 67.8, 21.1 ppm; HRMS (MALDI-FTMS) calcd for C₁₀H₁₂O₄Na⁺ [*M*+Na]⁺: 219.0628; found: 219.0623.

Data for 11: $R_{\rm f}$ =0.60 (silica gel, EtOAc/hexanes, 2:1); IR (film): $\nu_{\rm max}$ = 3418, 2961, 1636, 1467, 1360, 1247, 1194, 1085, 1027, 873, 713 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ =7.39 (s, 1H), 7.22 (s, 2H), 4.83 (dd, *J*= 8.1, 3.7 Hz, 1 H), 3.78 (dd, *J*=11.4, 3.7 Hz, 1 H), 3.72 (dd, *J*=11.4, 8.5 Hz, 1 H), 2.00 (brs, 2 H), 1.34 ppm (s, 18H); ¹³C NMR (125 MHz, CDCl₃): δ = 151.1, 140.0, 122.2, 120.2, 75.4, 68.2, 34.9, 31.4 ppm; HRMS (MALDI-FTMS) calcd for C₁₆H₂₆O₂Na⁺ [*M*+Na]⁺: 273.1825; found: 273.1831.

Data for 13: R_f =0.31 (silica gel, EtOAc/hexanes, 2:1); IR (film): ν_{max} = 3448, 1636, 1512, 1225, 1080, 656 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ = 7.34 (dd, J=8.1, 5.5 Hz, 2 H), 7.06 (t, J=8.4 Hz, 2 H), 4.82 (brs, 1 H), 3.76 (brs, 1 H), 3.64 (brs, 1 H), 2.31 ppm (brs, 2 H); ¹³C NMR (125 MHz, CDCl₃): δ =162.4 (d, J=977 Hz), 136.2, 127.7 (d, J=30.6 Hz), 115.4 (d, J=83.9 Hz), 74.0, 68.0 ppm; MS (GC/MS) calcd for C₈H₉FO₂+ [M]+: 156; found: 156.

Data for 15: $R_f = 0.35$ (silica gel, EtOAc/hexanes, 2:1); IR (film): $\nu_{max} = 3448$, 1636, 1490, 1454, 1194, 1071, 1025, 890, 760, 702 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): $\delta = 7.35 - 7.28$ (m, 5 H), 4.79 (dd, J = 8.5, 3.3 Hz, 1 H), 3.72 (dd, J = 11.4, 3.3 Hz, 1 H), 3.63 (dd, J = 11.7, 8.4 Hz, 1 H), 3.28 ppm (brs, 2 H); ¹³C NMR (125 MHz, CDCl₃): $\delta = 140.4$, 128.5, 127.9, 126.0, 74.7, 68.0 ppm; HRMS (MALDI-FTMS) calcd for C₈H₁₀O₂Na⁺ [*M*+Na]⁺: 161.0573; found: 161.0575.

FULL PAPER

Data for 17: R_f =0.23 (silica gel, EtOAc/hexanes, 2:1); IR (film): ν_{max} = 3391, 1620, 1323, 1174, 1117, 1059, 887, 830, 601 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ =7.63 (d, *J*=8.2 Hz, 2H), 7.50 (d, *J*=7.9 Hz, 2H), 4.90 (dd, *J*=8.2, 3.2 Hz, 1H), 3.81 (dd, *J*=11.4, 3.5 Hz, 1H), 3.65 (dd, *J*= 11.4, 8.2 Hz, 1H), 2.11 ppm (brs, 2H); ¹³C NMR (100 MHz, CDCl₃): δ = 126.3, 125.5, 125.4, 74.0, 67.9 ppm; MS (GC/MS) calcd for C₉H₉F₃O₂+ [*M*]+: 206; found: 206.

Data for 19: R_f =0.14 (silica gel, EtOAc/hexanes, 2:1); IR (film): ν_{max} = 3391, 2932, 1528, 1352, 1195, 1072, 809, 736, 686 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ =8.28 (s, 1H), 8.16 (dd, J=8.2, 1.2 Hz, 1H), 7.72 (d, J=7.9 Hz, 1H), 7.55 (t, J=7.9 Hz, 1H), 4.96 (dd, J=8.0, 3.2 Hz, 1H), 3.86 (dd, J=11.2, 3.2 Hz, 1H), 3.67 (dd, J=11.4, 8.2 Hz, 1H), 2.40 ppm (s, 2H); ¹³C NMR (100 MHz, CDCl₃): δ =142.7, 132.2, 129.5, 122.9, 121.1, 73.5, 67.7 ppm; MS (GC/MS) calcd for C₇H₆NO₃⁺ [M-CH₂OH]⁺: 152; found: 152.

Data for 27: R_f =0.38 (silica gel, EtOAc/hexanes, 2:1); IR (film): ν_{max} = 3448, 1636, 1455, 1318, 1075, 594 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ = 7.39–7.36 (m, 4H), 7.30 (m, 1H), 4.69 (d, *J*=4.4 Hz, 1H), 4.03 (dq, *J*= 6.6, 4.4 Hz, 1H), 2.08 (brs, 2H), 1.10 ppm (d, *J*=6.3 Hz, 2H); ¹³C NMR (125 MHz, CDCl₃): δ =140.3, 128.4, 127.8, 126.6, 77.5, 71.3, 17.3 ppm; MS (GC/MS) calcd for C₉H₁₂O₂+ [*M*]+: 152; found: 152.

Data for 29: R_f =0.29 (silica gel, EtOAc/hexanes, 2:1); IR (film): ν_{max} = 3418, 1636, 1491, 1461, 1243, 1075, 1025, 756 cm⁻¹; ¹H NMR (600 MHz, CDCl₃): δ =7.37 (d, J=7.4 Hz, 1H), 7.26 (t, J=7.7 Hz, 1H), 6.96 (t, J=7.4 Hz, 1H), 6.86 (d, J=7.9 Hz, 1H), 5.05 (dd, J=7.9, 3.1 Hz, 1H), 3.83 (s, 1H), 3.79 (m, 1H), 3.66 ppm (dd, J=11.0, 8.3 Hz, 1H); ¹³C NMR (150 MHz, CDCl₃): δ =156.4, 128.8, 128.3, 127.2, 120.8, 110.3, 71.1, 66.5, 55.2 ppm; HRMS (MALDI-FTMS) calcd for C₉H₁₂O₃Na⁺ [*M*+Na]⁺: 191.0679; found: 191.0678.

Data for 31: R_f =0.28 (silica gel, EtOAc/hexanes, 2:1); IR (film): ν_{max} = 3444, 2953, 1636, 1440, 1081, 598 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ = 6.83 (s, 2H), 5.26 (dd, *J*=9.7, 2.6 Hz, 1H), 3.97 (t, *J*=11.2 Hz, 1H), 3.59 (d, *J*=9.1 Hz, 1H), 2.52 (brs, 2H), 2.41 (s, 6H), 2.25 ppm (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ =137.2, 136.6, 132.4, 130.1, 72.6, 64.6, 20.8, 20.7 ppm; HRMS (MALDI-FTMS) calcd for C₁₁H₁₆O₂Na⁺ [*M*+Na]⁺: 203.1042; found: 203.1040.

Data for 33: R_f =0.29 (silica gel, EtOAc/hexanes, 2:1); IR (film): ν_{max} = 3190, 2931, 1089, 1049, 903, 863, 823, 742 cm⁻¹; ¹H NMR (600 MHz, CDCl₃): δ =7.85 (m, 4H), 7.49 (m, 3H), 5.02 (dd, *J*=7.9, 3.5 Hz, 1H), 3.87 (dd, *J*=11.4, 3.5 Hz, 1H), 3.77 ppm (dd, *J*=11.3, 8.3 Hz, 1H); ¹³C NMR (125 MHz, 310 K, CDCl₃): δ =138.0, 133.3, 133.2, 128.4, 128.0, 127.7, 126.3, 126.1, 125.1, 124.0, 74.8, 68.0 ppm; HRMS (MALDI-FTMS) calcd for C₁₂H₁₂O₂Na⁺ [*M*+Na]⁺: 211.0729; found: 211.0727.

Data for 35: R_f =0.46 (silica gel, EtOAc/hexanes, 2:1); IR (film): ν_{max} = 3441, 2953, 1735, 1632, 1453, 1370, 1254, 1119, 1046, 977, 906, 710 cm⁻¹; ¹H NMR (600 MHz, CDCl₃): δ =7.39–7.32 (m, 5H), 4.83 (s, 1H), 3.83 (s, 3H), 1.17 ppm (s, 3H); ¹³C NMR (150 MHz, CDCl₃): δ =176.3, 138.6, 128.3, 128.1, 127.8, 78.0, 77.4, 53.1, 22.1 ppm; HRMS (MALDI-FTMS) calcd for C₁₁H₁₄O₄Na⁺ [*M*+Na]⁺: 233.0784; found: 233.0782.

Data for 37: R_f =0.22 (silica gel, EtOAc/hexanes, 2:1); IR (film): ν_{max} = 3420, 2981, 1736, 1639, 1443, 1381, 1277, 1215, 1163, 1095, 982, 756 cm⁻¹; ¹H NMR (600 MHz, CDCl₃): δ =3.94 (s, 1H), 3.76 (s, 3H), 3.33 (brs, 2H), 1.24 (s, 3H), 1.16 ppm (s, 3H); ¹³C NMR (150 MHz, CDCl₃): δ = 173.4, 72.0, 52.3, 43.1, 25.6, 24.8 ppm; HRMS (MALDI-FTMS) calcd for C₆H₁₂O₄Na⁺ [*M*+Na]⁺: 171.0628; found: 171.0626.

Data for 39: R_f =0.18 (silica gel, EtOAc/hexanes, 2:1); IR (film): ν_{max} = 3389, 2931, 2859, 1643, 1528, 1460, 1346, 1127, 1063 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ =3.68 (brm, 2H), 3.44 (brt, *J*=10.3 Hz, 1H), 2.67 (s, 2H), 1.43–1.33 (brm, 6H), 0.91 ppm (m, 3H); ¹³C NMR (100 MHz, CDCl₃): δ =72.3, 66.7, 32.8, 27.7, 22.7, 14.0 ppm; MS (GC/MS) calcd for C₅H₁₁O⁺ [*M*-CH₂OH]⁺: 87; found: 87.

Data for 41: R_f =0.24 (silica gel, EtOAc/hexanes, 1:1); IR (film): ν_{max} = 3440, 2949, 1643, 1138, 1071, 1027, 658 cm⁻¹; ¹H NMR (500 MHz, CDCl₃, 1:1 mixture of anomers): δ =5.50 (d, *J*=4.8 Hz, 1 H), 4.95 (d, *J*=5.5 Hz, 1 H), 4.92 (s, 1 H), 4.78 (dd, *J*=5.9, 4.4 Hz, 1 H), 3.95–3.87 (m, 3 H), 3.67 (brs, 1 H), 3.52–3.44 (m, 2 H), 3.42–3.35 (m, 2 H), 2.02 (m, 1 H), 1.82 (m, 1 H), 1.57 (m, 2 H), 1.56 (m, 2 H), 1.43 ppm (m, 2 H); ¹³C NMR (125 MHz, CDCl₃, 1:1 mixture of anomers): δ =98.5, 93.4, 70.2, 67.7, 65.1, 61.8, 29.3, 27.3, 24.1, 22.2 ppm; MS (GC/MS) calcd for C₃H₁₀O₃+ [*M*]+: 118; found: 118.

General procedure for the synthesis of CO₂Me-protected sulfamidates: The diol (0.5 mmol, 1.0 equiv) was dissolved in anhydrous THF (5 mL) and methoxycarbonylsulfamoyl-triethylammonium hydroxide (1, 0.293 g, 1.25 mmol, 2.5 equiv) was added at 25°C in a single portion. The resultant solution was immediately warmed to reflux (using a preheated oil bath) and stirred for 2 h. Upon completion, the reaction contents were cooled to 25°C, poured into saturated aqueous NH4Cl (25 mL), and extracted with CH_2Cl_2 (3×20 mL). The combined organic layers were then washed with water (50 mL), dried (MgSO₄), and concentrated. The resultant yellow residue was purified by flash column chromatography (silica gel) in an appropriate solvent system to give the desired product in high purity. Note: although analysis by thin-layer chromatography (TLC) indicated reaction completion after a few minutes, some non-cyclized material (II, Scheme 2) remained at the baseline, and heating for additional time was required to effect complete conversion to product. The use of a preheated oil bath also ensured high yield, as the reaction proceeded slowly at ambient temperature and appeared to have other reaction pathways apart from the desired formation of III.

Data for 6: $R_{\rm f}$ =0.12 (silica gel, EtOAc/hexanes, 1:1); IR (film): $\nu_{\rm max}$ = 2948, 1747, 1555, 1439, 1369, 1322, 1188, 1089, 898, 845, 822, 752, 607, 554 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ =7.51 (d, J=8.1 Hz, 1H), 7.45 (s, 1H), 7.41 (d, J=7.7 Hz, 1H), 7.32 (s, 1H), 7.16 (t, J=7.7 Hz, 1H), 5.47 (s, 2H), 5.34 (s, 1H), 3.93 (brs, 3H), 3.31 (s, 3H), 1.91 (s, 3H), 1.46 ppm (s, 3H); ¹³C NMR (150 MHz, CDCl₃): δ =163.4, 150.4, 137.7, 131.1, 127.3, 126.2, 124.4, 114.1, 110.2, 104.1, 89.5, 78.2, 64.2, 56.5, 55.2, 51.3, 27.1, 24.4 ppm; HRMS (MALDI-FTMS) calcd for C₁₉H₂₁BrN₃O₇S⁺ [M+H]⁺: 514.0278; found: 514.0280.

Data for 8: $R_{\rm f}$ =0.62 (silica gel, EtOAc/hexanes, 1:1); IR (film): $\nu_{\rm max}$ = 2961, 1746, 1612, 1516, 1441, 1380, 1321, 1252, 1189, 1031, 921, 822 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ =7.44 (d, *J*=8.8 Hz, 2H), 7.01 (d, *J*= 6.6 Hz, 2H), 5.38 (dd, *J*=6.3, 3.7 Hz, 1H), 4.98 (dd, *J*=9.2, 6.6 Hz, 1H), 4.54 (dd, *J*=9.6, 4.1 Hz, 1H), 3.91 (s, 3H), 3.89 ppm (s, 3H); ¹³C NMR (125 MHz, CDCl₃): δ =160.3, 150.1, 128.3, 127.8, 114.6, 72.4, 60.7, 55.3, 54.6 ppm; HRMS (MALDI-FTMS) for C₁₁H₁₃NO₆SNa⁺ [*M*+Na]⁺: calcd 310.0356; found: 310.0364.

Data for 10: R_f =0.30 (silica gel, EtOAc/hexanes, 1:1); IR (film): ν_{max} = 2949, 1742, 1634, 1373, 1320, 1192 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ = 7.46 (d, *J*=6.6 Hz, 2H), 7.16 (d, *J*=7.2 Hz, 2H), 5.36 (dd, *J*=6.6, 3.3 Hz, 1H), 4.94 (dd, *J*=9.2, 6.6 Hz, 1H), 4.49 (dd, *J*=9.5, 3.7 Hz, 1H), 3.87 (s, 3H), 2.32 ppm (s, 3H); ¹³C NMR (125 MHz, CDCl₃): δ =169.3, 151.3, 143.1, 134.0, 127.6, 122.6, 72.2, 60.5, 54.8, 21.1 ppm; HRMS (MALDI-FTMS) calcd for C₁₂H₁₃NO₇SNa⁺ [*M*+Na]⁺: 388.0305; found: 338.0304.

Data for 12: R_f =0.79 (silica gel, EtOAc/hexanes, 1:1); IR (film): ν_{max} = 2950, 1750, 1636, 1441, 1383, 1320, 1191, 947, 821 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ =7.45 (s, 1H), 7.26 (s, 2H), 5.35 (dd, *J*=6.6, 3.3 Hz, 1H), 4.94 (dd, *J*=9.2, 6.3 Hz, 1H), 4.50 (dd, *J*=9.2, 3.3 Hz, 1H), 3.87 (s, 3H), 1.33 ppm (s, 18H); ¹³C NMR (125 MHz, CDCl₃) δ =151.9, 150.2, 135.7, 123.4, 120.3, 72.7, 61.6, 54.6, 35.0, 31.4 ppm; MS (ESI) calcd for C₁₈H₂₈NO₅S⁺ [*M*+H]⁺: 370; found: 370.

Data for 14: R_f =0.56 (silica gel, EtOAc/hexanes, 1:1); IR (film): ν_{max} = 2953, 1750, 1654, 1608, 1512, 1442, 1381, 1321, 1231, 1190, 922, 815 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ =7.43 (dd, J=8.5, 4.8 Hz, 2H), 7.12 (t, J=8.8 Hz, 2H), 5.35 (dd, J=6.6, 3.7 Hz, 1H), 4.94 (dd, J=9.2, 6.6 Hz, 1H), 4.46 (dd, J=9.5, 3.3 Hz, 1H), 3.86 ppm (s, 3H); ¹³C NMR (125 MHz, CDCl₃): δ =164.1, 162.1, 150.0, 128.2 (d, J=30.6 Hz), 116.3 (d, J=87.8 Hz), 72.2, 60.4, 54.7 ppm; HRMS (MALDI-FTMS) calcd for C₁₀H₁₀FNO₅SNa⁺ [M+Na]⁺: 298.0156; found: 298.0153.

Data for 16: R_f =0.56 (silica gel, EtOAc/hexanes, 1:1); IR (film): ν_{max} = 2955, 1744, 1654, 1636, 1442, 1380, 1321, 1191 cm⁻¹; ¹H NMR (600 MHz, CDCl₃): δ =7.44–7.40 (m, 5H), 5.36 (dd, *J*=6.6, 3.5 Hz, 1H), 4.95 (dd, *J*=9.2, 6.6 Hz, 1H), 4.49 (dd, *J*=9.7, 4.0 Hz, 1H), 3.86 ppm (s, 3H); ¹³C NMR (150 MHz, CDCl₃): δ =150.1, 136.4, 129.3, 129.2, 126.2, 72.3, 61.0, 54.7 ppm; HRMS (MALDI-FTMS) calcd for C₁₀H₁₁NO₅SNa⁺ [*M*+Na]⁺: 280.0250; found: 250.0253.

Data for 18: R_f =0.66 (silica gel, EtOAc/hexanes, 1:1); IR (film): ν_{max} = 2924, 1747, 1622, 1443, 1384, 1324, 1193, 1117, 1069, 1017, 1002, 923, 822, 771, 665 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ =7.78 (d, *J*=8.1 Hz, 2 H), 7.65 (d, *J*=8.1 Hz, 2 H), 5.49 (dd, *J*=6.3, 3.3 Hz, 1 H), 5.06 (dd, *J*=9.6, 6.6 Hz, 1 H), 4.54 (dd, *J*=9.5, 3.3 Hz, 1 H), 3.96 ppm (s, 3 H); ¹³C NMR (125 MHz, CDCl₃): δ =150.0, 140.4, 126.8, 126.5, 126.4, 71.9, 60.5,

55.0 ppm; HRMS (MALDI-FTMS) calcd for $C_{11}H_{10}F_3NO_5SNa^+$ [*M*+Na]⁺: 348.0124; found: 348.0121.

Data for 20: R_f =0.36 (silica gel, EtOAc/hexanes, 1:1); IR (film): ν_{max} = 2994, 1732, 1643, 1538, 1324, 1192 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ = 8.36 (d, J=8.1 Hz, 1 H), 8.28 (d, J=7.4 Hz, 1 H), 7.87 (t, J=7.7 Hz, 1 H), 7.67 (t, J=7.7 Hz, 1 H), 5.48 (dd, J=6.6, 2.9 Hz, 1 H), 5.02 (dd, J=9.2, 6.6 Hz, 1 H), 4.48 (dd, J=9.3, 6.3 Hz, 1 H), 3.91 ppm (s, 3 H); ¹³C NMR (125 MHz, CDCl₃): δ =150.1, 132.2, 132.0, 130.7, 125.3, 124.4, 121.7, 78.4, 60.2, 55.0 ppm; MS (ESI) calcd for C₁₀H₁₀N₂O₇SNa⁺ [M+Na]⁺: 325; found: 325.

Data for 28: R_f =0.60 (silica gel, EtOAc/hexanes, 1:1); IR (film): ν_{max} = 2977, 1747, 1439, 1375, 1311, 1188, 1136, 1037, 964, 914, 870, 830, 755, 700, 611, 551 cm⁻¹; ¹H NMR (600 MHz, CDCl₃): δ =7.43–7.39 (m, 5H), 4.93 (d, *J*=7.4 Hz, 1H), 4.77 (quin, *J*=6.1 Hz, 1H), 3.80 (s, 3H), 1.61 ppm (d, *J*=6.1 Hz, 3H); ¹³C NMR (150 MHz, CDCl₃): δ =150.3, 135.5, 129.6, 126.8, 82.6, 68.4, 54.6, 17.4 ppm; HRMS (MALDI-FTMS) calcd for C₁₁H₁₃NO₅SNa⁺ [*M*+Na]⁺: 294.0407; found: 294.0402.

Data for 30: R_f =0.58 (silica gel, EtOAc/hexanes, 1:1); IR (film): ν_{max} = 2961, 1747, 1603, 1493, 1441, 1381, 1323, 1249, 1194, 1085, 1025, 1002, 921, 827, 777, 663 cm⁻¹; ¹H NMR (600 MHz, CDCl₃): δ =7.38–7.34 (m, 2H), 7.02 (t, *J*=7.4 Hz, 1H), 6.93 (d, *J*=7.9 Hz, 1H), 5.74 (d, *J*=5.7 Hz, 1H), 4.93 (dd, *J*=9.2, 6.6 Hz, 1H), 4.44 (dd, *J*=9.2, 2.2 Hz, 1H), 3.89 (s, 3H), 3.87 ppm (s, 3H); ¹³C NMR (150 MHz, CDCl₃): δ =155.9, 150.3, 130.1, 125.9, 124.2, 121.1, 110.6, 72.5, 56.7, 55.5, 54.8 ppm; HRMS (MALDI-FTMS) calcd for C₁₁H₃₀NO₆Na⁺ [*M*+Na]⁺: 310.0356; found: 310.0369.

Data for 32: R_f =0.63 (silica gel, EtOAc/hexanes, 1:1); IR (film): ν_{max} = 2954, 1747, 1612, 1442, 1378, 1312, 1190, 1047, 962, 931, 819, 776, 734, 632 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ =6.89 (s, 2H), 5.87 (t, *J*= 8.8 Hz, 1 H), 4.74 (dd, *J*=9.6, 8.1 Hz, 1 H), 4.59 (t, *J*=7.5 Hz, 1 H), 3.84 (s, 3 H), 2.45 (s, 6 H), 2.27 ppm (s, 3 H); ¹³C NMR (125 MHz, CDCl₃): δ = 150.6, 138.9, 136.8, 136.6, 126.3, 68.4, 57.3, 54.6, 20.8, 20.2 ppm; MS (ESI) calcd for C₁₄H₁₇NO₅S⁺ [*M*+H]⁺: 300; found: 300.

Data for 34: R_f =0.59 (silica gel, EtOAc/hexanes, 1:1); IR (film): ν_{max} = 2961, 1740, 1435, 1376, 1317, 1188, 1000, 923, 812, 753 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ =7.94–7.85 (m, 4H), 7.56–7.52 (m, 3H), 5.53 (dd, J=6.6, 3.7 Hz, 1H), 5.00 (dd, J=9.6, 7.0 Hz, 1H), 4.56 (dd, J=9.6, 4.0 Hz, 1H), 3.85 ppm (s, 3H); ¹³C NMR (125 MHz, CDCl₃): δ =150.2, 133.6, 133.5, 133.1, 129.6, 128.2, 127.8, 126.9, 126.8, 126.1, 123.0, 72.1, 61.2, 54.7 ppm; HRMS (MALDI-FTMS) calcd for C₁₄H₁₃NO₅SNa⁺ [*M*+Na]⁺: 330.0407; found: 330.0409.

Data for 36: R_f =0.40 (silica gel, EtOAc/hexanes, 1:1); IR (film): ν_{max} = 2966, 1746, 1441, 1376, 1311, 1194, 1135, 1059, 959, 918, 841, 765, 694 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ =7.43 (m, 2H), 7.36 (m, 3H), 5.23 (s, 1H), 3.86 (s, 3H), 3.31 (s, 3H), 2.11 ppm (s, 3H); ¹³C NMR (125 MHz, CDCl₃): δ =163.3, 150.0, 134.3, 129.8, 128.9, 127.8, 88.7, 69.7, 55.1, 53.1, 23.9 ppm; HRMS (MALDI-FTMS) calcd for C₁₃H₁₅NO₇SNa⁺ [*M*+Na]⁺: 352.0461; found: 352.0474.

Data for 38: R_f =0.65 (silica gel, EtOAc/hexanes, 1:1); IR (film): ν_{max} = 2955, 1749, 1588, 1443, 1378, 1321, 1227, 1177, 1115, 1049, 976, 837, 643 cm⁻¹; ¹H NMR (600 MHz, CDCl₃): δ =5.32 (s, 1H), 3.93 (s, 3H), 3.85 (s, 3H), 1.56 ppm (s, 3H); ¹³C NMR (150 MHz, CDCl₃): δ = 164.9, 158.6, 83.4, 59.2, 53.5, 25.3, 19.3 ppm; MS (ESI) calcd for C₈H₁₃NO₇SNa⁺ [*M*+Na]⁺: 290; found: 290.

Data for 40: R_f =0.60 (silica gel, EtOAc/hexanes, 1:1); IR (film): ν_{max} = 2948, 1747, 1444, 1375, 1328, 1194, 985, 851, 764 cm⁻¹; ¹H NMR (600 MHz, CDCl₃): δ =4.86 (m, 1H), 4.12 (dd, J=10.1, 4.8 Hz, 1H), 3.91 (s, 3H), 3.73 (t, J=9.7 Hz, 1H), 1.95 (m, 1H), 1.78 (m, 1H), 1.47 (m, 1H), 1.40 (m, 3H), 0.94 ppm (t, J=5.0 Hz, 3H); ¹³C NMR (150 MHz, CDCl₃): δ =150.7, 80.5, 54.8, 51.0, 32.3, 26.8, 22.3, 13.9 ppm; HRMS (MALDI-FTMS) calcd for C₈H₁₅NO₅SNa⁺ [M+Na]⁺: 260.0563; found: 260.0556.

Data for 42: R_f =0.15 (silica gel, EtOAc/hexanes, 1:1); IR (film): ν_{max} = 2962, 1749, 1443, 1380, 1327, 1295, 1182, 1123, 1071, 965, 899, 877, 831, 603, 560 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ =5.50 (d, *J*=2.6 Hz, 1 H), 4.83 (q, *J*=3.0 Hz, 1 H), 4.02 (m, 1 H), 3.91 (s, 3 H), 3.58 (ddd, *J*=13.2, 10.3, 3.3 Hz, 1 H), 2.36 (dt, *J*=13.2, 2.2 Hz, 1 H), 2.01–1.85 (m, 2 H), 1.60 ppm (m, 1 H); ¹³C NMR (125 MHz, CDCl₃): δ =149.5, 81.9, 76.6, 63.4, 54.6, 23.8, 17.6 ppm; HRMS (MALDI-FTMS) calcd for C₇H₁₁NO₆SNa⁺ [*M*+Na]⁺: 260.0199; found: 260.0200.

General procedure for the synthesis of alternative Burgess reagents 48– 51: A solution of the appropriate alcohol (105 mmol, 1.05 equiv) in CH_2Cl_2 (25 mL) was added over the course of 30 minutes to a solution of chlorosulfonylisocyanate (8.71 mL, 100 mmol, 1.0 equiv) in CH_2Cl_2 (25 mL) at 0°C. Once the addition was complete, the reaction contents were concentrated directly to give the desired sulfamoyl chloride intermediate (44–47) as a white solid. Pressing forward without any additional purification steps, a solution of the newly formed sulfamoyl chloride (20.0 mmol, 1.0 equiv) in benzene (40 mL) was added dropwise to a solution of Et_3N (6.27 mL, 45 mmol, 2.25 equiv) in benzene (25 mL) at 25°C. After the addition was complete (-1 hour), the triethylammonium hydrochloride precipitate was removed by filtration, and the filtrate was concentrated to give 48–51 as clear oils which solidified upon standing.

Cbz-protected Burgess-type reagent 48: $R_{\rm f}$ =0.03 (silica gel, EtOAc); IR (film): $\nu_{\rm max}$ =2985, 1688, 1455, 1376, 1330, 1255, 1097, 853, 786, 740, 700, 598, 548 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ =7.41–7.28 (m, 5H), 5.13 (s, 2H), 3.44 (q, *J*=7.4 Hz, 6H), 1.39 ppm (t, *J*=7.4 Hz, 9H); ¹³C NMR (125 MHz, CDCl₃): δ =157.5, 136.3, 128.4, 128.2, 128.0, 67.9, 50.4, 9.4 ppm; MS (ESI) calcd for C₁₄H₂₂N₂O₄SNa⁺ [*M*+Na]⁺: 337; found: 337.

o-NO₂-Cbz-protected Burgess-type reagent 49: R_f =0.03 (silica gel, EtOAc); IR (film): ν_{max} =3516, 1697, 1527, 1485, 1341, 1246, 1100, 1060, 856, 730, 600, 548 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ =7.99 (d, J=8.0 Hz, 1H), 7.61 (d, J=7.6 Hz, 1H), 7.55 (t, J=7.6 Hz, 1H), 7.36 (t, J=7.6 Hz, 1H), 5.42 (s, 2H), 3.38 (q, J=7.0 Hz, 6H), 1.32 ppm (t, J=7.3 Hz, 9H); ¹³C NMR (100 MHz, CDCl₃): δ =157.0, 133.8, 132.9, 129.0, 128.5, 128.3, 124.8, 64.5, 50.6, 9.3 ppm; MS (ESI) calcd for C₁₄H₂₂N₃O₆S⁺ [*M*+H]⁺: 360; found: 360.

Alloc-protected Burgess-type reagent 50: $R_{\rm f}$ =0.03 (silica gel, EtOAc); IR (film): $\nu_{\rm max}$ =2995, 2948, 1693, 1457, 1332, 1161, 1098, 970, 859, 788, 714, 597, 548 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ =5.91 (m, 1H), 5.30 (d, J=16.2 Hz, 1H), 5.18 (d, J=10.3 Hz, 1H), 4.54 (s, 2H), 3.45 (q, J= 7.4 Hz, 6H), 1.39 ppm (t, J=7.0 Hz, 9H); ¹³C NMR (125 MHz, CDCl₃): δ =157.2, 132.5, 117.9, 66.6, 50.5, 9.3 ppm; MS (ESI) calcd for C₁₀H₂₁N₂O₄S⁺ [*M*+H]⁺: 265; found: 265.

Troc-protected Burgess-type reagent 51: R_f =0.03 (silica gel, EtOAc); IR (film): ν_{max} =2950, 1702, 1457, 1368, 1339, 1254, 1111, 1059, 857, 816, 716, 605, 548 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ =4.75 (s, 2 H), 3.48 (q, *J*=7.4 Hz, 6 H), 1.43 ppm (t, *J*=7.3 Hz, 9 H); ¹³C NMR (100 MHz, CDCl₃): δ =156.0, 95.4, 75.3, 50.7, 9.3 ppm; MS (ESI) calcd for C₉H₁₈Cl₃N₂O₄S⁺ [*M*+H]⁺: 355; found: 355.

General procedure for synthesizing sulfamidates with alternate protection: The diol (0.5 mmol, 1.0 equiv) was dissolved in anhydrous THF (5 mL) and the appropriate Burgess-type reagent (**48–51**, 1.25 mmol, 2.5 equiv) was added at 25 °C in a single portion. The resultant solution was immediately warmed to reflux (using a preheated oil bath) and stirred for 2 h. Upon completion, the reaction contents were cooled to 25 °C, poured into saturated aqueous NH₄Cl (25 mL), and extracted with CH₂Cl₂ (3×20 mL). The combined organic layers were then washed with water (50 mL), dried (MgSO₄), and concentrated. The resultant yellow residue was purified by flash column chromatography (silica gel) in an appropriate solvent system to give the desired product in high purity.

Data for 52: R_f =0.49 (silica gel, EtOAc/hexanes, 1:1); IR (film): ν_{max} = 2998, 1740, 1612, 1516, 1381, 1306, 1252, 1192, 1030, 974, 808, 750 cm⁻¹; ¹H NMR (600 MHz, CDCl₃): δ =7.33–7.30 (m, 5H), 7.25 (m, 2H), 6.90 (d, *J*=8.8 Hz, 2H), 5.28 (dd, *J*=6.6, 4.4 Hz, 1H), 5.21 (AB, *J*=12.3 Hz, ν_{ab} =59.2 Hz, 2H), 4.87 (dd, *J*=9.2, 6.5 Hz, 1H), 4.44 (dd, *J*=9.2, 4.4 Hz, 1H), 3.81 ppm (s, 3H); ¹³C NMR (150 MHz, CDCl₃): δ =161.2, 150.4, 135.2, 129.4, 129.3, 129.2, 128.8, 128.7, 115.5, 73.1, 70.2, 61.6, 56.2 ppm; HRMS (MALDI-FTMS) calcd for C₁₇H₁₇NO₆SNa⁺ [*M*+Na]⁺: 386.0669; found: 386.0666.

Data for 53: R_f =0.51 (silica gel, EtOAc/hexanes, 1:1); IR (film): ν_{max} = 2974, 1746, 1637, 1457, 1377, 1306, 1195, 1136, 1065, 847, 764, 700 cm⁻¹; ¹H NMR (600 MHz, CDCl₃): δ =7.41–7.23 (m, 10H), 5.23 (AB, *J*= 12.2 Hz, ν_{ab} =65.8 Hz, 2H), 5.21 (s, 1H), 3.29 (s, 3H), 2.08 ppm (s, 3H); ¹³C NMR (150 MHz, CDCl₃): δ =167.0, 150.1, 134.9, 130.5, 129.6, 129.5, 128.6, 128.4, 89.2, 70.5, 70.3, 53.7, 24.6 ppm; HRMS (MALDI-FTMS) calcd for C₁₉H₁₉NO₇SNa⁺: [*M*+Na]⁺ 428.0774; found: 428.0780.

Data for 54: R_f =0.36 (silica gel, EtOAc/hexanes, 1:1); IR (film): ν_{max} = 2967, 1746, 1603, 1529, 1493, 1464, 1383, 1345, 1317, 1250, 1194, 1025,

Chem. Eur. J. 2004, 10, 5581-5606 www.chemeurj.org © 2004 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim

- 5595

921, 815, 729 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ = 8.15 (d, *J* = 8.1 Hz, 1H), 7.81–7.62 (brm, 2H), 7.51 (t, *J* = 8.4 Hz, 1H), 7.38 (d, *J* = 7.0 Hz, 1H), 7.36 (t, *J* = 8.1 Hz, 1H), 7.01 (t, *J* = 7.7 Hz, 1H), 6.94 (d, *J* = 8.1 Hz, 1H), 5.82–5.79 (m, 2H), 5.69 (brm, 1H), 4.99 (dd, *J* = 9.2, 6.3 Hz, 1H), 4.50 (dd, *J* = 9.2, 2.6 Hz, 1H), 3.87 ppm (s, 3H); ¹³C NMR (150 MHz, CDCl₃): δ = 155.9, 149.0, 146.6, 134.3, 131.3, 130.2, 128.8, 128.2, 125.8, 125.1, 123.8, 121.1, 110.7, 72.6, 66.0, 56.6, 55.5 ppm; HRMS (MALDI-FTMS) calcd for C₁₇H₁₂N₂O₈SNa⁺ [*M*+Na]⁺: 431.0520; found: 431.0530.

Data for 55: R_f =0.50 (silica gel, EtOAc/hexanes, 1:1); IR (film): ν_{max} = 2969, 1740, 1612, 1528, 1381, 1301, 1193, 962, 814, 730, 633 cm⁻¹; ¹H NMR (600 MHz, CDCl₃): δ =8.15 (d, *J*=7.9 Hz, 1H), 7.64–7.57 (m, 2H), 7.50 (t, *J*=7.9 Hz, 1H), 6.87 (s, 2H), 5.92 (t, *J*=8.8 Hz, 1H), 5.68 (AB, *J*=12.8 Hz, ν_{ab} =15.3 Hz, 2H), 4.77 (t, *J*=8.3 Hz, 1H), 4.64 (t, *J*= 9.2 Hz, 1H), 2.43 (s, 6H), 2.26 ppm (s, 3H); ¹³C NMR (150 MHz, CDCl₃): δ =163.1, 149.4, 146.5, 139.1, 134.3, 131.1, 128.8, 128.3, 128.0, 126.0, 125.1, 68.6, 66.0, 57.4, 20.8, 20.3 ppm; MS (ESI) calcd for C₁₉H₂₀N₂O₇SNa⁺ [*M*+Na]⁺: 443; found: 443.

Data for 56: R_f =0.43 (silica gel, EtOAc/hexanes, 1:1); IR (film): ν_{max} = 2945, 1745, 1603, 1494, 1464, 1380, 1314, 1249, 1193, 1025, 925, 826, 757 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ =7.37 (t, *J*=7.7 Hz, 1 H), 7.34 (d, *J*=7.7 Hz, 1 H), 7.02 (t, *J*=7.3 Hz, 1 H), 6.93 (d, *J*=8.4 Hz, 1 H), 5.89 (m, 1H), 5.76 (dd, *J*=6.3, 2.2 Hz, 1 H), 5.37 (brm, 1H), 5.27 (d, *J*= 10.3 Hz, 1 H), 4.94 (dd, *J*=9.2, 6.2 Hz, 1 H), 4.75 (ddd, *J*=25.3, 13.2, 5.1 Hz, 2 H), 4.45 (dd, *J*=9.2, 2.2 Hz, 1 H), 3.87 ppm (s, 3 H); ¹³C NMR (125 MHz, CDCl₃): δ =155.9, 149.4, 130.5, 130.0, 125.8, 124.1, 121.0, 119.1, 110.6, 72.4, 68.1, 56.5, 55.4 ppm; HRMS (MALDI-FTMS) calcd for C₁₃H₁₅NO₆SNa⁺ [*M*+Na]⁺: 336.0512; found: 336.0515.

Data for 57: R_f =0.56 (silica gel, EtOAc/hexanes, 1:1); IR (film): ν_{max} = 2953, 1740, 1649, 1381, 1305, 1192, 964, 819, 767, 632 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ =6.89 (s, 2H), 5.87 (dd, *J*=8.8, 8.1 Hz, 1H), 5.82 (m, 1H), 5.31 (d, *J*=16.9 Hz, 1H), 5.24 (dd, *J*=10.6, 1.1 Hz, 1H), 4.75–4.71 (m, 2H), 4.66 (m, 1H), 4.58 (t, *J*=9.2 Hz, 1H), 2.44 (s, 6H), 2.27 ppm (s, 3H); ¹³C NMR (125 MHz, CDCl₃): δ =158.1, 149.9, 138.9, 136.8, 130.4, 126.3, 119.2, 68.3, 68.0, 57.3, 20.8, 20.3 ppm; MS (ESI) calcd for C₁₅H₁₉NO₅SNa⁺ [*M*+Na]⁺: 348; found: 348.

Data for 58: R_f =0.48 (silica gel, EtOAc/hexanes, 1:1); IR (film): ν_{max} = 2954, 1749, 1455, 1373, 1306, 1189, 1131, 1060, 931, 849, 760, 696, 549 cm⁻¹; ¹H NMR (600 MHz, CDCl₃): δ =7.45 (m, 2H), 7.36 (m, 2H), 5.86 (m, 1H), 5.34 (d, *J*=17.1 Hz, 1H), 5.25 (d, *J*=10.6 Hz, 1H), 5.24 (s, 1H), 4.73 (ABX, *J*=13.6, 5.7 Hz, ν_{ab} =39.5 Hz, 2H), 3.32 (s, 3H), 2.11 ppm (s, 3H); ¹³C NMR (150 MHz, CDCl₃): δ =166.4, 149.4, 134.6, 130.6, 129.8, 128.9, 127.9, 119.5, 88.6, 69.9, 68.7, 53.0, 24.1 ppm; HRMS (MALDI-FTMS) calcd for C₁₅H₁₇NO₇SNa⁺ [*M*+Na]⁺: 378.0618; found: 378.0612.

Data for 59: R_f =0.47 (silica gel, EtOAc/hexanes, 1:1); IR (film): ν_{max} = 2966, 1754, 1603, 1494, 1464, 1384, 1316, 1250, 1196, 1149, 1025, 924, 830, 752 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ =7.40 (d, J=7.3 Hz, 1H), 7.36 (dd, J=7.7, 1.5 Hz, 1H), 7.02 (t, J=7.3 Hz, 1H), 6.93 (d, J=8.5 Hz, 1H), 5.84 (dd, J=6.3, 2.6 Hz, 1H), 4.98 (dd, J=9.2, 6.3 Hz, 1H), 4.86–4.78 (m, 2H), 4.48 (dd, J=9.2, 2.6 Hz, 1H), 3.87 ppm (s, 3H); ¹³C NMR (125 MHz, CDCl₃): δ =156.0, 148.3, 130.2, 126.0, 123.6, 121.1, 110.6, 75.7, 72.4, 56.6, 55.5, 43.3 ppm; MS (ESI) calcd for C₁₂H₁₃Cl₃NO₆S⁺ [*M*+H]⁺: 404; found: 404.

Data for 60: R_f =0.30 (silica gel, EtOAc/hexanes, 1:2); IR (film): ν_{max} = 2938, 1750, 1376, 1315, 1270, 1198, 1137, 1098, 902, 830, 752, 607 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ =7.52 (d, J=9.7 Hz, 1H), 7.44 (s, 1H), 7.42 (d, J=8.8 Hz, 1H), 7.35 (s, 1H), 7.17 (t, J=9.7 Hz, 1H), 5.48 (s, 2H), 5.39 (s, 2H), 4.97 (d, J=14.1 Hz, 1H), 4.78 (brs, 1H), 3.30 (s, 3H), 1.95 (s, 3H), 1.50 ppm (s, 3H); ¹³C NMR (125 MHz, CDCl₃): δ =156.3, 148.6, 147.1, 137.7, 131.1, 127.3, 126.3, 126.1, 124.4, 114.1, 110.2, 104.1, 93.8, 89.7, 78.2, 76.2, 64.3, 56.5, 27.2, 24.5; HRMS (MALDI-FTMS) calcd for C₂₀H₂₀BrCl₃N₃O₇SNa⁺ [*M*+Na]⁺: 629.9265; found: 629.9263.

General procedure for synthesizing 1,2-aminoalcohols from sulfamidates: The desired substrate (0.05 mmol, 1.0 equiv) was dissolved in 4 M aqueous HCl/1,4-dioxane (1:1, 1 mL), and the resultant solution was stirred at 25 °C until complete conversion was observed by TLC (~10–12 h). Once finished, the reaction mixture was poured into EtOAc (10 mL), washed with 5% aqueous NaHCO₃ (10 mL) and brine (10 mL), dried (MgSO₄), and concentrated to give the desired 1,2-aminoalcohol in high purity.

Data for 61: $R_{\rm f}$ =0.53 (silica gel, EtOAc/hexanes, 1:1); IR (film): $\nu_{\rm max}$ = 3204, 1694, 1537, 1438, 1265, 1053, 833, 750 cm⁻¹; ¹H NMR (600 MHz, CDCl₃): δ =7.87–7.84 (m, 3H), 7.79 (brs, 1H), 7.50 (m, 2H), 7.42 (brd, J=8.3 Hz, 1H), 5.47 (brs, 1H), 5.25 (brs, 1H), 3.72 (s, 3H), 2.16 ppm (m, 2H); ¹³C NMR (125 MHz, CDCl₃): δ =156.3, 136.0, 133.2, 133.0, 128.7, 128.0, 127.7, 126.5, 126.3, 125.6, 124.2, 55.7, 52.5, 47.9 ppm; MS (GC/MS) calcd for C₁₄H₁₃NO₂+ [*M*–H₂O]⁺: 227; found: 227.

Data for 62: R_f =0.59 (silica gel, EtOAc/hexanes, 1:1); IR (film): ν_{max} = 3418, 2966, 1698, 1534, 1452, 1376, 1254, 1192, 1058, 852, 776, 703 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ =6.85 (s, 2H), 5.42 (brs, 1H), 5.24 (brs, 2H), 3.89 (t, *J*=9.9 Hz, 1H), 3.73 (dd, *J*=11.4, 6.6 Hz, 1H), 3.68 (s, 3H), 2.42 (s, 6H), 2.25 ppm (s, 3H); ¹³C NMR (125 MHz, CDCl₃): δ =156.5, 137.6, 136.0, 131.7, 130.5, 52.4, 46.2, 44.8, 20.9, 20.7 ppm; MS (GC/MS) calcd for C₁₂H₁₆NO₂+ [*M*-OMe]⁺: 206; found: 206.

Data for 63: R_f =0.68 (silica gel, EtOAc/hexanes, 1:2); IR (film): ν_{max} = 3431, 2987, 1697, 1642, 1535, 1453, 1252, 1091, 702 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ =7.37–7.31 (m, 5H), 5.54 (brs, 1H) 4.93 (brs, 1H), 4.46 (brs, 1H), 3.68 (s, 3H), 1.38 ppm (d, *J*=6.6 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃): δ =156.1, 137.0, 128.3, 128.1, 127.9, 60.8, 59.6, 52.4, 21.6 ppm; GC-MS (ESI) calcd for C₉H₉NO₂⁺ [*M*-CH₃CH₂OH]⁺: 164; found: 164.

Data for 64: R_f =0.72 (silica gel, EtOAc/hexanes, 1:2); IR (film): ν_{max} = 3349, 2958, 1698, 1643, 1535, 1463, 1259, 614 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ =5.13 (brs, 1H), 3.99 (t, J=4.1 Hz, 1H), 3.69 (s, 3H), 3.64 (ddd, J=14.7, 7.3, 3.3 Hz, 1H), 3.24 (ddd, J=14.0, 8.1, 5.5 Hz, 1H), 1.74 (m, 1H), 1.68 (m, 1H), 1.53 (m, 1H), 1.44–1.30 (m, 3H), 0.91 ppm (t, J=7.3 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃): δ =157.0, 63.2, 52.3, 47.5, 35.2, 28.4, 22.1, 13.9 ppm; GC-MS (ESI) calcd for C₃H₆NO₂+ [M-CH₃CH₂CH₂CHOH]⁺: 88; found: 88.

Data for 65: R_f =0.56 (silica gel, EtOAc/hexanes, 1:1); IR (film): ν_{max} = 3332, 2956, 1693, 1611, 1513, 1462, 1294, 1248, 1179, 1036, 831, 740, 698 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ =7.40–7.29 (m, 5H), 7.24 (d, *J* = 8.4 Hz, 2H), 6.90 (d, *J*=8.4 Hz, 1H), 5.35 (brs, 1H), 5.12 (AB, *J*= 12.1 Hz, ν_{ab} =16.9 Hz, 2H), 5.03 (brs, 1H), 3.85 (m, 2H), 3.81 ppm (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ =159.4, 155.6, 136.1, 130.6, 128.5, 128.2, 128.1 (2C), 127.7, 114.1, 114.0, 67.1, 55.3, 55.1, 47.9 ppm; MS (GC/MS) calcd for C₁₇H₁₇NO₃+ [*M*-H₂O]+: 283; found: 283.

Data for 66: $R_{\rm f}$ =0.48 (silica gel, EtOAc/hexanes, 1:1); IR (film): $\nu_{\rm max}$ = 3417, 3342, 2955, 1712, 1609, 1523, 1463, 1344, 1244, 1050, 756, 731 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ =8.10 (d, *J*=8.1 Hz, 1 H), 7.63 (m, 2 H), 7.47 (t, *J*=7.0 Hz, 1 H), 7.32 (t, *J*=7.0 Hz, 1 H), 7.26 (d, *J*=8.7 Hz, 1 H), 6.98 (t, *J*=7.7 Hz, 1 H), 6.93 (d, *J*=8.5 Hz, 1 H), 5.94 (d, *J*=9.2 Hz, 1 H), 5.54 (AB, *J*=15.0 Hz, $\nu_{\rm ab}$ =31.2 Hz, 2 H), 5.22 (dt, *J*=9.2, 6.3 Hz, 1 H), 3.89 (s, 3 H), 3.85 ppm (d, *J*=5.5 Hz, 2 H); ¹³C NMR (125 MHz, CDCl₃): δ =156.7, 155.2, 133.7, 133.1, 129.5, 129.1, 128.8, 128.5, 125.8, 124.9, 120.8, 110.9, 63.5, 55.4, 54.2, 46.5 ppm; MS (GC/MS) calcd for C₁₆H₁₅N₂O₅⁺ [*M*-OMe]⁺: 315; found: 315.

Data for 67: R_f =0.56 (silica gel, EtOAc/hexanes, 1:1); IR (film): ν_{max} = 3318, 1682, 1643, 1539, 1484, 1235, 1049, 932, 752 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ =7.30 (dt, *J*=8.1, 1.5 Hz, 1H), 7.25 (d, *J*=7.3 Hz, 1H), 6.97 (t, *J*=7.7 Hz, 1H), 6.91 (d, *J*=8.1 Hz, 1H), 5.92 (m, 1H), 5.80 (d, *J*=8.8 Hz, 1H), 5.32 (d, *J*=16.5 Hz, 1H), 5.22 (m, 2H), 4.59 (m, 2H), 3.88 (s, 3H), 3.84 ppm (d, *J*=5.9 Hz, 2H); ¹³C NMR (125 MHz, CDCl₃): δ =156.7, 132.7, 129.4, 129.2, 126.1, 120.8, 118.0, 110.8, 65.8, 55.3, 54.0, 46.6 ppm; MS (GC/MS) calcd for C₁₂H₉NO₃⁺ [*M*-OMe]⁺: 220; found: 220.

Data for 68: R_f =0.68 (silica gel, EtOAc/hexanes, 1:1); IR (film): ν_{max} = 3435, 1716, 1636, 1497, 1244, 1033, 721 cm⁻¹; ¹H NMR (600 MHz, CDCl₃): δ =7.38 (t, *J*=7.4 Hz, 1H), 7.27 (m, 1H), 6.98 (t, *J*=7.4 Hz, 1H), 6.93 (d, *J*=8.3 Hz, 1H), 6.93 (d, *J*=8.3 Hz, 1H), 6.00 (d, *J*=8.8 Hz, 1H), 5.23 (dd, *J*=15.3, 6.1 Hz, 1H), 4.75 (AB, *J*=11.9 Hz, ν_{ab} =39.1 Hz, 2H), 3.91 (s, 3H), 3.86 ppm (dd, *J*=6.6, 2.6 Hz, 2H); ¹³C NMR (150 MHz, CDCl₃): δ =156.7, 154.0, 129.6, 129.0, 125.5, 120.9, 110.9, 74.6, 55.4, 54.3, 46.3 ppm; MS (GC/MS) calcd for C₁₁H₁₁Cl₃NO₃⁺ [*M*-OMe]⁺: 310; found: 310.

3,4,6-Tri-O-benzyl-D-glucosyldiol (69): 4-Methylmorpholine *N*-oxide (0.351 g, 3.0 mmol, 3.0 equiv) and OsO_4 (0.641 mL, 2.5 wt% in *t*BuOH, 0.05 mmol, 0.05 equiv) were added sequentially at 25 °C to a solution of 3,4,6-tri-O-benzyl-D-glucal (0.417 g, 1.0 mmol, 1.0 equiv) in THF/tBuOH/ H₂O (7:3:1, 5 mL), and the resulting orange solution was stirred for 12 h

at 25°C. Upon completion, the reaction contents were then diluted with water (10 mL), treated with Na₂SO₃ (0.630 g, 5.0 mmol, 5.0 equiv), and allowed to stir for an additional 2 h at 25 °C. Once this operation was complete, the reaction mixture was poured into water (10 mL) and extracted with EtOAc (3×25 mL). The combined organic layers were then washed with water (2×15 mL), dried (MgSO₄), and concentrated. The resultant light yellow solid was purified by flash column chromatography (silica gel, EtOAc/hexanes, 1:1) to give diol 69 (0.414 g, 92 %) as an amorphous white solid. $R_{\rm f} = 0.13$ (silica gel, EtOAc/hexanes, 1:1); IR (film): $v_{\rm max} =$ 3410, 2938, 1452, 1390, 1190, 1080, 886, 590 cm⁻¹; ¹H NMR (500 MHz, CDCl₃, 1:1 mixture of anomers): $\delta = 7.38-7.10$ (m, 30H), 5.18 (d, J =4.8 Hz, 1 H), 4.81 (s, 2 H), 4.75 (d, J=13.9 Hz, 2 H), 4.54-4.49 (m, 3 H), 4.47 (appt, J=5.5 Hz, 3 H), 4.43 (d, J=3.3 Hz, 1 H), 4.01 (t, J=6.4 Hz, 1 H), 3.98 (d, J = 6.2 Hz, 1 H), 3.74 (app t, J = 11.4 Hz, 1 H), 3.63–3.58 (m, 3H), 3.51-3.46 ppm (m, 2H); ¹³C NMR (125 MHz, CDCl₃, 1:1 mixture of anomers): $\delta = 138.5, 138.4, 138.0, 137.8, 137.6, 128.5, 128.4, 128.0, 127.9,$ 127.8, 127.7, 96.7, 92.3, 84.3, 82.5, 77.6, 77.5, 75.5, 75.3, 74.8, 73.4, 72.7, 70.4, 68.7 ppm; HRMS (MALDI-FTMS) calcd for $C_{27}H_{30}O_6Na^+$ [M+Na]+: 473.1934; found: 473.1925.

3,4,6-Tri-*O***-TBS-D-glucosyldiol (73)**: 3,4,6-Tri-*O*-TBS-β-D-glucal (0.416 g, 1.0 mmol, 1.0 equiv) was dihydroxylated in a manner similar to the preparation of **71** to give diol **73** (0.391 g, 87% yield) as a white amorphous solid. **73**: R_f =0.32 (silica gel, EtOAc/hexanes, 1:1); IR (film): v_{max} =3446, 2931, 2858, 1472, 1255, 1095, 837 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ = 4.96 (d, *J*=12.1 Hz, 1H), 4.03 (m, 3H), 4.00 (d, *J*=9.2 Hz, 1H), 3.93 (appt, *J*=7.7 Hz, 1H), 3.83 (dd, *J*=9.6, 6.3 Hz, 1H), 3.80 (m, 1H), 3.71 (d, *J*=11.0 Hz, 1H), 3.40 (dd, *J*=11.0, 3.7 Hz, 1H), 0.88 (s, 9H), 0.87 (s, 9H), 0.86 (s, 9H), 0.11 (s, 3H), 0.10 (s, 3H), 0.09 (apps, 6H), 0.03 (s, 3H), 0.02 ppm (s, 3H); ¹³C NMR (125 MHz, CDCl₃): δ =87.7, 80.9, 71.5, 70.9, 68.2, 61.3, 25.8, 25.6 (2C), 18.1, 17.8, 14.1, -4.8, -5.0, -5.1, -5.2, -5.4 ppm (2C); HRMS (MALDI-FTMS) calcd for C₂₄H₅₄O₆Si₃Na⁺ [*M*+Na]⁺: 545.3120; found: 545.3110.

3,4-Di-O-benzyl-L-rhamnosyldiol (75): 4-O-Benzyl-L-rhamnal (0.220 g, 1.0 mmol, 1.0 equiv) was dissolved in DMF (5 mL) and treated with NaH (0.400 g, 60% dispersion in mineral oil, 2.0 mmol, 2.0 equiv) at 25 °C. After stirring the resultant solution for 5 minutes at 25°C, the reaction contents were cooled to 0°C and benzyl bromide (0.238 mL, 2.0 mmol, 2.0 equiv) was added dropwise over the course of 10 minutes. The reaction mixture was then warmed to 25°C over the course of 30 minutes. Upon completion, the reaction mixture was poured into 1 N aqueous HCl (10 mL) and extracted with Et₂O (3×25 mL). The combined organic layers were then washed with water (2×15 mL), dried (MgSO₄), and concentrated. The resultant light yellow solid was purified by flash column chromatography (silica gel, Et₂O) to give the desired di-O-benzylated-Lrhamnal intermediate (0.292 g, 94%) as an amorphous white solid. This compound was then dihydroxylated in a manner similar to the preparation of 71 to give diol 75 (0.314 g, 91% yield) as a white amorphous solid. $R_{\rm f} = 0.40$ (silica gel, EtOAc/hexanes, 1:1); IR (film): $\nu_{\rm max} = 3388$, 2870, 1645, 1453, 1363, 1091, 994, 734, 694 $\rm cm^{-1};\ ^1H\ NMR$ (500 MHz, CDCl₃, 1:1 mixture of anomers): $\delta = 7.40-7.32$ (m, 20H), 5.34 (d, J =3.0 Hz, 1 H), 4.98 (d, J=2.6 Hz, 1 H), 4.95 (d, J=2.6 Hz, 1 H), 4.77 (br d, J=8.4 Hz, 1 H), 4.71-4.62 (m, 5 H), 4.04 (m, 2 H), 3.64 (ddd, J=13.1, 8.5, 4.8 Hz, 1H), 3.40 (dd, J=9.6, 6.3 Hz, 1H), 3.21 (brs, 1H), 3.15 (dt, J= 8.7, 3.7 Hz, 1 H), 2.60 (brs), 2.43 (ddd, J=12.5, 5.2, 2.2 Hz, 1 H), 2.32 (ddd, J=13.2, 5.2, 1.5 Hz, 1 H), 1.74 (m, 1 H), 1.43 (m, 1 H), 1.35 (d, J= 6.3 Hz, 3 H), 1.28 ppm (d, J=6.3 Hz, 3 H); ¹³C NMR (125 MHz, CDCl₃, 1:1 mixture of anomers): δ=138.6, 138.5, 138.3, 138.2, 128.4 (3 C), 128.3, 128.0 (2C), 127.7 (2C), 127.6 (2C), 93.8, 92.0, 84.3, 83.4, 78.9, 76.8, 75.2 (2C), 71.8 (2C), 71.5, 71.4, 67.4, 38.3, 37.7, 18.2 ppm (2C); MS (ESI) calcd for C₂₀H₂₂O₄+ [M-H₂O]+: 327; found: 327.

3,4,6-Tri-*O***-benzyl-D-galactosyldiol (77)**: 3,4,6-Tri-*O*-benzyl-β-D-galactal (0.417 g, 1.0 mmol, 1.0 equiv) was dihydroxylated in a manner similar to the preparation of **71** to give diol **77** (0.379 g, 91% yield) as a white amorphous solid. $R_{\rm f}$ =0.13 (silica gel, EtOAc/hexanes, 1:1); IR (film): $\nu_{\rm max}$ =3401, 2919, 2861, 1455, 1361, 1085, 738, 691 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ =7.41–7.26 (m, 15H), 5.31 (d, *J*=3.5 Hz, 1H), 4.87 (dd, *J*=11.8, 3.5 Hz, 1H), 4.70 (m, 2H), 4.61–4.39 (m, 4H), 4.14 (dd, *J*= 10.0, 3.8 Hz, 1H), 3.88 (m, 1H), 3.73 (dd, *J*=10.0, 2.6 Hz, 1H), 3.61–3.50 (m, 3H), 3.41 ppm (m, 1H); ¹³C NMR (100 MHz, CDCl₃): δ =138.3, 138.0, 137.6, 128.5, 128.4, 128.2, 128.0 (2 C), 127.8, 127.7, 92.6, 79.0, 74.5,

73.8, 73.4, 72.3, 69.6, 69.2, 68.9 ppm; HRMS (MALDI-FTMS) calcd for $C_{27}H_{30}O_6Na^+$ [*M*+Na]⁺: 473.1934; found: 473.1921.

3,5-Di-O-TBS-D-ribosyldiol (81): The requisite D-ribose glycal intermediate was prepared from thymidine following the procedure of Larsen and co-workers.^[48] The resultant product was then dihydroxylated in a manner similar to the preparation of 71 to give diol 81 (0.378 g, 88% yield) as a white amorphous solid. $R_f = 0.35$ (silica gel, EtOAc/hexanes, 1:2); IR (film): v_{max}=3425, 2930, 2858, 1471, 1391, 1255, 1095, 937, 779 cm⁻¹; ¹H NMR (400 MHz, CDCl₃, 1:1 mixture of anomers): $\delta = 5.24$ (d, J=6.8 Hz, 1 H), 5.13 (d, J=10.6 Hz, 1 H), 4.24 (brd, J=8.5 Hz, 1 H), 4.18 (appt, J=2.6 Hz, 1 H), 4.09-4.06 (m, 2 H), 3.91 (brd, J=11.1 Hz, 1 H), 3.86–3.81 (m, 2 H), 3.77 (dd, J=8.6, 2.6 Hz, 1 H), 3.71 (d, J=1.8 Hz, 1 H), 3.63 (dd, J = 10.8, 2.0 Hz, 1 H), 0.89 (s, 9 H), 0.87 (s, 9 H), 0.84 (s, 9H), 0.82 (s, 9H), 0.10 (s, 6H), 0.07–0.04 ppm (m, 18H); ¹³C NMR (100 MHz, CDCl₂, 1:1 mixture of anomers): $\delta = 104.1$, 97.6, 87.1, 84.8, 78.8, 78.5, 77.3, 69.9, 65.7, 63.5, 63.1, 25.7, 25.5, 17.7, 15.1, -4.7, -5.0, -5.1, -5.6, -5.7, -5.8 ppm; HRMS (MALDI-FTMS) calcd for C₁₇H₃₈O₅Si₂Na⁺ [*M*+Na]⁺: 401.2150; found: 401.2147.

General procedure for the synthesis of sulfamidates on carbohydrates: The appropriate carbohydrate diol (0.5 mmol, 1.0 equiv) was dissolved in THF/CH₂Cl₂ (4:1, 5 mL) and the desired Burgess-type reagent (1, 50, or 51, 1.25 mmol, 2.5 equiv) was added at 25 °C in a single portion. The resultant solution was immediately warmed to reflux (using a preheated oil bath) and stirred for 6 h. Upon completion, the reaction contents were cooled to 25 °C, poured into saturated aqueous NH₄Cl (25 mL), and extracted with CH₂Cl₂ (3×25 mL). The combined organic layers were then washed with water (50 mL), dried (MgSO₄), and concentrated. The resultant yellow residue was purified by flash column chromatography (silica gel) in an appropriate solvent system to give the desired product in high purity.

Data for 70: R_f =0.68 (silica gel, EtOAc/hexanes, 1:1); IR (film): ν_{max} = 3037, 2866, 1753, 1444, 1385, 1312, 1196, 1094, 842, 741, 699, 665 cm⁻¹; ¹H NMR (600 MHz, CDCl₃): δ =7.39–7.29 (m, 13 H), 7.21 (m, 2 H), 6.02 (d, J=4.8 Hz, 1 H), 4.90 (t, J=4.0 Hz, 1 H), 4.60 (s, 2 H), 4.47 (AB, J= 11.8 Hz, ν_{ab} =88.6 Hz, 2 H), 4.44 (AB, J=11.9 Hz, ν_{ab} =88.6 Hz, 2 H), 4.90 (t, J=3.5 Hz, 1 H), 3.96 (dd, J=11.4, 2.6 Hz, 1 H), 3.94 (s, 3 H), 3.92 (dd, J=9.2, 3.5 Hz, 1 H), 3.68 (dd, J=11.0, 2.2 Hz, 1 H), 3.61 ppm (dd, J= 10.9, 3.5 Hz, 1 H); ¹³C NMR (150 MHz, CDCl₃): δ =149.8, 137.8, 137.3, 136.6, 128.7, 128.5, 128.4, 128.3, 128.1, 128.0 (2 C), 127.8, 127.7, 81.6, 75.5, 73.3, 73.1, 72.9, 72.4, 68.9, 54.9 ppm; HRMS (MALDI-FTMS) calcd for C₂₉H₃₁NO₉SNa⁺ [*M*+Na]⁺: 592.1612; found: 592.1608.

Data for 71: R_i =0.67 (silica gel, EtOAc/hexanes, 1:1); IR (film): ν_{max} = 3363, 2923, 1763, 1453, 1390, 1294, 1199, 1092, 847, 738, 699 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ =7.30–7.20 (m, 15H), 6.09 (d, J=5.2 Hz, 1H), 4.95 (d, J=4.4 Hz, 1H), 4.90 (AB, J=12.1 Hz, ν_{ab} =48.4 Hz, 2H), 4.62 (s, 2H), 4.45 (AB, J=11.7 Hz, ν_{ab} =101.2 Hz, 2H), 4.43 (AB, J= 11.8 Hz, ν_{ab} =44.8 Hz, 2H), 4.12 (t, J=3.7 Hz, 1H), 3.99 (dt, J=9.2, 2.6 Hz, 1H), 3.93 (dd, J=9.2, 3.3 Hz, 1H), 3.68 (dd, J=11.0, 2.2 Hz, 1H), 3.61 ppm (dd, J=11.0, 3.3 Hz, 1H); ¹³C NMR (125 MHz, CDCl₃): δ = 148.1, 137.8, 137.3, 136.6, 128.7, 128.5, 128.4, 128.1, 128.0, 127.8, 127.7, 93.6, 81.8, 76.0, 75.4, 73.4, 73.3, 72.9, 72.8, 72.5, 68.8 ppm; HRMS (MALDI-FTMS) calcd for C₃₀H₃₀Cl₃NO₉SNa⁺ [M+Na]⁺: 708.0599; found: 708.0611.

Data for 72: R_f =0.68 (silica gel, EtOAc/hexanes, 1:1); IR (film): ν_{max} = 3398, 2865, 1746, 1453, 1376, 1300, 1284, 1197, 1088, 1028 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ =7.36–7.29 (m, 13H), 7.20–7.18 (m 2H), 6.02 (d, J=4.8 Hz, 1H), 5.93 (m, 1H), 5.42 (dd, J=17.0, 1.1 Hz, 1H), 5.30 (m, 1H), 4.88 (dt, J=8.1, 0.7 Hz, 1H), 4.79 (ABX, J=16.1, 5.5 Hz, ν_{ab} = 21.6 Hz, 2H), 4.60 (s, 2H), 4.53 (AB, J=12.1 Hz, ν_{ab} =21.3 Hz, 2H), 4.38 (AB, J=12.1 Hz, ν_{ab} =22.4 Hz, 2H), 4.08 (t, J=3.7 Hz, 1H), 3.95 (td, J= 7.4, 2.8 Hz, 1H), 3.89 (dd, J=7.4, 3.7 Hz, 1H), 3.67 (dd, J=9.3, 2.2 Hz, 1H), 3.59 ppm (dd, J=9.1, 3.7 Hz, 1H); ¹³C NMR (125 MHz, CDCl₃): δ =149.1, 137.9, 137.4, 136.7, 31.4, 130.4, 128.7, 128.5, 128.4 (2C), 128.1 (2C), 127.9, 127.7, 119.6, 119.2, 81.6, 77.4, 75.6, 73.5, 73.4, 72.9, 72.8, 72.4, 69.0, 68.5, 66.8 ppm; HRMS (MALDI-FTMS) calcd for C₃₁H₃₃NO₉SNa⁺ [*M*+Na]⁺: 618.1768; found: 618.1773.

Data for 74: R_f =0.75 (silica gel, EtOAc/hexanes, 1:2); IR (film): ν_{max} = 2932, 2858, 1757, 1636, 1442, 1389, 1314, 1256, 1196, 1114, 1008, 836, 778 cm⁻¹; ¹H NMR (600 MHz, CDCl₃): δ =5.86 (d, *J*=4.4 Hz, 1H), 4.70 (t, *J*=1.2 Hz, 1H), 4.11 (d, *J*=3.1 Hz, 1H), 3.95 (s, 3H), 3.87 (d, *J*=

FULL PAPER

7.4 Hz, 1 H), 3.81–3.73 (m, 3 H), 0.89 ppm (s, 27 H), 0.16–0.06 (m, 18 H); ¹³C NMR (150 MHz, CDCl₃): δ =150.2, 81.3, 75.7, 75.0, 70.8, 68.8, 62.4, 54.7, 25.8, 25.5 (2 C), 18.2, 17.8, 17.7, -4.2, -4.5, -4.8, -4.9, -5.2, -5.5 ppm; HRMS (MALDI-FTMS) calcd for C₂₆H₅₅NO₉SSi₃Na⁺ [*M*+Na]⁺: 664.2797; found: 664.2790.

Data for 76: R_f =0.60 (silica gel, EtOAc/hexanes, 1:1); IR (film): ν_{max} = 3248, 1752, 1636, 1494, 1444, 1381, 1314, 1196, 1146, 1077, 1001, 740 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ =7.41–7.29 (m, 8H), 7.27–7.25 (m, 2H), 5.88 (d, *J*=5.3 Hz, 1 H), 4.90 (ddd, *J*=6.2, 3.5, 1.2 Hz, 1 H), 4.57 (AB, *J*= 10.8 Hz, ν_{ab} =11.8 Hz, 2 H), 4.44 (AB, *J*=12.0 Hz, ν_{ab} =34.9 Hz, 2 H), 4.02 (dd, *J*=3.2, 2.0, Hz, 1 H), 3.98 (m, 1 H), 3.95 (s, 3 H), 3.36 (ddd, *J*=8.8, 1.8, 1.2 Hz, 1 H), 1.28 ppm (d, *J*=6.2 Hz, 3 H); ¹³C NMR (100 MHz, CDCl₃): δ =150.0, 137.3, 136.5, 128.8, 128.5 (2 C), 128.1, 128.0 (3 C), 81.5, 80.5, 75.2, 74.4, 72.6, 72.4, 67.9, 54.9, 19.3 ppm; HRMS (MALDI-FTMS) calcd for C₂₂H₂₅NO₈SNa⁺ [*M*+Na]⁺: 486.1193; found: 486.1202.

Data for 78: R_f =0.66 (silica gel, EtOAc/hexanes, 1:1); IR (film): ν_{max} = 2961, 1755, 1443, 1384, 1320, 1290, 1190, 1061, 991, 855, 732, 697 cm⁻¹; ¹H NMR (600 MHz, CDCl₃): δ =7.39–7.25 (m, 15H), 5.89 (d, *J*=4.0 Hz, 1H), 5.02 (dd, *J*=5.2, 3.5 Hz, 1H), 4.75 (AB, *J*=11.0 Hz, ν_{ab} =160.4 Hz, 2H), 4.73 (AB, *J*=11.9 Hz, ν_{ab} =68.8 Hz, 2H), 4.53 (AB, *J*=11.9 Hz, ν_{ab} =31.1 Hz, 2H), 4.20 (m, 1H), 4.15 (dd, *J*=4.0, 1.7 Hz, 1H), 4.03 (dd, *J*=5.3, 1.8 Hz, 1H), 3.92 (s, 3H), 3.71 (dd, *J*=9.7, 7.4 Hz, 1H), 3.65 ppm (dd, *J*=9.7, 6.5 Hz, 1H); ¹³C NMR (150 MHz, CDCl₃): δ =149.5, 137.7, 137.4, 136.8, 128.6, 128.4, 128.2, 128.1, 128.0, 127.8 (2 C), 127.6, 84.1, 80.3, 78.7, 75.4, 75.3, 73.7, 72.1, 66.9, 54.9 ppm; HRMS (MALDI-FTMS) calcd for C₂₉H₃₁NO₉SNa⁺ [*M*+Na]⁺: 592.1612; found: 592.1633.

Data for 80: R_f =0.33 (silica gel, EtOAc/hexanes, 1:2); IR (film): ν_{max} = 2978, 1746, 1437, 1412, 1294, 1249, 1187, 1073, 1023, 973, 861, 797, 609 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ =5.98 (d, J=3.8 Hz, 1H), 5.13 (d, J=2.4 Hz, 1H), 4.72 (dd, J=15.0, 2.9 Hz, 1H), 4.71 (d, J=3.5 Hz, 1H), 4.36 (q, J=2.6 Hz, 1H), 4.09 (dd, J=15.0, 2.6 Hz, 1H), 3.86 (s, 3 H), 1.49 (s, 3H), 1.33 ppm (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ =151.9, 113.0, 104.9, 87.3, 82.5, 70.6, 54.9, 48.2, 26.5, 26.1 ppm; HRMS (MALDI-FTMS) calcd for C₁₀H₁₅NO₈SNa⁺ [M+Na]⁺: 332.0411; found: 332.0418.

Data for 82: R_f =0.68 (silica gel, EtOAc/hexanes, 1:2); IR (film): ν_{max} = 2954, 2858, 1759, 1442, 1392, 1313, 1257, 1196, 1098, 1011, 838, 806, 781 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ =6.12 (d, J=4.4 Hz, 1H), 4.93 (d, J=4.1 Hz, 1H), 4.61 (s, 1H), 4.12 (ddd, J=8.5, 5.2, 1.9 Hz, 1H), 3.96 (s, 3H), 3.77 (dd, J=10.7, 5.5 Hz, 1H), 3.71 (dd, J=10.6, 8.8 Hz, 1H), 0.90 (s, 18H), 0.14 (d, J=5.5 Hz, 6H), 0.07 ppm (d, J=2.6 Hz, 6H); ¹³C NMR (125 MHz, CDCl₃): δ =149.8, 88.8, 87.7, 86.2, 74.3, 61.7, 55.0, 25.8, 25.5, 18.3, 17.9, -4.9, -5.0, -5.5 ppm (2C); HRMS (MALDI-FTMS) calcd for C₁₉H₄₀NO₈Si₂S⁺ [M+H]⁺: 498.2008; found: 498.2015.

Azide-opened tri-benzylated glucose derivative 83: NaN₃ (0.033 g, 0.50 mmol, 5.0 equiv) was added in a single portion to a solution of glucose-derived sulfamidate 70 (0.057 g, 0.10 mmol, 1.0 equiv) in THF/ CH₂Cl₂ (4:1, 1 mL) at 25 °C. The resulting clear solution was then warmed to 60 °C and stirred for 5 h. Upon completion, the reaction contents were diluted with Et₂O (5 mL), treated with 10% aqueous H₂SO₄ (1 mL), and allowed to stir for an additional 30 minutes at 25 °C. Once this operation was complete, the reaction mixture was poured into water (10 mL) and extracted with Et_2O (3×25 mL). The combined organic layers were then washed with water (2×15 mL), dried (MgSO₄), and concentrated. The resultant light yellow solid was purified by flash column chromatography (silica gel, Et₂O/hexanes, 1:1) to give the azide-opened tri-benzylated glucose derivative 83 (0.049 g, 92%) as an amorphous white solid. $R_{\rm f}$ = 0.47 (silica gel, EtOAc/hexanes, 1:1); IR (film): $\nu_{\rm max}$ = 3318, 2924, 2106, 1732, 1532, 1454, 1357, 1243, 1098, 1027, 738, 699 $\rm cm^{-1};$ ¹H NMR (600 MHz, CDCl₃): $\delta = 7.26 - 7.15$ (m, 15H), 5.42 (brs, 1H), 5.27 (brm, 1H), 4.65-4.47 (m, 5H), 3.82 (m, 2H), 3.74 (m, 2H), 3.68 ppm (s, 3H); ¹³C NMR (125 MHz, CDCl₃): $\delta = 155.7$, 138.0, 137.6, 137.1, 128.6, 128.4, 128.3, 128.1, 128.0, 127.9, 127.8, 127.6, 78.3, 73.8, 73.2, 72.8, 68.2, 60.0, 52.7, 53.4 ppm; HRMS (MALDI-FTMS) calcd for $C_{34}H_{38}NO_5^+$ [*M*+H]⁺: 555.2214; found: 555.2217.

Allylated sulfamidate 84: Et₂NH (0.354 mL, 6.71 mmol, 40 equiv) was added to a solution of sulfamidate 72 (0.100 g, 0.167 mmol, 1.0 equiv) in CH₃CN/H₂O (1:1, 3 mL) at 25 °C. After stirring this mixture for 5 minutes at 25 °C, Pd(OAc)₂ (0.002 g, 0.017 mmol, 0.1 equiv) and TPPTS (0.019 g, 0.033 mmol, 0.2 equiv) were added sequentially, providing a yellow solution which was stirred for an additional 30 minutes at 25 °C.

Upon completion, the reaction contents were poured into water (5 mL), and extracted with EtOAc (3×10 mL). The combined organic layers were then dried (MgSO₄) and concentrated to give the desired deprotected sulfamidate (0.075 g, 87 % yield) as a white oil.^[29] Pressing forward without any additional purification steps, this material (0.075 g, 0.146 mmol, 1.0 equiv) was dissolved in DMSO (2 mL) and treated with NaH (0.029 g, 60% dispersion in mineral oil, 0.730 mmol, 5.0 equiv) at 25°C. After stirring the resultant reaction mixture for 10 minutes at 25°C, allyl bromide (0.051 mL, 0.584 mmol, 4.0 equiv) was added in a single portion; the reaction mixture was then stirred for an additional 15 minutes at 25 °C. Upon completion, the reaction contents were poured into water (5 mL), and extracted with EtOAc (3×10 mL). The combined organic layers were then washed with water $(2 \times 15 \text{ mL})$, dried (MgSO₄). and concentrated. The resultant light yellow oil was purified by flash column chromatography (silica gel, EtOAc/hexanes, $1:3 \rightarrow 1:1$) to give the allylated sulfamidate 84 (0.067 g, 73 % yield over two steps) as an amorphous white solid. $R_f = 0.64$ (silica gel, EtOAc/hexanes, 1:1); IR (film): $v_{\rm max} = 2890, 1452, 1352, 1193, 1114, 1052, 988, 741, 694, 606 \,{\rm cm}^{-1};$ ¹H NMR (600 MHz, CDCl₃): δ = 7.30–7.24 (m, 15 H), 5.87 (m, 1 H), 5.35 (d, J=17.1 Hz, 1 H), 5.29 (s, 1 H), 5.28 (d, J=16.7 Hz, 1 H), 4.95 (dd, J= 7.4, 5.3 Hz, 1 H), 4.75 (AB, J = 11.0 Hz, $v_{ab} = 185.9$ Hz, 2 H), 4.73 (AB, J =11.8 Hz, $v_{ab} = 76.7$ Hz, 2H), 4.43 (AB, J = 11.8 Hz, $v_{ab} = 26.3$ Hz, 2H), 4.12 (dd, J=7.4, 2.6 Hz, 1H), 4.04 (t, J=5.3 Hz, 1H), 4.00 (apps, 1H), 3.79 (dd, J=14.5, 5.7 Hz, 1 H), 3.73 (dd, J=14.5, 7.9 Hz, 1 H), 3.52 ppm (AB, $J = 9.6 \text{ Hz}, v_{ab} = 16.2 \text{ Hz}, 2 \text{ H}$; ¹³C NMR (150 MHz, CDCl₃): $\delta = 137.8$, 137.6, 137.4, 130.4, 128.5 (2 C), 128.4, 128.2, 128.0 (2 C), 127.9, 127.7 (2 C), 121.1, 84.3, 82.2, 78.5, 74.9, 73.5 (2 C), 72.8, 72.4, 67.7, 47.0 ppm; HRMS (MALDI-FTMS) calcd for C₃₀H₃₃NO₇SNa⁺ [*M*+Na]⁺: 574.1870; found: 574.1866.

2,3,4-Tri-O-benzyl-D-fucose (90): Concentrated H₂SO₄ (1 mL) was added to a solution of D-fucose (1.64 g, 10.0 mmol, 1.0 equiv) in MeOH (30 mL) at 25°C, and the resultant mixture was stirred for 5 h. Upon completion, the reaction contents were neutralized by the addition of 3N aqueous NaOH (monitored using standard pH paper) and concentrated directly. The resulting white solid was then taken up in EtOAc (50 mL), filtered through a short silica gel, and concentrated to give 1-O-methyl-D-fucose (1.78 g, 100% yield) as a white solid. Pressing forward without any additional purification steps, this newly-formed material (1.78 g, 10.0 mmol, 1.0 equiv) was dissolved in DMF (10 mL) and treated with NaH (3.60 g, 60% dispersion in mineral oil, 90.0 mmol, 9.0 equiv) at 25°C. After stirring the resultant solution for 5 minutes at 25°C, the reaction contents were cooled to 0 °C and benzyl bromide (5.95 mL, 50.0 mmol, 5.0 equiv) added dropwise over the course of 10 minutes. The reaction mixture was then warmed to 25°C over the course of 4 h. Upon completion, the reaction mixture was poured into 1 n aqueous HCl (25 mL) and extracted with Et₂O (3×25 mL). The combined organic layers were then washed with water $(2 \times 15 \text{ mL})$, dried (MgSO₄), and concentrated. The resultant light yellow solid was purified by flash column chromatography (silica gel, Et₂O/hexanes, $1:3 \rightarrow 1:1$) to give the desired tri-O-benzylated-fucose intermediate (3.7 g, 82%) as an amorphous white solid. Finally, a portion of this newly-formed product (0.452 g, 1.0 mmol, 1.0 equiv) was dissolved 6м aqueous HCl/concentrated HCl (1:1, 5 mL) at 25°С. The resultant mixture was then warmed to 60 °C and stirred for 12 h. Upon completion, the reaction contents were concentrated directly. The resultant yellow oil was purified by flash column chromatography (silica gel, Et₂O/hexanes, 1:1) to give the desired D-fucose-derived starting material 90 (0.297 g, 68%) as an amorphous white solid. $R_{\rm f}$ =0.54 (silica gel, EtOAc/hexanes, 1:1); IR (film): v_{max} =3416, 3031, 2867, 1453, 1364, 1208, 1098, 740, 698 cm⁻¹; ¹H NMR (500 MHz, CDCl₃, 1:1 mixture of anomers): $\delta = 7.48$ -7.34 (m, 30 H), 5.55 (s, 1 H), 5.41 (dd, J=9.5, 4.4 Hz, 1 H), 4.83-4.49 (m, 11 H), 4.35 (appt, J=5.2 Hz, 1 H), 4.30 (brd, J=11.4 Hz, 1 H), 4.25 (appt, J = 5.2 Hz, 1 H), 4.13 (dd, J = 5.5, 4.8 Hz, 1 H), 4.10 (dd, J = 2.2, 1.1 Hz, 1 H), 4.05 (dd, J=5.2, 2.2 Hz, 1 H), 3.99 (dd, J=4.8, 3.0 Hz, 1 H), 3.78 (m, 1H), 3.63 (dd, J=6.3, 3.0 Hz, 1H), 3.55 (brs, 1H), 3.48 (m, 1H), 1.38 (d, J = 4.6 Hz, 3H), 1.28 ppm (d, J = 4.8 Hz, 3H); ¹³C NMR (125 MHz, $CDCl_3$, 1:1 mixture of anomers): $\delta = 138.5$, 137.7, 137.5, 137.4 (2C), 137.3, 128.4 (2C), 128.3 (2C), 128.2, 128.0, 127.9 (2C), 127.8 (3C), 127.7, 127.5, 127.4, 126.9, 100.7, 96.0, 87.3, 85.2, 84.5, 84.4, 82.8, 82.2, 74.0, 73.9, 71.9 (2 C), 71.8, 71.6, 71.2, 71.1, 65.1 ppm; MS (ESI) calcd for C₂₇H₃₀O₉Cl⁻ [*M*+Cl]⁻: 470; found: 470.

2,3,4,6-Tetra-O-methyl-D-mannose (92): D-Mannose (1.80 g, 10.0 mmol) was converted into **92** in a manner similar to the preparation of **90** by substituting methyl iodide for benzyl bromide, ultimately providing compound **92** (0.146 g, 62% yield) as a white amorphous solid. $R_{\rm f}$ =0.15 (silica gel, EtOAc/hexanes, 1:2); IR (film): $v_{\rm max}$ =3402, 2932, 2828, 1644, 1453, 1193, 1109, 1030, 958, 792 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ = 5.25 (s, 1H), 4.62 (brs, 1H), 3.86 (td, *J*=7.3, 1.8 Hz, 1H), 3.59–3.51 (m, 4H), 3.45 (s, 3H), 3.44 (s, 3H), 3.43 (s, 3H), 3.32 (s, 3H), 3.26 ppm (t, *J*= 9.2 Hz, 1H); ¹³C NMR (125 MHz, CDCl₃): δ =91.5, 80.8, 74.5, 77.1, 72.7, 70.3, 60.6, 59.1, 58.8, 57.6 ppm; HRMS (MALDI-FTMS) calcd for C₁₀H₂₀O₆Na⁺ [*M*+Na]⁺: 259.1152; found: 259.1152.

2,3,5-Tri-*O***-benzyl-L-arabinofuranose (95)**: Lactol **95** was prepared from L-arabinose using the sequence established by Tejima and Fletcher.^[49] R_t =0.51 (silica gel, EtOAc/hexanes, 1:1); IR (film): ν_{max} =3418, 3030, 2866, 1495, 1454, 1365, 1264, 1208, 1099, 1028, 738, 698 cm⁻¹; ¹H NMR (500 MHz, CDCl₃, 1:1 mixture of anomers): δ =7.36–7.26 (m, 30 H), 5.40 (s, 1H), 5.34 (d, *J*=3.7 Hz, 1H), 4.66 (d, *J*=9.5 Hz, 1H), 4.61–4.52 (m, 10H), 4.48–4.45 (m, 2H), 4.17 (t, *J*=4.0 Hz, 1H), 3.98 (d, *J*=1.5 Hz, 1H), 3.94 (m, 1H), 3.61–3.50 ppm (m, 4H); ¹³C NMR (125 MHz, CDCl₃, 1:1 mixture of anomers): δ =138.0, 137.4, 137.3, 137.2 (2 C), 128.6, 128.5 (4 C), 128.4 (2 C), 128.3, 128.0 (2 C), 127.9 (2 C), 127.8 (2 C), 127.7 (2 C), 127.6, 101.1, 96.2, 86.3, 84.0, 82.6, 82.0, 81.8, 80.5, 76.8, 73.5, 73.3, 72.2, 72.0 (2 C), 71.7, 70.4, 70.1 ppm; HRMS (MALDI-FTMS) calcd for C₂₆H₂₈O₃Na⁺ [*M*+Na]⁺: 443.1829; found: 443.1809.

Furanose 98: The requisite lactol intermediate was prepared from Dribose following the procedure of Kaskar and co-workers.^[50] R_f =0.51 (silica gel, EtOAc/hexanes, 1:2); IR (film): ν_{max} =3416, 2934, 2858, 1469, 1381, 1257, 1211, 1075, 1004, 939, 838, 779 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ =5.24 (d, *J*=11.4 Hz, 1H), 4.74 (d, *J*=11.7 Hz, 1H), 4.66 (d, *J*=5.9 Hz, 1H), 4.47 (d, *J*=5.9 Hz, 1H), 4.31 (s, 1H), 3.75–3.72 (m, 2H), 1.45 (s, 3H), 1.29 (s, 3H), 0.90 (s, 9H), 0.11 (s, 3H), 0.10 ppm (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ =111.9, 103.3, 87.5, 86.8, 81.7, 64.7, 26.4, 25.7, 24.8, 18.1, -5.7 ppm; HRMS (MALDI-FTMS) calcd for C₁₄H₂₈O₅SiNa⁺ [*M*+Na]⁺: 327.1598; found: 327.1592.

General procedure for the synthesis of β -disposed glycosylamines: The lactol starting material (0.5 mmol, 1.0 equiv) was dissolved in THF/ CH₂Cl₂ (4:1, 5 mL) and the desired Burgess-type reagent (1, 50, or 51, 0.75 mmol, 1.5 equiv) was added at 25 °C in a single portion. The resultant solution was immediately warmed to reflux (using a preheated oil bath) and stirred for 6 h. Upon completion, the reaction contents were cooled to 25 °C, poured into saturated aqueous NH₄Cl (25 mL), and extracted with CH₂Cl₂ (3×25 mL). The combined organic layers were then washed with water (50 mL), dried (MgSO₄), and concentrated. The resultant yellow residue was purified by flash column chromatography (silica gel) in an appropriate solvent system to give the desired product in high purity.

CO₂Me-protected 2,3,4,6-tetra-*O***-methyl-β-D-glucosylamine (86): R_{\rm f}= 0.13 (silica gel, EtOAc/hexanes, 1:1); IR (film): \nu_{\rm max}=3329, 2937, 2836, 1712, 1544, 1450, 1278, 1158, 1099, 989, 945, 647 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): \delta=5.30 (d,** *J***=8.8 Hz, 1H), 4.75 (t,** *J***=8.4 Hz, 1H), 3.68 (brs, 3 H), 3.62 (s, 3H), 3.58–3.53 (m, 2H), 3.52 (s, 3H), 3.51 (s, 3H), 3.41 (s, 3H), 3.30 (m, 1H), 3.22 (d,** *J***=6.7 Hz, 2H), 2.91 ppm (br m, 1H); ¹³C NMR (100 MHz, CDCl₃): \delta=156.1, 99.5, 87.2, 82.8, 81.6, 78.9, 75.8, 70.5, 60.8, 60.3, 59.1, 52.4 ppm; HRMS (MALDI-FTMS) calcd for C₁₂H₂₃NO₇Na⁺ [***M***+Na]⁺: 316.1367; found: 316.1363.**

CO₂Me-protected 2,3,4,6-tetra-*O***-benzyl-β-D-glucosylamine (88): R_i= 0.67 (silica gel, EtOAc/hexanes, 1:1); IR (film): \nu_{max}=3326, 2869, 1733, 1535, 1496, 1454, 1362, 1252, 1101, 737, 698 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): \delta=7.34–7.27 (m, 18 H), 7.17 (m, 2 H), 5.12 (brd,** *J***=6.4 Hz, 1 H), 4.97 (m, 1 H), 4.93 (AB,** *J***=10.8 Hz, \nu_{ab}=15.0 Hz, 2 H), 4.84 (dd,** *J***=10.8, 3.5 Hz, 1 H), 4.74 (d,** *J***=11.1 Hz, 1 H), 4.65 (d,** *J***=12.0 Hz, 1 H), 4.56 (d,** *J***=10.8 Hz, 1 H), 4.51 (d,** *J***=11.1 Hz, 1 H), 3.76 (m, 4H), 3.72 (brs, 3 H), 3.54 (brd,** *J***=7.9 Hz, 1 H), 3.38 ppm (appt,** *J***=6.8 Hz, 1 H); ¹³C NMR (100 MHz, CDCl₃): \delta=156.1, 138.3, 137.9, 137.7, 128.4, 128.3 (2 C), 128.2, 127.9, 127.7, 127.6, 85.8, 81.7, 80.1, 77.4, 76.0, 75.6, 74.8, 74.6, 73.4, 68.0, 52.3 ppm; HRMS (MALDI-FTMS) calcd for C₃₆H₃₉NO₇Na⁺ [***M***+Na]⁺: 620.2610; found: 620.2614.**

Alloc-protected 2,3,4,6-tetra-*O*-benzyl-β-D-glucosylamine (89): $R_{\rm f}$ =0.64 (silica gel, EtOAc/hexanes, 1:1); IR (film): $\nu_{\rm max}$ =3331, 3030, 2867, 1703,

1537, 1453, 1360, 1280, 1071, 735, 697 cm⁻¹; ¹H NMR (600 MHz, CDCl₃): δ =7.45–7.32 (m, 18H), 7.19–7.17 (m, 2H), 5.93 (ddd, *J*=22.7, 10.9, 5.7 Hz, 1H), 5.32 (d, *J*=17.1 Hz, 1H), 5.23 (d, *J*=10.1 Hz, 1H), 5.07 (d, *J*=10.1 Hz, 1H), 4.92 (m, 1H), 4.91 (AB, *J*=11.0 Hz, v_{ab} =18.8 Hz, 2H), 4.82 (d, *J*=10.9 Hz, 2H), 4.72 (d, *J*=11.0 Hz, 1H), 4.64–4.60 (m, 3H), 4.53 (d, *J*=10.5 Hz, 1H), 4.47 (d, *J*=12.3 Hz, 1H), 3.73 (m, 4H), 3.52 (d, *J*=7.9 Hz, 1H), 3.38 ppm (t, *J*=8.3 Hz, 1H); ¹³C NMR (150 MHz, CDCl₃): δ =155.3, 138.3, 138.0, 137.7, 132.4, 128.5, 128.4 (3C), 128.3 (3C), 128.2, 128.0, 127.8, 127.7, 127.6, 117.8, 85.9, 81.6, 80.1, 77.4, 76.1, 75.6, 74.9, 74.7, 73.5, 68.1 ppm; HRMS (MALDI-FTMS) calcd for C₃₈H₄₁NO₇Na⁺ [*M*+Na]⁺: 646.2775; found: 646.2766.

CO₂Me-protected 2,3,4-tri-O-benzyl-β-D-fucosylamine (91): R_f =0.70 (silica gel, EtOAc/hexanes, 1:1); IR (film): ν_{max} =3326, 2927, 1730, 1504, 1453, 1351, 1067, 736, 697 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ =7.36–7.31 (m, 15H), 5.81 (brd, J=6.4 Hz, 1H), 5.76 (brs, 1H), 4.69 (AB, J=9.4 Hz, ν_{ab} =21.4 Hz, 2H), 4.67 (m, 1H), 4.57 (m, 3H), 4.24 (dd, J=4.7, 2.6 Hz, 1H), 4.04 (d, J=1.5 Hz, 1H), 3.98 (brs, 1H), 3.80 (m, 1H), 3.77 (brs, 3H), 1.20 ppm (d, J=4.9 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃): δ =155.8, 138.6, 137.2, 128.5, 128.4, 128.3, 128.0, 127.9, 127.8 (2 C), 127.6, 127.4, 86.1, 85.3 (2 C), 82.4, 74.1, 71.8, 71.4, 52.3, 15.7 ppm; HRMS (MALDI-FTMS) calcd for C₂₉H₃₃NO₆Na⁺ [*M*+Na]⁺: 514.2200; found: 514.2191.

CO₂Me-protected 2,3,4,6-tetra-O-methyl-β-D-mannosylamine (93): $R_{\rm f}$ = 0.27 (silica gel, EtOAc); IR (film): $\nu_{\rm max}$ = 3205, 2928, 1722, 1445, 1257, 1100 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ =5.59 (brs, 1H), 5.44 (brs, 1H), 3.83 (m, 1H), 3.80 (s, 3H), 3.67–3.64 (m, 4H), 3.62 (m, 1H), 3.61 (s, 6H), 3.58 (s, 3H), 3.48 (m, 1H), 3.46 ppm (s, 3H); ¹³C NMR (125 MHz, CDCl₃): δ =156.3, 80.4, 77.1, 76.4, 73.3, 71.7, 68.4, 60.5, 59.7, 58.8, 58.4, 53.0 ppm; HRMS (MALDI-FTMS) calcd for C₁₂H₂₃NO₇Na⁺ [*M*+Na]⁺: 316.1367; found: 316.1362.

Alloc-protected 2,3,4,6-tetra-*O*-methyl-β-D-mannosylamine (94): $R_{\rm f}$ =0.38 (silica gel, EtOAc); IR (film): $\nu_{\rm max}$ =3332, 2934, 1726, 1529, 1450, 1305, 1237, 1100 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ =5.90 (ddd, *J*=23.1, 10.7, 4.8 Hz, 1 H), 5.52 (brs, 1 H), 5.32 (d, *J*=17.2 Hz, 1 H), 5.22 (d, *J*=10.3 Hz, 1 H), 4.60 (s, 2 H), 3.63–3.48 (m, 15H), 3.45–3.42 ppm (m, 4H); ¹³C NMR (100 MHz, CDCl₃): δ =155.5, 132.7, 118.7, 80.4, 77.1, 76.4, 73.3, 71.6, 66.5, 59.7, 58.8, 58.3, 51.5 ppm; HRMS (MALDI-FTMS) calcd for C₁₄H₂₃NO₇Na⁺ [*M*+Na]⁺: 342.1523; found: 342.1522.

CO₂Me-protected 2,3,5-tri-*O*-benzyl-β-L-arabinofuranosylamine (96): $R_{\rm f}$ =0.63 (silica gel, EtOAc/hexanes, 1:1); IR (film): $\nu_{\rm max}$ =3317, 3030, 2865, 1732, 1498, 1454, 1363, 1238, 1058, 739, 698 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ =7.35–7.27 (m, 15 H), 5.88 (brd, *J*=9.4 Hz, 1H), 5.76 (brd, *J*=10.0 Hz, 1H), 4.61–4.45 (m, 6 H), 4.38 (appt, *J*=5.6 Hz, 1H), 4.02 (s, 1H), 3.93 (s, 1H), 3.70 (brs, 3H), 3.64 (dd, *J*=9.4, 5.9 Hz, 1H), 3.52 ppm (appt, *J*=8.8 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃): δ = 155.8, 137.9, 137.1, 128.4 (2C), 128.3, 128.2, 127.9, 127.8, 127.7, 127.6 (2C), 85.5, 84.9, 82.7, 82.1, 73.2, 71.6, 71.4, 70.0, 52.2 ppm; HRMS (MALDI-FTMS) calcd for C₂₈H₃₁NO₆Na⁺ [*M*+Na]⁺: 500.2043; found: 500.2033.

Alloc-protected 2,3,5-tri-*O*-benzyl-β-L-arabinofuranosylamine (97): R_t = 0.55 (silica gel, EtOAc/hexanes, 1:1); IR (film): ν_{max} =3322, 3030, 2866, 1730, 1503, 1454, 1366, 1232, 1094, 992, 738, 698 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ =7.41–7.32 (m, 15H), 6.01 (ddd, J=22.8, 11.0, 5.9 Hz, 1H), 5.94 (d, J=9.9 Hz, 1H), 5.84 (d, J=9.9 Hz, 1H), 5.40 (d, J= 16.9 Hz, 1H), 5.31 (dd, J=10.2, 1.1 Hz, 1H), 4.69–4.58 (m, 7H), 4.53 (d, J=11.7 Hz, 1H), 4.48 (ddd, J=9.8, 7.3, 1.8 Hz, 1H), 4.08 (brs, 1H), 4.00 (brs, 1H), 3.70 (dd, J=9.5, 5.5 Hz, 1H), 3.59 ppm (appt, J=7.7 Hz, 1H); ¹³C NMR (125 MHz, CDCl₃): δ =155.5, 138.5, 137.6, 133.0, 129.0, 128.9, 128.8 (2 C), 128.3, 128.2, 128., 1280, 118.5, 86.1, 85.4, 83.2, 82.8, 73.8, 72.2, 71.9, 70.6, 66.3 ppm; HRMS (MALDI-FTMS) calcd for C₃₀H₃₃NO₆Na⁺ [*M*+Na]⁺: 526.2200; found: 526.2190.

CO₂Me-protected ribosylamine 99: R_i =0.67 (silica gel, EtOAc/hexanes, 1:2); IR (film): ν_{max} =3347, 2933, 1737, 1509, 1461, 1377, 1251, 1082, 931, 837, 779 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ =6.27 (brd, J=11.8 Hz, 1H), 5.68 (brd, J=10.0 Hz, 1H), 4.72 (d, J=5.9 Hz, 1H), 4.50 (d, J=6.2 Hz, 1H), 4.29 (s, 1H), 3.77 (m, 1H), 3.71 (m, 3H), 3.66 (brs, 3H), 1.51 (s, 3H), 1.33 (s, 3H), 0.94 (s, 9H), 0.13 ppm (s, 6H); ¹³C NMR (100 MHz, CDCl₃): δ =155.8, 112.2, 89.0, 86.6, 86.0, 82.1, 79.4, 65.0, 51.8, 25.7, 24.8, 18.1 ppm; HRMS (MALDI-FTMS) calcd for C₁₆H₃₁NO₆SiNa⁺ [*M*+Na]⁺: 84.1813; found: 384.1814.

FULL PAPER

CO₂Me-protected 101: $R_{\rm f}$ =0.41 (silica gel, EtOAc/hexanes, 1:1); IR (film): $\nu_{\rm max}$ =3304, 2988, 1702, 1541, 1377, 1296, 1248, 1209, 1067, 1039, 1018, 850 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ =5.61 (brs, 1H), 5.22 (brs, 1 h), 4.87 (brs, 2H), 4.36 (m, 1H), 4.08–3.98 (m, 3H), 3.67 (s, 3H), 1.47 (s, 3H), 1.43 (s, 3H), 1.35 (s, 3H), 1.32 ppm (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ =156.1, 112.9, 109.1, 87.9, 85.2, 73.3, 66.6, 52.4, 26.9, 25.9, 25.0, 24.8 ppm; HRMS (MALDI-FTMS) calcd for C₁₄H₂₃NO₇Na⁺ [*M*+Na]⁺: 340.1367; found: 340.1364.

2,3,4,6-Tetra-O-benzyl-β-D-glucosylamine (102): Et₂NH (0.179 mL, 3.40 mmol, 40 equiv) was added to a solution of intermediate 89 (0.053 g, 0.085 mmol, 1.0 equiv) in CH₃CN/H₂O (1:1, 2 mL) at 25 °C. After stirring this mixture for 5 minutes at 25 °C, Pd(OAc)2 (0.002 g, 0.009 mmol, 0.1 equiv) and TPPTS (0.010 g, 0.017 mmol, 0.2 equiv) were added sequentially, providing a yellow solution which was stirred for an additional 30 minutes at 25 °C. Upon completion, the reaction contents were poured into water (5 mL), and extracted with EtOAc (3×10 mL). The combined organic layers were then dried (MgSO₄) and concentrated to give 2,3,4,6tetra-O-benzyl-β-D-glucosylamine (0.043 g, 95% yield)^[29] as an amorphous white solid. $R_{\rm f} = 0.48$ (silica gel, EtOAc/hexanes, 1:1); IR (film): $v_{\rm max} = 3352, 3030, 2862, 1453, 1351, 1122, 1094, 1086, 1027, 750, 698 \text{ cm}^{-1};$ ¹H NMR (600 MHz, CDCl₃): $\delta = 7.48-7.21$ (m, 20 H), 5.08 (d, J = 13.2 Hz, 1 H), 5.03 (d, J=13.1 Hz, 1 H), 4.94–4.86 (m, 3 H), 4.65 (AB, J=14.3 Hz, v_{ab} =37.4 Hz, 2 H), 4.58 (m, 1 H), 4.20 (d, J=9.9 Hz, 1 H), 3.85–3.80 (m, 5H), 3.56 (dd, J=11.5, 3.3 Hz, 1H), 3.30 (t, J=10.4 Hz, 1H), 1.97 ppm (brs, 2H); 13 C NMR (150 MHz, CDCl₃): $\delta = 138.6$, 138.3, 138.0, 137.9, 128.7, 128.4 (2 C), 128.3, 128.2, 127.9, 127.8 (2 C), 127.7 (2 C), 127.6, 86.2, 85.8, 83.4, 78.1, 75.7, 75.6, 75.0, 74.9, 73.5, 68.9 ppm; HRMS (MALDI-FTMS) calcd for $C_{34}H_{38}NO_5^+$ [*M*+H]⁺: 540.2744; found: 540.2750.^[25]

General procedure for making epoxy alcohol starting materials: All epoxy alcohols were prepared following the method of Katsuki and Sharpless, and their spectral data matched that published.^[51]

Perillyl epoxide 109: $R_{\rm f}$ =0.33 (silica gel, EtOAc/hexanes, 1:1); IR (film): $\nu_{\rm max}$ =3347, 2933, 1632, 1509, 1461, 1371, 1224, 1042, 939, 837, 777 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ =4.67 (s, 1H), 4.64 (s, 1H), 3.58 (AB, J= 12.0 Hz, $\nu_{\rm ab}$ =43.7 Hz, 2H), 3.32 (s, 1H), 2.36 (brs, 3H), 2.12 (AB, J= 13.5 Hz, $\nu_{\rm ab}$ =22.6 Hz, 2H), 1.80 (m, 2H), 1.66 (s, 3H), 1.58 (appt, J= 11.4 Hz, 2H), 1.17 ppm (dd, J=11.4, 6.8 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃): δ =148.6, 109.1, 64.2, 60.0, 56.7, 36.7, 30.2, 24.6, 20.8 ppm; MS (GC/MS) calcd for C₁₀H₁₆O₂+ [M]+: 168; found: 168.

Myrtenol epoxide 111: VO(acac)₂ (0.100 g, catalytic) and tert-butyl hydroperoxide (0.70 mL, 2.0 mmol, 2.0 equiv) were added sequentially to a solution of (-)-myrtenol (0.152 g, 1.0 mmol, 1.0 equiv) in CH₂Cl₂ (5 mL) at 25°C. After stirring the resultant solution for 2 h at 25°C, the reaction mixture was diluted with CH2Cl2 (10 mL) and quenched by the addition of water (5 mL) and Na₂SO₃ (0.063 g, 0.5 mmol, 0.5 equiv). The reaction contents were then poured into water (25 mL) and extracted with CH₂Cl₂ (3×25 mL). The combined organic layers were washed with water (50 mL), dried (MgSO₄), and concentrated. The resultant yellow residue was purified by flash column chromatography (silica gel, EtOAc/hexanes, 1:1) to provide myrtenol epoxide 111 (0.146 g, 87%) as a colorless oil. $R_{\rm f}$ =0.42 (silica gel, EtOAc/hexanes, 1:1); IR (film): $\nu_{\rm max}$ =2976, 2908, 1461, 1433, 1368, 1270, 1230, 1088, 1062, 1025, 865, 835, 770, 692 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): $\delta = 3.66$ (AB, J = 12.6 Hz, $v_{ab} = 69.5$ Hz, 2H), 3.37 (d, J=4.1 Hz, 1H), 2.15 (brs, 1H), 2.04 (m, 1H), 2.01 (d, J= 2.9 Hz, 1H), 1.98 (t, J=5.6 Hz, 1H), 1.93–1.87 (m, 1H), 1.75 (br m, 1H), 1.63 (d, J=9.7 Hz, 1H), 1.25 (s, 3H), 0.89 ppm (s, 3H); ¹³C NMR $(100 \text{ MHz}, \text{ CDCl}_3): \delta = 63.9, 62.9, 53.3, 40.5, 40.1, 27.1, 26.4, 25.5,$ 20.0 ppm; HRMS (MALDI-FTMS) calcd for $C_6H_{11}O_2^+$ [M+H]+: 115.0754; found: 115.0758.

General procedure for the synthesis of sulfamidates from epoxy alcohols: The epoxy alcohol (1.0 mmol, 1.0 equiv) was dissolved in THF/CH₂Cl₂ (4:1, 5 ml) and the Burgess reagent (0.309 g, 1.3 mmol, 1.3 equiv) was added at 25 °C in a single portion. The resultant solution was immediately warmed to reflux (using a preheated oil bath) and stirred for 3 h. Upon completion, the reaction contents were concentrated directly, and the resultant residue was purified by flash column chromatography (Florisil[®], EtOAc/MeOH, 1:0 \rightarrow 98:2) to give the desired sulfamidate product in high purity.

Sulfamidate 104: $R_{\rm f}$ =0.35 (silica gel, EtOAc/MeOH, 98:2); IR (film): $\nu_{\rm max}$ =3436, 3002, 1744, 1636, 1467, 1383, 1255, 1174, 953, 700, 597 cm⁻¹;

¹H NMR (400 MHz, CD₃CN): δ =7.37–7.28 (m, 5H), 4.70 (dd, *J*=11.8, 2.5 Hz, 1H), 4.24 (dd, *J*=11.7, 6.6 Hz, 1H), 3.90 (d, *J*=2.1 Hz, 1H), 3.72 (s, 3H), 3.40 ppm (dt, *J*=6.4, 2.5 Hz, 1H); ¹³C NMR (100 MHz, CD₃CN): δ =152.1, 136.9, 129.4, 126.7, 73.5, 59.1, 56.5, 54.2 ppm; HRMS (MALDI-FTMS) calcd for C₁₁H₁₄NO₆S⁺ [*M*+H]⁺: 288.0536; found: 288.0537.

Sulfamidate 106: $R_{\rm f}$ =0.32 (silica gel, EtOAc/MeOH, 98:2); IR (film): $\nu_{\rm max}$ =3480, 2955, 1743, 1649, 1446, 1291, 1167, 1108, 1050, 987, 885, 796, 749, 702, 621 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ=7.24–7.17 (m, 5H), 4.22 (AB, *J*=17.2 Hz, $\nu_{\rm ab}$ =68.6 Hz, 2H), 4.15 (s, 1H), 3.55 (s, 3H), 1.03 ppm (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ=157.3, 134.6, 128.0, 127.7, 126.5, 126.3, 72.3, 61.7, 61.0, 53.5, 13.1 ppm; MS (ESI) calcd for C₁₂H₁₅NO₆NaS⁺ [*M*+Na]⁺: 323; found: 323.

Sulfamidate 108: $R_{\rm f}$ =0.28 (silica gel, EtOAc/MeOH, 98:2); IR (film): $\nu_{\rm max}$ =3482, 2930, 1735, 1650, 1442, 1290, 1166, 1107, 985, 885 cm⁻¹; ¹H NMR (500 MHz, CD₃CN): δ=5.09 (m, 1 H), 4.17 (dd, *J*=11.4, 3.7 Hz, 1 H), 3.88 (dd, *J*=11.8, 7.0 Hz, 1 H), 3.50 (s, 3 H), 2.99 (dd, *J*=7.0, 4.0 Hz, 1 H), 2.05 (m, 2 H), 1.65 (s, 3 H), 1.58 (s, 3 H), 1.55 (m, 1 H), 1.40 (m, 1 H), 1.24 ppm (s, 3 H); ¹³C NMR (125 MHz, CD₃CN): δ=161.8, 132.6, 124.4, 68.1, 61.2, 60.7, 52.5, 38.8, 25.6, 24.1, 17.5, 16.9 ppm; HRMS (MALDI-FTMS) calcd for C₁₂H₂₁NO₆SNa⁺ [*M*+Na]⁺: 330.0982; found: 330.0987.

Sulfamidate 110: $R_{\rm f}$ =0.31 (silica gel, EtOAc/MeOH, 98:2); IR (film): $\nu_{\rm max}$ =3260, 2937, 1755, 1644, 1452, 1382, 1247, 1173, 959, 890, 776, 599 cm⁻¹; ¹H NMR (600 MHz, CD₃CN): δ = 4.72 (t, J = 1.3 Hz, 1H), 4.68 (q, J=0.9 Hz, 1H), 4.18 (AB, J=10.9 Hz, $\nu_{\rm ab}$ =178.0 Hz, 2H), 3.73 (s, 3H), 3.23 (brs, 1H), 2.12–2.08 (m, 1H), 2.05–1.95 (m, 2H), 1.78 (ddd, J= 17.5, 11.4, 6.1 Hz, 1H), 1.67 (s, 3H), 1.54 (m, 1H), 1.24–1.18 ppm (m, 2H); ¹³C NMR (150 MHz, CD₃CN): δ = 151.9, 149.8, 109.6, 77.8, 58.1, 57.3, 54.2, 37.1, 30.6, 26.1, 20.9 ppm; HRMS (MALDI-FTMS) calcd for C₁₂H₁₉NO₆SNa⁺ [*M*+Na]⁺: 328.0825; found: 328.0826.

Sulfamidate 112: $R_{\rm f}$ =0.30 (silica gel, EtOAc/MeOH, 98:2); IR (film): $v_{\rm max}$ =3482, 2924, 1644, 1445, 1389, 1296, 1166, 1109, 1052, 964, 883, 804, 736, 619 cm⁻¹; ¹H NMR (500 MHz, CD₃CN): δ=4.05 (AB, J=11.8 Hz, $v_{\rm ab}$ =162.9 Hz, 2H), 3.52 (s, 3H), 3.32 (m, 1H), 2.15 (t, J=5.9 Hz, 1H), 2.06 (dt, J=7.2, 5.8 Hz, 1H), 1.96 (m, 2H), 1.72 (m, 1H), 1.54 (d, J= 9.6 Hz, 1H), 1.29 (s, 3H), 0.92 ppm (s, 3H); ¹³C NMR (125 MHz, CD₃CN): δ=162.3, 70.1, 62.2, 54.0, 52.9, 41.2, 40.9, 40.7, 27.7, 26.7, 26.0, 20.3 ppm; HRMS (MALDI-FTMS) calcd for C₁₂H₁₉NO₆SNa⁺ [*M*+H]⁺: 328.0825; found: 328.0820.

Synthesis of aminoalcohol starting materials (Procedure A): The appropriate aniline (5.0 mmol, 1.0 equiv) was dissolved in 2-bromoethanol (5 mL), and the resulting solution was heated at 70 °C until most of the starting material had been consumed (typically 2–8 h). Upon completion, the reaction contents were cooled to 25 °C, poured into water (5 mL), and extracted with EtOAc (3×10 mL). The combined organic layers were then washed with water (2×15 mL), dried (MgSO₄), and concentrated. The resultant oil was purified by flash column chromatography (silica gel) in an appropriate solvent system to give the desired aminoal-cohol product in high purity.

Data for 131: R_f =0.32 (silica gel, CH₂Cl₂); IR (film): ν_{max} =3385, 2919, 1602, 1537, 1504, 1467, 1305, 1185, 1112, 1049, 833 cm⁻¹; ¹H NMR (500 MHz, CD₃CN): δ =8.10 (dd, *J*=7.0, 1.9 Hz, 2H), 6.72 (dd, *J*=7.0, 1.9 Hz, 2H), 3.77 (brt, *J*=5.2 Hz, 2H), 3.39 ppm (t, *J*=5.5 Hz, 2H); ¹³C NMR (125 MHz, CD₃CN): δ =154.8, 137.5, 126.5, 111.4, 60.2, 45.6 ppm; HRMS (MALDI-FTMS) calcd for C₈H₁₁N₂O₃⁺ [*M*+H]⁺: 183.0764; found: 183.0765.

Data for 133: $R_{\rm f}$ =0.28 (silica gel, CH₂Cl₂); IR (film): $\nu_{\rm max}$ =3280, 2955, 1618, 1519, 1465, 1391, 1292, 1119, 964, 870, 700 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ =7.16 (s, 1H), 6.97 (s, 2H), 3.89 (t, *J*=5.0 Hz, 2H), 3.87 (dd, *J*=5.6, 4.1 Hz, 1H), 3.67 (dd, *J*=5.3, 5.0 Hz, 1H), 3.35 ppm (brt, *J*=4.7 Hz, 2H); ¹³C NMR (100 MHz, CDCl₃): δ =148.7, 132.3 (d, *J*=133.4 Hz), 112.1, 110.5, 60.8, 45.4 ppm; MS (ESI) calcd for C₁₀H₁₀F₆NO⁺ [*M*+H]⁺: 274; found: 274.

Data for 135: $R_{\rm f}$ =0.22 (silica gel, CH₂Cl₂); IR (film): $v_{\rm max}$ =3378, 2937, 1606, 1512, 1459, 1236, 1128, 1005, 601 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ =5.89 (s, 2H), 3.83 (t, *J*=5.3 Hz, 2H), 3.81 (s, 6H), 3.76 (s, 3H), 3.27 ppm (t, *J*=5.3 Hz, 2H); ¹³C NMR (100 MHz, CDCl₃): δ =153.9, 144.9, 92.6, 90.8, 61.3, 61.1, 55.9, 46.6 ppm; HRMS (MALDI-FTMS) calcd for C₁₁H₁₈NO₄⁺ [*M*+H]⁺: 228.1230; found: 228.1239.

Synthesis of aminoalcohol starting materials (Procedure B): $NaCNBH_3$ (0.200 g, 3.5 mmol, 1.0 equiv) was added to a solution of the desired alde-

5600 —

5581-5606

hyde (3.5 mmol, 1.0 equiv) and amine (10.0 mmol, 2.85 equiv) in MeOH (25 mL) at 25 °C, and the resultant mixture was stirred for 12 h. Upon completion, the pH of the reaction media was acidified to a value of less than 2 using concentrated HCl; the contents were then concentrated directly. The resultant yellow residue was dissolved in water (10 mL) and extracted with Et₂O (15 mL) to remove any neutral impurities. The aqueous layer was then made alkaline (pH > 10) using saturated aqueous K₂CO₃ and was extracted with CH₂Cl₂ (3 × 25 mL). The combined organic layers were washed with water (50 mL), dried (MgSO₄), and concentrated. The resultant yellow residue was purified by flash column chromatography (silica gel) in an appropriate solvent system to give the desired aminoalcohol product in high purity.

Data for 118: $R_{\rm f}$ =0.01 (silica gel, EtOAc); IR (film): $\nu_{\rm max}$ =3435, 2940, 1636, 1513, 1357, 694 cm⁻¹; ¹H NMR (600 MHz, CD₃CN): δ =8.18 (s, 1 H), 8.04 (d, *J*=7.9 Hz, 1 H), 7.70 (d, *J*=7.5 Hz, 1 H), 7.52 (t, *J*=7.9 Hz, 1 H), 3.85 (s, 2 H), 3.55 (t, *J*=5.3 Hz, 2 H), 2.65 (t, *J*=5.2 Hz, 2 H), 2.58 ppm (brs, 2 H); ¹³C NMR (150 MHz, CD₃CN): δ =149.2, 144.2, 135.3, 130.2, 123.4, 122.5, 61.5, 52.9, 51.6 ppm; HRMS (MALDI-FTMS) calcd for C₉H₁₃N₂O₃⁺ [*M*+H]⁺: 197.0921; found: 197.0921.

Data for 120: $R_{\rm f}$ =0.04 (silica gel, EtOAc); IR (film): $\nu_{\rm max}$ =3439, 1636, 1452, 1041, 629, 542 cm⁻¹; ¹H NMR (600 MHz, CD₃CN): δ =6.70 (d, J=3.1 Hz, 1H), 6.59 (d, J=2.2 Hz, 1H), 3.85 (s, 2H), 3.54 (t, J=5.3 Hz, 2H), 2.82 (brs, 2H), 2.66 (t, J=5.3 Hz, 2H), 2.41 ppm (s, 3H); ¹³C NMR (150 MHz, CD₃CN): δ =142.8, 139.6, 125.8, 125.5, 61.3, 51.4, 48.6, 15.3 ppm; HRMS (MALDI-FTMS) calcd for C₈H₁₄NOS⁺ [*M*+H]⁺: 172.0791; found: 172.0791.

Data for 143: R_t =0.01 (silica gel, EtOAc); IR (film): ν_{max} =3418, 2953, 1636, 1514, 1467, 1303, 1249, 1180, 1030, 818, 602 cm⁻¹; ¹H NMR (600 MHz, CD₃CN): δ =7.24 (d, *J*=8.3 Hz, 2H), 6.87 (d, *J*=8.8 Hz, 2H), 3.75 (s, 3H), 3.67 (brs, 2H), 3.59 (t, *J*=6.2 Hz, 2H), 2.69 (t, *J*=6.6 Hz, 2H), 1.65 ppm (quin, *J*=6.1 Hz, 2H); ¹³C NMR (150 MHz, CD₃CN): δ = 159.6, 132.7, 130.5, 114.5, 62.0, 55.8, 53.4, 47.9, 32.4 ppm; HRMS (MALDI-FTMS) calcd for C₁₁H₁₈NO₂S⁺ [*M*+H]⁺: 196.1332; found: 196.1330.

Data for 145: $R_{\rm f}$ =0.02 (silica gel, EtOAc); IR (film): $\nu_{\rm max}$ =3434, 2970, 1636, 1471, 1409, 1309, 1061, 639 cm⁻¹; ¹H NMR (600 MHz, CD₃CN): δ = 7.65 (d, *J*=8.3 Hz, 2H), 7.47 (d, *J*=8.3 Hz, 2H), 3.79 (s, 2H), 3.58 (t, *J*=5.7 Hz, 2H), 2.77 (brs, 2H), 2.66 (t, *J*=6.6 Hz, 2H), 1.63 ppm (quin, *J*=6.1 Hz, 2H); ¹³C NMR (150 MHz, CD₃CN): δ =147.5, 133.0, 129.6, 119.8, 111.0, 62.1, 53.7, 48.1, 32.7 ppm; HRMS (MALDI-FTMS) calcd for C₁₁H₁₅N₂O⁺ [*M*+H]⁺: 191.1179; found: 191.1178.

Data for 147: $R_{\rm f}$ =0.02 (silica gel, EtOAc); IR (film): $\nu_{\rm max}$ =3429, 2940, 1641, 1566, 1471, 1067, 778, 667 cm⁻¹; ¹H NMR (600 MHz, CD₃CN): δ = 7.49 (s, 1H), 7.37 (d, *J*=7.8 Hz, 1H), 7.26 (d, *J*=7.4 Hz, 1H), 7.21 (t, *J*= 7.9 Hz, 1H), 3.69 (s, 2H), 3.57 (t, *J*=6.2 Hz, 2H), 3.05 (brs, 2H), 2.65 (t, *J*=6.5 Hz, 2H), 1.63 ppm (quin, *J*=6.1 Hz, 2H); ¹³C NMR (150 MHz, CD₃CN): δ =144.3, 131.8, 131.1, 130.6, 127.9, 122.8, 62.0, 53.5, 48.0, 32.8 ppm; HRMS (MALDI-FTMS) calcd for C₁₀H₁₅BrNO⁺ [*M*+H]⁺: 244.0331; found: 244.0333.

Data for 149: $R_{\rm f}$ =0.05 (silica gel, EtOAc); IR (film): $\nu_{\rm max}$ =3447, 2940, 1636, 1469, 1060, 798, 602 cm⁻¹; ¹H NMR (600 MHz, CD₃CN): δ =6.70 (d, *J*=3.1 Hz, 1 H), 6.59 (d, *J*=2.2 Hz, 1 H), 3.83 (s, 2 H), 3.59 (t, *J*=6.1 Hz, 2 H), 3.09 (brs, 2 H), 2.70 (t, *J*=6.2 Hz, 2 H), 2.41 (s, 3 H), 2.13 ppm (quin, *J*=6.1 Hz, 2 H); ¹³C NMR (150 MHz, CD₃CN): δ =142.7, 139.5, 125.8, 125.6, 62.2, 48.9, 47.9, 32.7, 15.4 ppm; HRMS (MALDI-FTMS) calcd for C₉H₁₆NOS⁺ [*M*+H]⁺: 186.0947; found: 186.0946.

Data for 151: R_f =0.07 (silica gel, EtOAc/hexanes, 1:2); IR (film): ν_{max} = 3376, 2934, 2861, 1650, 1528, 1476, 1349, 1062, 806, 733, 690 cm⁻¹; ¹H NMR (600 MHz, CDCl₃): δ =8.13 (s, 1H), 8.06 (d, *J*=8.3 Hz, 1H), 7.66 (d, *J*=7.4 Hz, 1H), 7.47 (t, *J*=7.9 Hz, 1H), 3.86 (s, 2H), 3.56 (t, *J*=4.9 Hz, 2H), 3.28 (brs, 2H), 2.66 (t, *J*=5.7 Hz, 2H), 1.61 ppm (m, 4H); ¹³C NMR (125 MHz, CDCl₃): δ =148.1, 141.4, 134.4, 129.4, 122.9, 122.1, 62.3, 52.8, 49.1, 31.5, 27.6 ppm; HRMS (MALDI-FTMS) calcd for C₁₁H₁₇N₂O₃S⁺ [*M*+H]⁺: 225.1234; found: 225.1239.

General procedure for the synthesis of sulfamides from precursor aminoalcohols: The aminoalcohol (0.5 mmol, 1.0 equiv) was dissolved in anhydrous THF (5 mL) and the appropriate Burgess-type reagent (1.25 mmol, 2.5 equiv) was added at 25 °C in a single portion. The resultant solution was immediately warmed to reflux (using a preheated oil bath) and stirred for 8 h. Upon completion, the reaction contents were cooled to 25 °C, poured into saturated aqueous NH₄Cl (25 mL), and extracted with CH_2Cl_2 (3×20 mL). The combined organic layers were then washed with water (50 mL), dried (MgSO₄), and concentrated. The resultant yellow residue was purified by flash column chromatography (silica gel) in an appropriate solvent system to give the desired product in high purity.

Data for 114: R_f =0.33 (silica gel, CH₂Cl₂); IR (film): ν_{max} =3447, 2877, 1730, 1458, 1328, 1245, 1217, 1159, 1133, 1081, 1018, 963, 936, 792, 764, 712, 644, 614 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ =3.84 (s, 3H), 3.82 (t, *J*=6.8 Hz, 2H), 3.33 (t, *J*=6.8 Hz, 2H), 2.75 ppm (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ =150.9, 54.1, 46.0, 42.7, 33.1 ppm; HRMS (MALDI-FTMS) calcd for C₅H₁₀N₂O₄SNa⁺ [*M*+Na]⁺: 217.0253; found: 217.0250.

Data for 115: $R_{\rm f}$ =0.40 (silica gel, CH₂Cl₂); IR (film): $\nu_{\rm max}$ =2966, 1731, 1458, 1390, 1323, 1166, 1079, 1018, 976, 942, 908, 842, 760, 700, 643 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ =7.42–7.32 (m, 5H), 5.30 (s, 2H), 3.84 (t, *J*=6.4 Hz, 2H), 3.33 (t, *J*=6.8 Hz, 2H), 2.77 ppm (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ =150.4, 134.7, 128.5, 128.4, 127.8, 68.8, 46.0, 42.7, 33.2 ppm; HRMS (MALDI-FTMS) calcd for C₁₁H₁₄N₂O₄SNa⁺ [*M*+Na]⁺: 293.0566; found: 293.0568.

Data for 117: $R_{\rm f}$ =0.67 (silica gel, EtOAc); IR (film): $\nu_{\rm max}$ =2984, 1730, 1449, 1349, 1320, 1216, 1174, 1146, 1059, 1001, 972, 945, 919, 780, 732, 698, 641, 601, 542, 488 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ =7.36 (m, 5H), 4.21 (s, 2H), 3.90 (s, 3H), 3.80 (t, *J*=6.8 Hz, 2H), 3.24 ppm (t, *J*=6.4 Hz, 2H); ¹³C NMR (100 MHz, CDCl₃): δ =151.1, 133.8, 128.9, 128.8, 128.5, 54.3, 50.4, 43.0, 42.9 ppm; HRMS (MALDI-FTMS) calcd for C₁₁H₁₄N₂O₄SNa⁺ [*M*+Na]⁺: 293.0566; found: 293.0565.

Data for 119: R_f =0.20 (silica gel, EtOAc/hexanes, 1:1); IR (film): ν_{max} = 2957, 1736, 1636, 1532, 1442, 1326, 1162, 729, 645, 545 cm⁻¹; ¹H NMR (600 MHz, CDCl₃): δ =8.24 (s, 1H), 8.20 (d, *J*=8.3 Hz, 1H), 7.76 (d, *J*= 7.5 Hz, 1H), 7.59 (t, *J*=7.9 Hz, 1H), 4.33 (s, 2H), 3.90 (s, 3H), 3.88 (t, *J*=6.2 Hz, 2H), 3.34 ppm (t, *J*=6.6 Hz, 2H); ¹³C NMR (150 MHz, CDCl₃): δ =150.9, 148.4, 136.3, 134.6, 130.0, 123.5, 123.4, 54.4, 49.8, 43.7, 42.9 ppm; HRMS (MALDI-FTMS) calcd for C₁₁H₁₃N₃O₆SNa⁺ [*M*+Na]⁺: 338.0417; found: 338.0416.

Data for 121: $R_{\rm f}$ =0.43 (silica gel, EtOAc/hexanes, 1:1); IR (film): $\nu_{\rm max}$ = 2957, 1737, 1640, 1442, 1323, 1221, 1161, 1096, 1040, 792, 758, 645 cm⁻¹; ¹H NMR (600 MHz, CDCl₃): δ =6.85 (d, *J*=3.5 Hz, 1H), 6.62 (m, 1H), 3.90 (s, 2H), 3.77 (t, *J*=6.5 Hz, 2H), 3.48 (s, 3H), 3.34 (t, *J*=6.5 Hz, 2H), 2.46 ppm (s, 3H); ¹³C NMR (150 MHz, CDCl₃): δ =151.1, 141.9, 133.3, 128.5, 124.9, 54.3, 45.7, 43.2, 42.7, 15.4 ppm; HRMS (MALDI-FTMS) calcd for C₁₀H₁₄N₂O₄S₂Na⁺ [*M*+Na]⁺: 313.0287; found: 313.0297.

Data for 123: $R_{\rm f}$ =0.34 (silica gel, CH₂Cl₂); IR (film): $\nu_{\rm max}$ =2981, 1728, 1446, 1364, 1343, 1314, 1255, 1198, 1148, 1077, 1007, 954, 866, 806, 760, 675, 616, 501 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ =3.86 (s, 3H), 3.77 (t, J=6.0 Hz, 2H), 3.40 (t, J=6.4 Hz, 2H), 1.41 ppm (s, 9H); ¹³C NMR (100 MHz, CDCl₃): δ =151.0, 57.1, 54.1, 41.6, 39.7, 27.3 ppm; HRMS (MALDI-FTMS) calcd for C₈H₁₆N₂O₄SNa⁺ [*M*+Na]⁺: 259.0723; found: 259.0721.

Data for 124: $R_{\rm f}$ =0.30 (silica gel, CH₂Cl₂); IR (film): $\nu_{\rm max}$ =2989, 2908, 1724, 1472, 1455, 1378, 1314, 1208, 1143, 1079, 1002, 938, 901, 862, 803, 761, 673, 615 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ =5.90 (m, 1 H), 5.41 (dd, *J*=17.2, 1.6 Hz, 1 H), 5.25 (dd, *J*=10.4, 1.6 Hz, 1 H), 4.74 (dt, *J*=5.2, 1.6 Hz, 2 H), 3.77 (t, *J*=6.0 Hz, 2 H), 3.41 (t, *J*=6.4 Hz, 2 H), 1.42 ppm (s, 9 H); ¹³C NMR (100 MHz, CDCl₃): δ =150.3, 130.9, 118.6, 67.4, 57.1, 41.5, 39.6, 27.3 ppm; HRMS (MALDI-FTMS) calcd for C₁₀H₁₈N₂O₄SNa⁺ [*M*+Na]⁺: 285.0879; found: 285.0879.

Data for 126: $R_{\rm f}$ =0.29 (silica gel, CH₂Cl₂); IR (film): $\nu_{\rm max}$ =2957, 1734, 1444, 1320, 1273, 1224, 1183, 1159, 1006, 944, 896, 787, 761, 612 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ =3.90 (dd, J=9.2, 6.0 Hz, 1H), 3.86 (s, 3H), 3.48 (m, 1H), 3.42 (dd, J=10.4, 9.2 Hz, 1H), 3.24 (m, 1H), 2.71 (dt, J=9.2, 2.8 Hz, 1H), 1.94 (m, 1H), 1.87 (m, 2H), 1.61 (m, 1H), 1.47-1.31 ppm (m, 2H); ¹³C NMR (100 MHz, CDCl₃): δ =150.9, 54.1, 53.5, 49.3, 42.6, 28.5, 23.1, 22.0 ppm; HRMS (MALDI-FTMS) calcd for C₈H₁₄N₂O₄SNa⁺ [*M*+Na]⁺: 257.0566; found: 257.0558.

Data for 127: R_f =0.51 (silica gel, CH₂Cl₂); IR (film): ν_{max} =3423, 2931, 1731, 1390, 1320, 1167, 1002, 885, 615 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ =7.42–7.32 (m, 5H), 5.30 (s, 2H), 3.92 (dd, *J*=9.2, 5.6 Hz, 1H), 3.50 (dt, *J*=11.2, 3.4 Hz, 1H), 3.45 (app t, *J*=9.2 Hz, 1H), 3.22 (m, 1H), 2.74 (dt, *J*=12.4, 3.2 Hz, 1H), 1.91–1.82 (m, 2H), 1.64 (m, 2H), 1.40 ppm (m, 2H); ¹³C NMR (100 MHz, CDCl₃): δ =150.5, 134.9, 128.6, 128.4, 127.8,

FULL PAPER

68.8, 53.6, 49.3, 42.7, 28.7, 23.3, 22.1 ppm; HRMS (MALDI-FTMS) calcd for $C_{14}H_{18}N_2O_4SNa^+$ [*M*+Na]⁺: 333.0879; found: 333.0875.

Data for 129: $R_{\rm f}$ =0.30 (silica gel, CH₂Cl₂); IR (film): $\nu_{\rm max}$ =2955, 1743, 1602, 1590, 1496, 1149, 1372, 1326, 1273, 1214, 1167, 1143, 1079, 1061, 950, 756, 703, 650, 585 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ =7.43–7.34 (m, 4H), 7.27 (t, *J*=7.2 Hz, 1H), 4.00 (t, *J*=6.4 Hz, 2H), 3.91 (s, 3H), 3.83 ppm (t, *J*=6.8 Hz, 2H); ¹³C NMR (75 MHz, CDCl₃): δ =150.9, 136.3, 129.6, 126.6, 121.7, 54.4, 43.5, 42.2 ppm; HRMS (MALDI-FTMS) calcd for C₁₀H₁₂N₂O₄SNa⁺ [*M*+Na]⁺: 279.0410; found: 279.0411.

Data for 130: $R_{\rm f}$ =0.43 (silica gel, CH₂Cl₂); IR (film): $\nu_{\rm max}$ =1720, 1661, 1543, 1496, 1422, 1332, 1198, 1010, 920, 740, 602 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ =7.43–7.40 (m, 2H), 7.39–7.35 (m, 2H), 7.28 (t, *J*=6.6 Hz, 1H), 5.96 (m, 1H), 5.47 (dd, *J*=17.3, 1.5 Hz, 1H), 5.30 (dt, *J*=11.8, 1.5 Hz, 1H), 4.81 (dt, *J*=5.5, 1.5 Hz, 2H), 4.04 (t, *J*=6.6 Hz, 2H), 3.87 ppm (t, *J*=5.9 Hz, 2H); ¹³C NMR (125 MHz, CDCl₃): δ =150.3, 136.5, 130.8, 129.7, 126.8, 21.9, 119.1, 68.0, 43.6, 42.2 ppm; HRMS (MALDI-FTMS) calcd for C₁₂H₁₄N₂O₄SNa⁺ [*M*+Na]⁺: 305.0566; found: 305.0566.

Data for 132: R_f =0.22 (silica gel, CH₂Cl₂); IR (film): ν_{max} =2986, 1727, 1639, 1509, 1433, 1339, 1286, 1163, 1133, 1081, 834, 751, 722, 687, 622 cm⁻¹; ¹H NMR (400 MHz, CD₃CN): δ =8.28 (dt, *J*=9.2, 3.2 Hz, 2 H), 7.47 (dt, *J*=8.8, 3.6 Hz, 2 H), 4.05 (t, *J*=6.2 Hz, 2 H), 3.98 (t, *J*=6.4 Hz, 2 H), 3.88 ppm (s, 3 H); ¹³C NMR (100 MHz, CD₃CN): δ =151.6, 126.3, 119.2, 118.3 (2 C), 55.1, 43.9, 43.0 ppm; HRMS (MALDI-FTMS) calcd for C₁₀H₁₁N₃O₆SNa⁺ [*M*+Na]⁺: 324.0261; found: 324.0257.

Data for 134: R_f =0.40 (silica gel, CH₂Cl₂); IR (film): ν_{max} =2958, 1733, 1619, 1472, 1437, 1390, 1325, 1273, 1173, 1120, 1073, 1006, 871, 806, 760, 698, 682, 612 cm⁻¹; ¹H NMR (400 MHz, CD₃CN): δ =7.89 (s, 1H), 7.86 (s, 2H), 4.04 (m, 2H), 3.98 (m, 2H), 3.88 ppm (s, 3H); ¹³C NMR (100 MHz, CD₃CN): δ =151.3, 139.9, 133.1 (d, *J*=132.0 Hz), 120.9, 119.7, 54.9, 44.0, 43.1 ppm; HRMS (MALDI-FTMS) calcd for C₁₂H₁₀F₆N₂O₄SNa⁺ [*M*+Na]⁺: 415.0158; found: 415.0169.

Data for 136: $R_{\rm f}$ =0.14 (silica gel, CH₂Cl₂); IR (film): $\nu_{\rm max}$ =2942, 2837, 1713, 1601, 1502, 1461, 1431, 1326, 1249, 1213, 1112, 1014, 864, 806, 763, 622 cm⁻¹; ¹H NMR (400 MHz, CD₃CN): δ =6.64 (s, 2 H), 3.97 (t, *J*=6.4 Hz, 2 H), 3.85 (s, 3 H), 3.83 (m, 2 H), 3.82 (s, 6 H), 3.72 ppm (s, 3 H); ¹³C NMR (100 MHz, CD₃CN): δ =155.5, 152.6, 138.3, 134.3, 101.7, 61.5, 57.5, 55.5, 45.5, 44.1 ppm; HRMS (MALDI-FTMS) calcd for C₁₃H₁₈N₂O₇SNa⁺ [*M*+Na]⁺: 369.0727; found: 369.0738.

Data for 138: $R_{\rm f}$ =0.46 (silica gel, CH₂Cl₂); IR (film): $\nu_{\rm max}$ =3472, 2966, 1737, 1572, 1455, 1443, 1396, 1326, 1273, 1243, 1179, 1149, 1096, 1070, 955, 861, 791, 773, 621 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ =8.26 (m, 1H), 7.83 (m, 1H), 7.54–7.47 (m, 3H), 7.37 (t, *J*=7.6 Hz, 1H), 6.89 (d, *J*=7.6 Hz, 1H), 4.67 (dt, *J*=11.6, 8.4 Hz, 1H), 4.44 (dd, *J*=9.2, 3.6 Hz, 1H), 4.35 (t, *J*=9.2 Hz, 1H), 3.94 (s, 3H), 3.88 (sep, *J*=6.4 Hz, 1H), 3.58 (m, 2H), 1.30 ppm (appt, *J*=7.2 Hz, 6H); ¹³C NMR (100 MHz, CDCl₃): δ =153.6, 151.1, 134.5, 127.6, 126.6, 125.8, 125.5, 121.7, 121.2, 104.9, 65.4, 52.7, 43.3, 41.0, 20.9, 19.8 ppm; HRMS (MALDI-FTMS) calcd for C₁₈H₂₂N₂O₅SNa⁺ [*M*+Na]⁺: 401.1142; found: 401.1129.

Data for 140: R_t =0.40 (silica gel, EtOAc); IR (film): ν_{max} =3420, 1637, 1432, 1329, 1156, 1024, 984, 756, 702, 657 cm⁻¹; ¹H NMR (400 MHz, DMSO-*d*₆): δ =2.90 (t, *J*=6.4 Hz, 4H), 2.84 (s, 6H), 2.57 (t, *J*=6.4 Hz, 4H), 2.35 ppm (s, 4H); ¹³C NMR (100 MHz, DMSO-*d*₆): δ =150.6, 54.0, 44.8, 44.0, 43.5 ppm; HRMS (MALDI-FTMS) calcd for C₁₀H₁₈N₄O₈S₂Na⁺ [*M*+Na]⁺: 409.0458; found: 409.0447.

Data for 142: R_f =0.24 (silica gel, MeOH/CH₂Cl₂, 3:97); IR (film): ν_{max} = 3272, 2919, 1731, 1496, 1455, 1355, 1326, 1237, 1161, 961, 861, 756, 591 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ =7.45 (d, *J*=7.6 Hz, 1H), 7.29 (dt, *J*=8.4, 1.6 Hz, 1H), 7.22 (dd, *J*=8.0, 1.6 Hz, 1H), 7.16 (t, *J*=7.2 Hz, 1H), 5.29 (brs, 1H), 4.72 (s, 2H), 3.71 ppm (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ =151.9, 135.1, 131.8, 129.5, 129.2, 125.9, 122.3, 63.2, 53.7 ppm; HRMS (MALDI-FTMS) calcd for C₉H₁₀N₂O₄SNa⁺ [*M*+Na]⁺: 265.0253; found: 265.0256.

Data for 144: R_f =0.40 (silica gel, EtOAc/hexanes, 1:1); IR (film): ν_{max} = 2957, 1724, 1636, 1513, 1440, 1382, 1291, 1250, 1176, 1030, 775, 624 cm⁻¹; ¹H NMR (600 MHz, CDCl₃): δ =7.23 (d, *J*=8.8 Hz, 2H), 6.87 (d, *J*=8.3 Hz, 2H), 4.30 (s, 2H), 4.01 (t, *J*=5.7 Hz, 2H), 3.86 (s, 3H), 3.79 (s, 3H), 3.42 (t, *J*=6.1 Hz, 2H), 1.79 ppm (quin, *J*=6.1 Hz, 2H); ¹³C NMR (150 MHz, CDCl₃): δ =159.4, 153.7, 129.8, 126.6, 114.0, 55.2, 54.2, 51.5,

47.4, 46.6, 19.2 ppm; HRMS (MALDI-FTMS) calcd for $C_{13}H_{18}N_2O_5SNa^+$ [*M*+Na]⁺: 337.0829; found: 337.0828.

Data for 146: R_f =0.24 (silica gel, EtOAc/hexanes, 1:1); IR (film): ν_{max} = 2982, 2231, 1732, 1636, 1435, 1359, 1297, 1253, 1170, 1032, 949, 864, 584 cm⁻¹; ¹H NMR (600 MHz, CDCl₃): δ =7.65 (d, J=8.3 Hz, 2H), 7.46 (d, J=7.9 Hz, 2H), 4.42 (s, 2H), 4.06 (t, J=5.7 Hz, 2H), 3.86 (s, 3H), 3.49 (t, J=5.7 Hz, 2H), 1.86 ppm (quin, J=6.1 Hz, 2H); ¹³C NMR (150 MHz, CDCl₃): δ =153.5, 140.8, 132.5, 128.6, 118.3, 111.9, 54.4, 51.9, 48.2, 47.5, 19.5 ppm; HRMS (MALDI-FTMS) calcd for C₁₃H₁₅N₃O₄SNa⁺ [*M*+Na]⁺: 332.0675; found: 332.0681.

Data for 148: $R_{\rm f}$ =0.44 (silica gel, EtOAc/hexanes, 1:1); IR (film): $\nu_{\rm max}$ = 2956, 1729, 1571, 1437, 1383, 1307, 1273, 1176, 1023, 953, 843, 777, 609, 564 cm⁻¹; ¹H NMR (600 MHz, CDCl₃): δ =7.46 (s, 1H), 7.42 (d, *J*= 7.9 Hz, 1H), 7.24 (d, *J*=7.9 Hz, 1H), 7.21 (t, *J*=7.4 Hz, 1H), 4.31 (s, 2H), 4.02 (t, *J*=5.7 Hz, 2H), 3.84 (s, 3H), 3.45 (t, *J*=5.7 Hz, 2H), 1.81 ppm (quin, *J*=6.1 Hz, 2H); ¹³C NMR (150 MHz, CDCl₃): δ =153.6, 137.4, 131.2, 131.1, 130.3, 126.8, 122.7, 54.3, 51.5, 47.5, 47.4, 19.4 ppm; HRMS (MALDI-FTMS) calcd for C₁₂H₁₆BrN₂O₄S⁺ [*M*+H]⁺: 363.0009; found: 363.0011.

Data for 150: $R_{\rm f}$ =0.45 (silica gel, EtOAc/hexanes, 1:1); IR (film): $\nu_{\rm max}$ = 2970, 1726, 1636, 1439, 1383, 1298, 1265, 1176, 854, 775, 596 cm⁻¹; ¹H NMR (600 MHz, CDCl₃): δ =6.78 (s, 1 H), 6.59 (s, 1 H), 4.46 (s, 2 H), 4.00 (t, *J*=6.1 Hz, 2 H), 3.86 (s, 3 H), 3.52 (t, *J*=5.7 Hz, 2 H), 2.45 (s, 3 H), 1.78 ppm (brm, 2 H); ¹³C NMR (150 MHz, CDCl₃): δ =153.8, 141.4, 134.7, 127.8, 124.9, 54.4, 47.5, 47.3, 46.7, 19.6, 15.4 ppm; HRMS (MALDI-FTMS) calcd for C₁₁H₁₆N₂O₄S₂Na⁺ [*M*+Na]⁺: 327.0444; found: 327.0443.

Data for 152: R_f =0.42 (silica gel, EtOAc/hexanes, 1:2); IR (film): ν_{max} = 2953, 1725, 1531, 1437, 1350, 1274, 1164, 925, 765, 602 cm⁻¹; ¹H NMR (600 MHz, CDCl₃): δ =8.25–8.19 (m, 2H), 7.78 (d, *J*=9.2 Hz, 1H), 7.59 (t, *J*=8.3 Hz, 1H), 7.69 (s, 2H), 3.90 (s, 3H), 3.85 (t, *J*=4.8 Hz, 2H), 3.35 (t, *J*=5.2 Hz, 2H), 1.97 (brm, 2H), 1.87 ppm (brm, 2H); ¹³C NMR (150 MHz, CDCl₃): δ =153.6, 148.2, 138.0, 133.7, 129.9, 123.0, 122.5, 54.2, 51.1, 46.3, 46.1, 28.0, 23.7 ppm; HRMS (MALDI-FTMS) calcd for C₁₃H₁₈N₃O₆S⁺ [*M*+H]⁺: 344.0911; found: 344.0909.

Data for 154: $R_{\rm f}$ =0.63 (silica gel, EtOAc); IR (film): $\nu_{\rm max}$ =3251, 2958, 1743, 1661, 1602, 1473, 1455, 1367, 1237, 1167, 1108, 1061, 985, 856, 756, 591 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ =7.31 (d, *J*=8.0 Hz, 1 H), 7.20-7.16 (m, 2 H), 7.03 (t, *J*=7.6 Hz, 1 H), 5.28 (brs, 1 H), 4.31 (t, *J*=8.8 Hz, 2 H), 3.64 (s, 3 H), 3.15 ppm (t, *J*=8.8 Hz, 2 H); ¹³C NMR (100 MHz, CDCl₃): δ =151.7, 140.6, 131.5, 127.6, 125.3, 123.8, 113.9, 53.5, 51.6, 27.9 ppm; HRMS (MALDI-FTMS) calcd for C₁₀H₁₂N₂O₅SNa⁺ [*M*+Na]⁺: 279.0410; found: 279.0412.

Data for 156: R_f =0.25 (silica gel, CH₂Cl₂); IR (film): ν_{max} =3252, 2962, 1730, 1443, 1408, 1337, 1208, 1167, 1097, 1021, 950, 921, 786, 757, 651, 633 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ =3.81 (t, *J*=6.4 Hz, 2H), 3.76 (s, 3H), 3.49 (brs, 1H), 3.40 ppm (t, *J*=6.4 Hz, 2H); ¹³C NMR (100 MHz, CDCl₃): δ =151.5, 54.0, 48.2, 39.1 ppm; HRMS (MALDI-FTMS) calcd for C₄H₈N₂O₄SNa⁺ [*M*+Na]⁺: 203.0097; found: 203.0097.

Data for 158: R_f =0.49 (silica gel, CH₂Cl₂); IR (film): v_{max} =3286, 1732, 1470, 1454, 1347, 1252, 1154, 1057, 882, 771, 590 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ =5.63 (brs, 1H), 3.89 (s, 3H), 3.62 (s, 2H), 1.40 ppm (s, 6H); ¹³C NMR (125 MHz, CDCl₃): δ =152.5, 69.6, 58.9, 53.9, 24.3 ppm; HRMS (MALDI-FTMS) calcd for C₆H₁₂N₂O₄SNa⁺ [*M*+Na]⁺: 231.0410; found: 231.0412.

Data for 160: $R_{\rm f}$ =0.44 (silica gel, CH₂Cl₂); IR (film): $\nu_{\rm max}$ =3270, 1731, 1443, 1351, 1270, 1174, 1081, 1010, 774, 625, 568 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ =4.91 (brt, J=7.7 Hz, 1H), 4.09 (t, J=5.5 Hz, 2H), 3.93 (s, 3H), 3.62 (dt, J=7.4, 5.9 Hz, 2H), 1.95 ppm (quin, J=5.9 Hz, 2H); ¹³C NMR (125 MHz, CDCl₃): δ =153.7, 54.5, 47.3, 44.3, 24.7 ppm; HRMS (MALDI-FTMS) calcd for C₅H₁₀N₂O₄SNa⁺ [*M*+Na]⁺: 217.0253; found: 217.0254.

Data for 162: $R_{\rm f}$ =0.52 (silica gel, CH₂Cl₂); IR (film): $\nu_{\rm max}$ =3288, 1732, 1472, 1352, 1250, 1160, 1065, 874, 764, 702, 587 cm⁻¹; ¹H NMR (600 MHz, CDCl₃): δ =7.32–7.25 (m, 5H), 6.10 (br t, *J*=5.7 Hz, 1H), 4.87 (dd, *J*=8.8, 3.1 Hz, 1H), 3.72 (s, 3H), 3.37 (m, 1H), 3.22 ppm (m, 1H); ¹³C NMR (150 MHz, CDCl₃): δ =152.5, 140.6, 128.9, 128.4, 126.1, 72.7, 53.9, 50.8 ppm; HRMS (MALDI-FTMS) calcd for C₁₀H₁₂N₂O₄SNa⁺ [*M*+Na]⁺: 279.0410; found: 279.0411.

^{5602 -}

Data for 164: $R_{\rm f}$ =0.55 (silica gel, CH₂Cl₂); IR (film): $\nu_{\rm max}$ =3540, 3301, 1730, 1455, 1416, 1360, 1253, 1165, 1092, 1060, 969, 852, 772, 702, 606, 552 cm⁻¹; ¹H NMR (600 MHz, CD₃CN): δ =7.30–7.21 (m, 10H), 6.46 (d, J=9.2 Hz, 1H), 4.98 (d, J=6.1 Hz, 1H), 4.54 (dd, J=9.2, 6.1 Hz, 1H), 3.43 ppm (s, 3H); ¹³C NMR (150 MHz, CD₃CN): δ =152.4, 142.1, 138.4, 129.3, 129.3, 128.8, 128.6, 128.5, 128.4, 127.7, 76.4, 64.6, 53.4 ppm; HRMS (MALDI-FTMS) calcd for C₁₆H₁₆N₂O₄SNa⁺ [*M*+Na]⁺: 355.0723; found: 355.0724.

General conditions for the removal of methyl carbamate protection from cyclic sulfamides: 10% aqueous NaOH (0.5 mL) was added to a solution of the CO₂Me-protected sulfamidate (0.2 mmol, 1.0 equiv) in MeOH/ H_2O (2:1, 3 mL) at 25 °C. After stirring this mixture for 2 h at 25 °C, the reaction contents were poured into saturated aqueous NH₄Cl (5 mL), acidified with 1 m aqueous HCl (2 mL), and extracted with EtOAc (3× 10 mL). The combined organic layers were then dried (MgSO₄) and concentrated to give the desired deprotected sulfamidate in high purity.

Data for 165: R_f =0.14 (silica gel, MeOH/CH₂Cl₂, 3:97); IR (film): ν_{max} = 3440, 3225, 1621, 1473, 1387, 1318, 1282, 1176, 1127, 1002, 788 cm⁻¹; ¹H NMR (600 MHz, CDCl₃): δ =7.61 (s, 1H), 7.58 (s, 2H), 4.99 (t, *J*= 7.9 Hz, 1H), 4.00 (t, *J*=6.5 Hz, 2H), 3.77 ppm (q, *J*=6.6 Hz, 2H); ¹³C NMR (150 MHz, CDCl₃): δ =139.4, 132.9 (q, *J*=137.3 Hz), 123.8, 122.0, 116.8, 48.8, 39.4 ppm; MS (ESI) calcd for C₁₀H₇F₆N₂O₂S⁺ [*M*-H]⁺: 333; found: 333.

Data for 166: $R_{\rm f}$ =0.12 (silica gel, CH₂Cl₂); IR (film): $\nu_{\rm max}$ =3244, 2904, 1449, 1296, 1161, 1021, 897, 779, 715, 688, 616 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ =7.37–7.30 (m, 5H), 4.71 (brs, 1H), 4.17 (s, 2H), 3.46 (t, *J*= 6.4 Hz, 2H), 3.27 ppm (t, *J*=6.8 Hz, 2H); ¹³C NMR (100 MHz, CDCl₃): δ =135.1, 128.7, 128.6, 128.1, 50.4, 48.1, 39.9 ppm; HRMS (MALDI-FTMS) calcd for C₉H₁₂N₂O₂SNa⁺ [*M*+Na]⁺: 235.0512; found: 235.0515.

General conditions for the removal of allyl carbamate protection from cyclic sulfamides: Et₂NH (0.828 mL, 8.0 mmol, 40 equiv) was added to a solution of the Alloc-protected sulfamidate (0.2 mmol, 1.0 equiv) in CH₃CN/H₂O (1:1, 3 mL) at 25 °C. After stirring this mixture for 5 minutes at 25 °C, Pd(OAc)₂ (0.002 g, 0.020 mmol, 0.1 equiv) and TPPTS (0.023 g, 0.040 mmol, 0.2 equiv) were added sequentially, providing a yellow solution which was stirred for an additional 30 minutes at 25 °C. Upon completion, the reaction contents were poured into water (5 mL), and extracted with EtOAc (3×10 mL). The combined organic layers were then dried (MgSO₄) and concentrated to give the desired deprotected sulfamidate in high purity.^[29]

Data for 167: $R_{\rm f}$ =0.11 (silica gel, CH₂Cl₂); IR (film): $\nu_{\rm max}$ =3258, 3056, 2982, 1374, 1266, 1206, 1155, 1005, 739 cm⁻¹; ¹H NMR (600 MHz, CDCl₃): δ =4.27 (brs, 1H), 3.51 (d, *J*=6.6 Hz, 6H), 3.45 (d, *J*=6.6 Hz, 2H), 1.42 ppm (s, 9H); ¹³C NMR (100 MHz, CDCl₃): δ =63.2, 45.2, 39.0, 27.2 ppm; HRMS (MALDI-FTMS) calcd for C₆H₁₄N₂O₄SNa⁺ [*M*+Na]⁺: 201.0668; found: 201.0665.

Data for 168: $R_{\rm f}$ =0.14 (silica gel, CH₂Cl₂); IR (film): $\nu_{\rm max}$ =3190, 1596, 1417, 1298, 1232, 1154, 1118, 1031, 950, 747, 688, 615, 464 cm⁻¹; ¹H NMR (600 MHz, CDCl₃): δ =7.38–7.35 (m, 2 H), 7.23 (d, *J*=7.5 Hz, 2 H), 7.15 (t, *J*=7.4 Hz, 1H), 4.86 (brs, 1 H), 3.88 (t, *J*=6.1 Hz, 2 H), 3.65 ppm (t, *J*=6.6 Hz, 2 H); ¹³C NMR (125 MHz, CDCl₃): δ =137.7, 129.5, 124.1, 118.2, 48.7, 39.6 ppm; MS (ESI) calcd for C₈H₁₀N₂O₂SNa⁺ [*M*+Na]⁺: 221; found: 221.

General conditions for the removal of benzyl carbamate protection from cyclic sulfamides: Pd/C (0.002 g, 10 wt %, catalytic) was added to a solution of the Cbz-protected sulfamidate (0.2 mmol, 1.0 equiv) in EtOH/ EtOAc (4:1, 3 mL) at 25 °C. The resultant suspension was then equipped with a balloon containing hydrogen gas (pressure of ~2 atm) and allowed to stir for 24 h at 25 °C. Upon completion, the reaction contents were filtered through Celite and concentrated to give the desired deprotected sulfamidate in high purity.

Data for 169: $R_{\rm f}$ =0.22 (silica gel, CH₂Cl₂); IR (film): $\nu_{\rm max}$ =3548, 3254, 2925, 1454, 1389, 1295, 1201, 1154, 1014, 914, 703 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ =4.61 (brs, 1 H), 3.58 (t, *J*=5.2 Hz, 2 H), 3.47 (t, *J*=5.2 Hz, 2 H), 2.82 ppm (s, 3 H); ¹³C NMR (100 MHz, CDCl₃): δ =50.5, 39.7, 32.7 ppm; HRMS (MALDI-FTMS) calcd for C₃H₉N₂O₄S⁺ [*M*+H]⁺: 137.0379; found: 137.0373.

Data for 170: $R_{\rm f}$ =0.10 (silica gel, CH₂Cl₂); IR (film): $\nu_{\rm max}$ =3559, 3264, 2944, 2854, 1636, 1444, 1397, 1303, 1220, 1159, 1064, 1025, 1003, 726 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ =4.32 (brs, 1H), 3.50 (m, 2H), 3.22–3.14

(m, 2H), 2.67 (dt, J=11.2, 3.2 Hz, 1H), 1.90–1.80 (m, 3H), 1.59 (m, 1H), 1.42–1.26 ppm (m, 2H); ¹³C NMR (100 MHz, CDCl₃): δ =57.6, 47.6, 43.1, 29.6, 23.6, 22.5 ppm; HRMS (MALDI-FTMS) calcd for C₆H₁₂N₂O₂SNa⁺ [*M*+Na]⁺: 199.0512; found: 199.0515.

Alkylated sulfamide 171: Sulfamide 166 (0.053 g, 0.250 mmol, 1.0 equiv) was dissolved in DMSO (2 mL) and treated with NaH (0.050 g, 60 % dispersion in mineral oil, 1.25 mmol, 5.0 equiv) at 25 °C. After stirring the resultant reaction mixture for 10 minutes at 25 °C, 4-bromo-1-butene (0.102 mL, 1.0 mmol, 4.0 equiv) and TBAI (0.01 g, catalytic) were added sequentially; the reaction mixture was then stirred for an additional 15 minutes at 25 °C. Upon completion, the reaction contents were poured into water (5 mL), and extracted with EtOAc (3×10 mL). The combined organic layers were then washed with water (2×15 mL), dried (MgSO₄), and concentrated. The resultant light yellow oil was purified by flash column chromatography (silica gel, EtOAc/hexanes, 1:3→1:1) to give alkylated sulfamidate 171 (0.059 g, 89% yield) as an amorphous white solid. $R_f = 0.18$ (silica gel, CH₂Cl₂/hexanes, 2:1); IR (film): $\nu_{max} = 3524$, 2925, 1635, 1448, 1301, 1166, 1143, 1113, 914, 779, 689 cm⁻¹; ¹H NMR $(500 \text{ MHz}, \text{ CDCl}_3): \delta = 7.37 - 7.30 \text{ (m, 5H)}, 5.82 \text{ (m, 1H)}, 5.14 \text{ (dd, } J =$ 17.0, 2.0 Hz, 1 H), 5.11 (dd, J=10.5, 1.6 Hz, 1 H), 4.19 (s, 2 H), 3.29 (dd, J=6.0, 1.2 Hz, 2H), 3.18–3.13 (m, 4H), 2.40 ppm (m, 2H); ¹³C NMR (125 MHz, CDCl₃): $\delta = 134.9$, 134.5, 128.7, 128.6, 128.1, 77.2, 51.3, 47.3, 45.6, 44.8, 32.1 ppm; HRMS (MALDI-FTMS) calcd for C13H18N2O2SNa+ [*M*+Na]⁺: 289.0981; found: 289.0981.

General conditions for the synthesis of linear sulfamides: The diol (0.5 mmol, 1.0 equiv) was dissolved in anhydrous THF (5 mL) and the Burgess reagent (1, 0.75 mmol, 1.5 equiv) was added at 25 °C in a single portion. The resultant solution was immediately warmed to reflux (using a preheated oil bath) and stirred for 2 h. Upon completion, the reaction contents were cooled to 25 °C, poured into saturated aqueous NH₄Cl (25 mL), and extracted with CH₂Cl₂ (3×20 mL). The combined organic layers were then washed with water (50 mL), dried (MgSO₄), and concentrated. The resultant yellow residue was purified by flash column chromatography (silica gel) in an appropriate solvent system to give the desired product in high purity.

Data for 173: R_f =0.25 (silica gel, CH₂Cl₂); IR (film): v_{max} =3276, 3201, 2940, 1714, 1490, 1454, 1348, 1166, 1084, 1008, 850, 778, 608 cm⁻¹; ¹H NMR (600 MHz, CDCl₃): δ =7.83 (s, 1H), 5.29 (d, *J*=7.0 Hz, 1H), 3.81 (s, 3H), 3.30 (br dd, *J*=7.0, 3.5 Hz, 1H), 1.94 (m, 2H), 1.74 (m, 2H), 1.58 (m, 1H), 1.36–1.27 (m, 4H), 1.18 ppm (m, 1H); ¹³C NMR (150 MHz, CDCl₃): δ =152.0, 53.6, 53.5, 33.2, 25.1, 24.5 ppm; HRMS (MALDI-FTMS) calcd for C₈H₁₆N₂O₄SNa⁺ [*M*+Na]⁺: 259.0723; found: 259.0728. **Data for 175**: R_f =0.16 (silica gel, CH₂Cl₂); IR (film): v_{max} =3260, 2924, 1750, 1460, 1419, 1355, 1231, 1155, 1131, 1002, 943, 855, 773, 732, 603, 579 cm⁻¹; ¹H NMR (300 MHz, CD₃CN): δ =7.31–7.20 (m, 5H), 5.24 (s, 1H), 4.43 (s, 2H), 3.74 (s, 3H), 2.80 ppm (s, 3H); ¹³C NMR (100 MHz, CD₃CN): δ =152.0, 135.6, 128.7, 128.1 128.0, 55.1, 53.5, 35.1 ppm; HRMS (MALDI-FTMS) calcd for C₁₀H₁₄N₂O₄SNa⁺ [*M*+Na]⁺: 281.0566; found: 281.0567.

Data for 177: $R_{\rm f}$ =0.38 (silica gel, CH₂Cl₂); IR (film): $\nu_{\rm max}$ =3448, 3271, 2919, 1748, 1449, 1361, 1331, 1225, 1137, 1102, 1049, 1026, 979, 861, 585 cm⁻¹; ¹H NMR (400 MHz, CD₃CN): δ =7.49 (brs, 1 H), 3.75 (s, 3 H), 3.43 (brm, 2 H), 1.81–1.60 (m, 14 H), 1.31–1.24 (m, 4 H), 1.08 ppm (m, 2 H); ¹³C NMR (100 MHz, CD₃CN): δ =151.3, 58.9, 53.1, 32.1, 26.3, 25.1 ppm; HRMS (MALDI-FTMS) calcd for C₁₄H₂₆N₂O₄SNa⁺ [*M*+Na]⁺: 341.1505; found: 341.1501.

Data for 179: $R_{\rm f}$ =0.47 (silica gel, EtOAc); IR (film): $v_{\rm max}$ =3275, 2907, 1748, 1461, 1361, 1261, 1167, 1114, 1079, 1015, 950, 862, 768, 721, 575 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ =8.41 (brs, 1H), 3.73 (s, 3H), 3.70 (t, *J*=4.8 Hz, 4H), 3.33 ppm (t, *J*=4.8 Hz, 4H); ¹³C NMR (100 MHz, CDCl₃): δ =151.8, 66.1, 53.4, 46.4 ppm; HRMS (MALDI-FTMS) calcd for C₆H₁₂N₂O₅SNa⁺ [*M*+Na]⁺: 247.0359; found: 247.0361. **Data for 181**: $R_{\rm f}$ =0.63 (silica gel, EtOAc); IR (film): $v_{\rm max}$ =3256, 2957, 1742, 1466, 1420, 1355, 1308, 1238, 1155, 1062, 950, 856, 759, 591 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ =8.19 (brs, 1H), 4.51 (s, 2H), 3.79 (t, *J*=6.4 Hz, 2H), 3.75 (s, 3H), 3.03 ppm (t, *J*=6.4 Hz, 2H); ¹³C NMR (100 MHz, CDCl₃): δ =151.6, 53.6, 51.7, 50.6, 30.9 ppm; HRMS (MALDI-FTMS) calcd for C₅H₁₀N₂O₄S₂Na⁺ [*M*+Na]⁺: 248.9974; found: 248.9981.

Chem. Eur. J. 2004, 10, 5581–5606 www.chemeurj.org © 2004 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim

K. C. Nicolaou et al.

Data for 183: $R_{\rm f}$ =0.20 (silica gel, MeOH/CH₂Cl₂, 3:97); IR (film): $\nu_{\rm max}$ = 3260, 2959, 1731, 1510, 1468, 1351, 1250, 1215, 1162, 1030, 962, 865, 826, 772, 587, 541 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ =7.53 (d, *J*=8.8 Hz, 2H), 7.24 (d, *J*=8.8 Hz, 2H), 5.84 (s, 1H), 5.70 (brs, 1H), 4.12 (s, 3 H), 4.07 ppm (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ =158.0, 152.1, 128.3, 124.8, 114.5, 55.4, 53.5 ppm; HRMS (MALDI-FTMS) calcd for C₉H₁₂N₂O₅SNa⁺ [*M*+Na]⁺: 283.0359; found: 283.0359.

Data for 185: $R_{\rm f}$ =0.53 (silica gel, EtOAc); IR (film): $\nu_{\rm max}$ =3465, 3111, 2954, 2225, 1743, 1607, 1507, 1460, 1361, 1225, 1161, 955, 932, 879, 832, 767, 573 cm⁻¹; ¹H NMR (400 MHz, CD₃OD): δ =7.42 (d, *J*=8.8 Hz, 2H), 7.08 (d, *J*=8.8 Hz, 2H), 4.71 (brs, 2H), 3.42 ppm (s, 3H); ¹³C NMR (100 MHz, CD₃OD): δ =153.4, 143.4, 134.6, 119.8, 119.0, 107.6, 53.6 ppm; MS (ESI) calcd for C₉H₉N₃O₄SNa⁺ [*M*+Na]⁺: 278; found: 278.

Data for 187: $R_{\rm f}$ =0.14 (silica gel, EtOAc); IR (film): $\nu_{\rm max}$ =3248, 2945, 2838, 1749, 1467, 1361, 1237, 1149, 1073, 983, 860, 776, 584 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ =7.91 (brs, 1H), 4.49 (t, *J*=5.2 Hz, 1H), 3.76 (s, 3H), 3.40 (s, 6H), 3.39 (m, 2H), 3.01 ppm (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ =151.7, 103.7, 54.7, 53.4, 52.7, 37.2 ppm; HRMS (MALDI-FTMS) calcd for C₇H₁₆N₂O₆SNa⁺ [*M*+Na]⁺: 279.0621; found: 279.0622.

Acknowledgement

We thank Drs. D. H. Huang, G. Siuzdak, and R. Chadha for NMR spectroscopic, mass spectrometric, and X-ray crystallographic assistance, respectively. Financial support for this work was provided by The Skaggs Institute for Chemical Biology, the National Institutes of Health (USA), predoctoral fellowships from the National Science Foundation, Pfizer, and Bristol–Myers Squibb (all to S.A.S.), postdoctoral fellowships from the Royal Society Fulbright Commission (to D.A.L.) and the Skaggs Institute for Chemical Biology (to X.H.), and a grant from American Bio-Science.

- a) G. M. Atkins, E. M. Burgess, J. Am. Chem. Soc. 1968, 90, 4744– 4745; b) G. M. Atkins, E. M. Burgess, J. Am. Chem. Soc. 1972, 94, 6135–6141; c) E. M. Burgess, H. R. Penton, E. A. Taylor, J. Org. Chem. 1973, 38, 26–31.
- [2] For reviews on the chemistry of the Burgess reagent, see: a) P. Taibe, S. Mobashery, in *Encyclopedia of Reagents for Organic Synthesis, Vol. 5* (Ed.: L. A. Paquette), Wiley, Chichester, **1995**, pp. 3345–3347; b) S. Burckhardt, *Synlett* **2000**, 559.
- [3] For selected examples, see: a) R. McCague, J. Chem. Soc. Perkin Trans. 1 1987, 1011–1015; b) H. Stalder, Helv. Chim. Acta 1986, 69, 1887–1897; c) D. J. Goldsmith, H. S. Kezar, Tetrahedron Lett. 1980, 21, 3543–3546; d) J. P. Marino, M. P. Ferro, J. Org. Chem. 1981, 46, 1912–1914; e) P. Crabbé, C. Léon, J. Org. Chem. 1970, 35, 2594– 2596.
- [4] D. A. Claremon, B. Phillips, Tetrahedron Lett. 1988, 29, 2155.
- [5] For selected examples, see: a) P. Wipf, C. P. Miller, *Tetrahedron Lett.* 1992, *33*, 907–910; b) P. Wipf, S. Venkatraman, *Synlett* 1997, 1–10.
 [6] C. T. Brain, J. M. Paul, *Synlett* 1999, 1642–1644.
- [7] For a leading reference, see: K. C. Nicolaou, S. A. Snyder, X. Huang, K. B. Simonsen, A. E. Koumbis, A. Bigot, J. Am. Chem. Soc.
- 2004, 126, 10162-10173, and subsequent articles in this series.
 [8] See references [1a,b]. For a later application of this approach using the novel Burgess-type reagents that were developed as part of this program (vide infra), see: M. R. Wood, J. Y. Kim, K. M. Books, *Tetrahedron Lett.* 2002, 43, 3887-3890.
- [9] a) K. C. Nicolaou, X. Huang, S. A. Snyder, P. Bheema Rao, M. Bella, M. V. Reddy, Angew. Chem. 2002, 114, 862–866; Angew. Chem. Int. Ed. 2002, 41, 834–838; b) K. C. Nicolaou, D. A. Longbottom, S. A. Snyder, A. Z. Nalbandian, X. Huang, Angew. Chem. 2002, 114, 4022–4026; Angew. Chem. Int. Ed. 2002, 41, 3866–3870; c) K. C. Nicolaou, S. A. Snyder, A. Z. Nalbandian, D. A. Longbottom, J. Am. Chem. Soc. 2004, 126, 6234–6235.
- [10] For a review on these approaches, see: a) R. E. Melendez, W. D. Lubell, *Tetrahedron* 2003, 59, 2581–2616. For recent papers, see: b) F. Duran, L. Leman, A. Ghini, G. Burton, P. Dauban, R. H.

Dodd, Org. Lett. 2002, 4, 2481–2483; c) J.-L. Liang, S.-X. Yuan, J.-S. Huang, W.-Y. Yu, C.-M. Che, Angew. Chem. 2002, 114, 3615–3618; Angew. Chem. Int. Ed. 2002, 41, 3465–3468.

- [11] For selected primary literature related to both sulfamidate synthesis and nucleophilic ring-opening, see: a) L. Wei, W. D. Lubell, Org. Lett. 2000, 2, 2595-2598; b) L. T. Boulton, H. T. Stock, J. Raphy, D. C. Horwell, J. Chem. Soc. Perkin Trans. 1 1999, 1421-1429; c) D. Ok, M. H. Fisher, M. J. Wyvratt, P. T. Meinke, Tetrahedron Lett. 1999, 40, 3831-3834; d) B. M. Kim, S. M. So, Tetrahedron Lett. 1998, 39, 5381-5384; e) B. Aguilera, A. Fernandez-Mayorales, C. Jaramillo, Tetrahedron 1997, 53, 5863-5876; f) M. E. Van Dort, Y.-W. Jung, P. S. Sherman, M. R. Kilbourn, D. M. Wieland, J. Med. Chem. 1995, 38, 810-815; g) K. K. Andersen, M. G. Kociolek, J. Org. Chem. 1995, 60, 2003-2007; h) M. Okuda, K. Tomioka, Tetrahedron Lett. 1994, 35, 4585-4586; i) K. K. Andersen, D. D. Bray, S. Chumpradit, M. E. Clark, G. J. Habgood, C. D. Hubbard, K. M. Young, J. Org. Chem. 1991, 56, 6508-6516; j) G. J. White, M. E. Garst, J. Org. Chem. 1991, 56, 3177-3178; k) J. E. Baldwin, A. C. Spivey, C. J. Schofield, Tetrahedron: Asymmetry 1990, 1, 877-880; l) D. Alker, K. J. Doyle, L. M. Harwood, A. McGregor, Tetrahedron: Asymmetry 1990, 1, 873-876; m) T. A. Lyle, C. A. Magill, S. M. Pitzenberger, J. Am. Chem. Soc. 1987, 109, 7890-7891.
- [12] For literature pertaining to the ubiquity and uses of β-aminoalcohols in synthesis, see: a) *The Merck Index, Vol.* 7, 12th ed., Chapman & Hall, New York, **1996**; b) G. Shaw, in *Comprehensive Heterocyclic Chemistry II*, (Eds.: A. R. Katritzky, C. W. Rees, E. F. V. Scriven) Pergamon, New York, **1996**, pp. 397–429; c) S. Wallbaum, J. Martens, *Tetrahedron: Asymmetry* **1992**, *3*, 1475–1504; d) R. Noyori, M. Kitamura, *Angew. Chem.* **1991**, *103*, 34–55; *Angew. Chem. Int. Ed. Engl.* **1991**, *30*, 49–69; e) V. K. Singh, *Synthesis* **1991**, 605–617. For some examples employing *cis*-1,2-aminoalcohols, see: f) B. Di Simone, D. Savoia, E. Tagliavini, A. Umani-Ronchi, *Tetrahedron: Asymmetry* **1995**, *6*, 301–306; g) Y. Hong, Y. Gao, X. Nie, C. M. Zepp, *Tetrahedron Lett.* **1994**, *35*, 6631–6634.
- [13] Interestingly, attempted carbamate-based AA (see reference [15a,b]) on the olefinic precursor to 5 led to the desired product in modest yield with little control of regioselectivity, while concurrent efforts employing the Ritter reaction under acidic conditions led solely to decomposition: a) C. M. Bellucci, A. Bergamini, P. G. Cozzi, A. Papa, E. Tagliavini, A. Umani-Ronchi, *Tetrahedron: Asymmetry* 1997, *8*, 895–902; b) C. H. Senanayake, L. M. DiMichele, J. Liu, L. E. Fredenburgh, K. M. Ryan, F. E. Roberts, R. D. Larsen, T. R. Verhoeven, P. J. Reider, *Tetrahedron Lett.* 1995, *36*, 7615–7618; c) C. H. Senanayake, F. E. Roberts, L. M. DiMichele, K. M. Ryan, J. Liu, L. E. Fredenburgh, B. S. Foster, A. W. Douglas, R. D. Larsen, T. R. Verhoeven, P. J. Reider, *Tetrahedron Lett.* 1995, *36*, 3993–3996.
- [14] H. C. Kolb, M. S. VanNieuwenhze, K. B. Sharpless, *Chem. Rev.* 1994, 94, 2483–2547.
- [15] a) K. L. Reddy, K. B. Sharpless, J. Am. Chem. Soc. 1998, 120, 1207-1217; b) G. Li, H. H. Angert, K. B. Sharpless, Angew. Chem. 1996, 108, 2995-2999; Angew. Chem. Int. Ed. Engl. 1996, 35, 2813-2817. For other lead references for other variants of the AA process, see: c) G. Li, H.-T. Chang, K. B. Sharpless, Angew. Chem. 1996, 108, 449-452; Angew. Chem. Int. Ed. Engl. 1996, 35, 451-454; d) G. Li, K. B. Sharpless, Acta Chem. Scand. 1996, 35, 451-454; e) M. Bruncko, G. Schlingloff, K. B. Sharpless, Angew. Chem. 1997, 109, 1580-1583; Angew. Chem. Int. Ed. Engl. 1997, 36, 1483-1486; f) K. L. Reddy, K. R. Dress, K. B. Sharpless, Tetrahedron Lett. 1998, 39, 3667-3670; g) L. K. Goossen, H. Liu, K. R. Dress, K. B. Sharpless, Angew. Chem. 1999, 111, 1149-1152; Angew. Chem. Int. Ed. 1999, 38, 1080-1083; h) Z. P. Demko, M. Bartsch, K. B. Sharpless, Org. Lett. 2000, 2, 2221-2223. For alternate, multistep approaches to cis-1,2-aminoalcohols from diols, see: i) M. K. Lakshman, B. Zajc, Tetrahedron Lett. 1996, 37, 2529-2532; j) A. K. Ghosh, S. P. Mckee, W. M. Sanders, Tetrahedron Lett. 1991, 32, 711-714.
- [16] U. Rinner, D. R. Adams, M. L. dos Santos, K. A. Abboud, T. Hudlicky, *Synlett* 2003, 1247–1252.
- [17] Chiral HPLC analysis was performed using a Diacel[®] Chiralpack Column AD, 85% hexane/15% isopropanol, 1.5 mL min⁻¹, 254 nm, 8.72 min (S-34), 12.2 min (R-34).

5604 -

- [18] Enantiopure (*R*)-34 was prepared using AD-mix-β as described by H. Becker, S. B. King, M. Tanaguchi, K. P. M. Vanhessche, K. B. Sharpless, J. Org. Chem. 1995, 60, 3940–3941.
- [19] The only other Burgess-type reagent prepared was the ethyl carbamate variant of 1 as described in reference [1c].
- [20] The relative facility of these preparations implies that virtually any carbamate-based Burgess-type salt can be accessed by this approach. Moreover, our handling of 48–51 suggests that they possess unique thermal and moisture-sensitivity profiles relative to 1, physical features which could prove significant in effecting transformations typically achieved by the Burgess reagent on recalcitrant substrates. It is important to note, however, that while carbamate-derived Burgess-type salts should be quite stable, the corresponding amide-based compounds are unlikely to be readily isolable. For efforts to attempt the synthesis of such reagents, see reference [1 c] and H. Vorbruggen, K. Krolikiewicz, *Tetrahedron* 1994, 50, 6549–6558.
- [21] D. Crich, J. Carbohydr. Chem. 2002, 21, 667-690.
- [22] For recent contributions from this group regarding the synthesis of aminoglycosides, see: K. C. Nicolaou, P. S. Baran, Y.-L. Zhong, J. A. Vega, Angew. Chem. 2000, 112, 2625–2629; Angew. Chem. Int. Ed. 2000, 39, 2525–2529. For a review on our expeditions in the total synthesis of carbohydrate-containing molecules, see: K. C. Nicolaou, H. J. Mitchell, Angew. Chem. 2001, 113, 1624–1672; Angew. Chem. Int. Ed. 2001, 40, 1576–1624.
- [23] S. J. Danishefsky, M. T. Bilodeau, Angew. Chem. 1996, 108, 1482– 1522; Angew. Chem. Int. Ed. Engl. 1996, 35, 1380–1419.
- [24] a) L. M. Likhoshertov, O. S. Novikova, V. A. Derevitskaya, N. K. Kochetkov, *Carbohydr. Res.* **1986**, *146*, C1–C5; b) A. Lubineau, J. Auge, B. Drouillat, *Carbohydr. Res.* **1995**, *266*, 211–219.
- [25] A. D. Dorsey, J. E. Barbarow, D. Trauner, Org. Lett. 2003, 5, 3237– 3239.
- [26] The only incompatibility with these conditions that we have identified is the presence of carbonyl-based protecting groups such as acetate or benzoate at the C-3 position.
- [27] CCDC-174599 (36), CCDC-230677 (42), and CCDC-230678 (86) contain the supplementary crystallographic data for this paper. These data can be obtained free of charge via www.ccdc.cam.ac.uk/ conts/retrieving.html (or from the Cambridge Crystallographic Data Centre, 12 Union Road, Cambridge CB21EZ, UK; fax: (+44)1223-336-033; or deposit@ccdc.cam.uk).
- [28] It is important to note that this protocol does not provide a general synthesis of aminals from lactols, as a number of conventional lactols gave inconsistent yields of the desired products under the same reaction conditions.
- [29] J. P. Genêt, E. Blart, M. Savignac, S. Lemeure, J.-M. Paris, *Tetrahe*dron Lett. **1993**, 34, 4189–4192.
- [30] For reviews, see: a) G. Arsequell, G. Valencia, *Tetrahedron: Asymmetry* 1999, 10, 3045–3094; b) M. J. Grogan, M. R. Pratt, L. A. Marcaurelle, C. R. Bertozzi, *Annu. Rev. Biochem.* 2002, 71, 593–634.
- [31] Although we have been unable to completely characterize these products, many are polymeric in nature, suggesting side-reactions initiated by the free alcohol with the sulfamidate ring either in intraor intermolecular modes.
- [32] It is important to note that although the nitrogen atom attached to the Burgess reagent is nucleophilic enough to attack an epoxide ring in the absence of direct Lewis acid activation, we could not induce similar attack onto the olefin of an α , β -unsaturated ester.
- [33] For a small sampling of this extensive literature, see: a) R. J. Cherney, B. W. King, 2002, WO-2002028846 [Chem. Abstr. 2002, 136, 309923]; b) N.-Y. Shih, H.-J. Shue, G. A. Reichard, S. Paliwal, D. J. Blythin, J. J. Piwinski, D. Xiao, X. Chen, 2001, WO-2001044200 [Chem. Abstr. 2001, 135, 61331]; c) G. M. Benson, M. C. Rutledge, K. L. Widdowson, 2000, WO-2000076501 [Chem. Abstr. 2001, 134, 56675]; d) R. D. Tung, F. G. Salituro, D. D. Deininger, G. R. Bhisetti, C. T. Baker, A. Spaltenstein, 1999, US-5945413 [Chem. Abstr. 1999, 131, 185247]; e) I. M. McDonald, D. J. Dunstone, M. J. Tozer, 1999, WO-9905141 [Chem. Abstr. 1999, 130, 168372].
- [34] a) W. Schaal, A. Karlsson, G. Ahlsén, J. Lindberg, H. O. Andersson, U. H. Danielson, B. Classon, T. Unge, B. Samuelsson, J. Hultén, A. Hallberg, A. Karlén, *J. Med. Chem.* 2001, 44, 155–169; b) A. Spaltenstein, M. R. Almond, W. J. Bock, D. Cleary, E. S. Furfine, R. J. Hazen, W. M. Kazmierski, F. G. Salituro, R. D. Tung, L. L. Wright,

Bioorg. Med. Chem. Lett. 2000, 10, 1159-1162; c) K. Bückbro, S.
Löwgren, K. Österlund, J. Atepo, T. Unge, J. Hultén, N.M.
Bonham, W. Schaal, A. Karlén, A. Hallberg, J. Med. Chem. 1997, 40, 898-902; d) J. Hultén, N.M. Bonham, U. Nillroth, T. Hansson, G. Zuccarello, A. Bouzide, J. Aqvist, B. Classon, U. H. Danielson, A. Karlén, I. Kvarnstrom, B. Samuelsson, A. Hallberg, J. Med. Chem. 1997, 40, 885-897.

- [35] a) R. Kuang, J. B. Epp, S. Ruan, L. S. Chong, R. Venkataraman, J. Tu, S. He, T. Truong, W. C. Groutas, *Bioorg. Med. Chem.* 2000, *8*, 1005–1016; b) R. Kuang, J. B. Epp, S. Ruan, H. Yu, P. Huang, S. He, J. Tu, N. M. Schechter, J. Turbov, C. J. Froelich, W. C. Groutas, *J. Am. Chem. Soc.* 1999, *121*, 8128–8129; c) W. C. Groutas, N. M. Schechter, S. He, H. Yu, P. Huang, J. Tu, *Bioorg. Med. Chem. Lett.* 1999, *9*, 2199–2204; d) W. C. Groutas, R. Kuang, S. Ruan, J. B. Epp, R. Venkataraman, T. M. Truong, *Bioorg. Med. Chem.* 1998, *6*, 661–671.
- [36] J. L. Castro, R. Baker, A. R. Guiblin, S. C. Hobbs, M. R. Jenkins, M. G. N. Russell, M. S. Beer, J. A. Stanton, K. Scholey, R. J. Hargreaves, M. I. Graham, V. G. Matassa, *J. Med. Chem.* **1994**, *37*, 3023–3032.
- [37] M. J. Tozer, I. M. Buck, T. Cooke, S. B. Kalindjian, I. M. McDonald, M. J. Pether, K. I. M. Steel, *Bioorg. Med. Chem. Lett.* **1999**, *9*, 3103– 3108.
- [38] a) S. V. Pansare, A. N. Rai, S. N. Kate, Synlett 1998, 623-624;
 b) K. H. Ahn, D. J. Yoo, J. S. Kim, Tetrahedron Lett. 1992, 33, 6661-6664;
 c) D. Sartor, J. Saffrich, G. Helmchen, C. J. Richards, H. Lambert, Tetrahedron: Asymmetry 1991, 2, 639-642. The use of sulfamides as chiral auxiliaries was inspired by their close structural homology to Oppolzer's family of versatile chiral sultams which are chartered in the following papers: d) W. Oppolzer, A. J. Kingma, S. K. Pillai, Tetrahedron Lett. 1991, 32, 4893-4896; e) W. Oppolzer, C. Starkemann, I. Rodriguez, G. Bernardinelli, Tetrahedron Lett. 1991, 32, 61-64.
- [39] a) F. Hof, P. M. Iovine, D. W. Johnson, J. Rebek, Org. Lett. 2001, 3, 4247–4249; b) F. Hof, C. Nuckolls, S. L. Craig, T. Martín, J. Rebek, J. Am. Chem. Soc. 2000, 122, 10991–10996; c) B. Gong, C. Zheng, H. Zeng, J. Zhu, J. Am. Chem. Soc. 1999, 121, 9766–9767, and references cited in each.
- [40] a) M. Preiss, *Chem. Ber.* 1978, 111, 1915–1921; b) S. H. Rosenberg, J. F. Dellaria, D. J. Kempf, C. W. Hutchins, K. W. Woods, R. G. Maki, E. de Lara, K. P. Spina, H. H. Stein, J. Cohen, W. R. Baker, J. J. Plattner, H. D. Kleinert, T. J. Perun, *J. Med. Chem.* 1990, 33, 1582–1590; c) G. Dewynter, N. Aouf, J.-L. Montero, *Tetrahedron Lett.* 1991, 32, 6545–6548.
- [41] An online search of the available chemicals directory revealed just over 200 unsubstituted 1,2-diamine substrates. By contrast, over 3000 unsubstituted β -aminoalcohols are available for purchase.
- [42] See reference [36a] and: a) J. M. Dougherty, D. A. Probst, R. E. Robinson, J. D. Moore, T. A. Klein, K. A. Snelgrove, P. R. Hanson, *Tetrahedron* 2000, 56, 9781–9790; b) G. Dewynter, M. Abdaoui, L. Toupet, J.-L. Montero, *Tetrahedron Lett.* 1997, 38, 8691–9694; c) Z. Regaïnia, M. Abdaoui, N.-E. Aouf, G. Dewynter, J.-L. Montero, *Tetrahedron* 2000, 56, 381–387; d) A. M. Harned, S. Mukherjee, D. L. Flynn, P. R. Hanson, *Org. Lett.* 2003, 5, 15–18.
- [43] Aminoalcohol substrates 131, 133, and 135 were prepared by the method of H. W. Heine, B. L. Kapur, J. L. Bove, R. W. Greiner, K. H. Klinger, C. Mitch, C. J. Am. Chem. Soc. 1954, 76, 2503. For alternative approaches to fashion these compounds, see: J. T. Rudesill, R. F. Severson, J. G. Pomonis, J. Org. Chem. 1971, 36, 3071– 3076.
- [44] Several of the aminoalcohols and amines employed in these studies are available commercially as their HCl salts. In order to obtain the yields disclosed above these starting materials were converted to their free-base form prior to reaction. Failure to perform this simple step led either to drastically reduced yields of the sulfamide product, or no detectable reaction whatsoever.
- [45] For literature pertaining to carbamate cleavage and N-alkylation of such substrates, see references [36a, 39a] and: a) R. M. Acheson, M. G. Bite, J. E. G. Kemp, J. Med. Chem. 1981, 24, 1300–1304; b) C.-H. Lee, H. Kohn, J. Org. Chem. 1990, 55, 6098–6104.

Chem. Eur. J. 2004, 10, 5581–5606 www.chemeurj.org © 2004 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim

FULL PAPER

- [46] For an alternative synthesis of linear sulfamides, see: F. A. Davis, M. A. Giangiordano, W. E. Starner, *Tetrahedron Lett.* 1986, 27, 3957–3960.
- [47] For a recent synthesis of linear sulfamides from chlorosulfonylisocyanate using Burgess-type intermediates, see: Y. Masui, H. Watanabe, T. Masui, *Tetrahedron Lett.* 2004, 45, 1853–1856.
- [48] E. Larsen, P. T. Jørgensen, M. A. Sofan, E. B. Pedersen, Synthesis 1994, 1037–1038.
- [49] S. Tejima, H. G. Fletcher, J. Org. Chem. 1963, 28, 2999-3004.
- [50] B. Kaskar, G. L. Heise, R. S. Michalak, B. R. Vishnuvajjala, Synthesis 1990, 1031–1032.
- [51] T. Katsuki, K. B. Sharpless, J. Am. Chem. Soc. 1980, 102, 5976-5978.

Received: May 20, 2004 Published online: October 7, 2004